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Abstract
Prostate cancer (PCa) remains a leading cause of death in men, primarily due to ineffective
treatment in the metastatic setting. During this phase of PCa, circulating tumor cells (CTCs)
are shed into the bloodstream and their presence and number are important in patient
prognosis. The CellSearch® system (CSS) is the only U.S. Food and Drug Administration
(FDA) and Health Canada approved instrument for detection of CTCs, making it the current
clinical gold standard in CTC technology. Although the CSS provides a minimally invasive
means of patient monitoring in the metastatic setting, little is known about the role of CTCs
in early-stage PCa. Additionally, examination of the utility of CTC molecular
characterization in personalized patient care is an area of great interest. However, the
underlying biology of CTCs remains poorly understood. In the present study, we
demonstrated that CTCs are detectable in early-stage, post-surgical PCa patients undergoing
adjuvant and salvage radiotherapy, and that in combination with other clinicopathological
risk factors, CTCs may be useful in predicting treatment failure earlier then currently utilized
clinical techniques. Additionally, we provide 2 technical resources outlining the FDA and
Health Canada approved process of CTC identification and enumeration using the CSS, the
detailed experimental process of user-defined protein molecular characterization using the
CSS, and a comparable CTC assay for use in in vivo pre-clinical mouse models of metastasis.
Finally, a comprehensive biological examination of the role of the epithelial-to-mesenchymal
transition (EMT) in CTC kinetics and metastatic dissemination in PCa is presented,
demonstrating that highly mesenchymal PCa cells shed CTCs earlier and in greater numbers
during the metastatic cascade and have a greater metastatic capacity then PCa cells with an
epithelial phenotype. Collectively these data improve our understanding biology of CTCs in
PCa, including CTC kinetics, their relationship with EMT, and metastasis. These results will
ii

guide future research and technology development in the identification and capture of CTCs
with the greatest metastatic potential, and may ultimately lead to changes in patient treatment
guidelines.

Keywords
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Molecular Characterization, Epithelial-to-Mesenchymal Transition
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Chapter 1
Introduction
A version of this chapter has been published as a review paper:
Lowes LE and Allan, AL. Recent advances in the molecular characterization of
circulating tumor cells. Cancers (Basel). 2014; 6(1):595-624.

1.1

Prostate cancer
Prostate cancer (PCa) is the second leading cause of cancer diagnosis and the

third leading cause of cancer-related mortalities in men in North America1. The prostate
is located just below the bladder in the male reproductive system and is responsible for
the production of seminal fluid which will eventually mix with sperm from the testicles to
produce semen2. There are several pre-cancerous conditions associated with the
development of prostate cancer including prostatic intraepithelial neoplasia (PIN) and
proliferative inflammatory atrophy (PIA)3. Although there are several different types of
PCa, 95% are classified as adenocarcinomas and develop from the mucus-secreting gland
cells of the prostate4. There are currently two tests which are commonly utilized when
screening for PCa, the digital rectal examination (DRE) and the prostate specific antigen
(PSA) test5. DRE involves inspection of the prostate for abnormal regions using manual
palpation of the prostate via the rectum6. The PSA test involves the collection of a blood
sample and subsequent testing for elevated levels of the PSA protein. This protein is
typically secreted by the prostate, however, elevated levels may indicate changes in
prostate physiology7,8. If abnormal results are obtained during the screening process, a
prostate biopsy may be ordered and multiple biopsy specimens will be collected for

1

pathological assessment. Following biopsy, Gleason scoring is performed by a trained
pathologist on each biopsy specimen. The Gleason score ranks each specimen on a scale
from 2-10 based on the sum of primary and secondary patterns (1-5) of differentiation
when compared to normal prostate tissue, with a low number indicating more
differentiated tissue (less aggressive disease) and a high number indicating more
undifferentiated tissue (more aggressive disease)9.

1.1.1

Disease staging and prognosis
PCa is staged based on categorization of patients using the TNM classification

system, which relies on the size and extent of the primary tumor (T), the spread of disease
to regional lymph nodes (N), and tumor dissemination to other organs (M). The details of
this classification system are presented in Table 1.1. Along with TNM stage, additional
criteria such as PSA levels and Gleason score are important in determining prognosis and
in assigning risk. Table 1.2 outlines the prognostic grouping of patients based on TNM,
PSA, and Gleason score as defined by the Union for International Cancer Control
(UICC). Based on these criteria, patients in group I have a better prognosis then those in
group IV9. PCa patients may also be further categorized into low, intermediate, and high
risk groups. To be classified as low risk, patients must have a TNM stage of T2a or
lower, PSA ≤ 9, and a Gleason score of ≤ 6. Intermediate risk patients are those that
present with any of the following; TNM stage of T2b-T2c, PSA of 10-20, and/or a
Gleason score of 7. Finally patients are classified as high risk if any of the following are
present, TNM stage of T3a or higher, PSA > 20, and/or a Gleason score of 8-1010,11.

2

Table 1.1. Clinical classifications of prostate cancer using the TNM system
Primary Tumour (T)
TX
T0
T1
T1a
T1b
T1c
T2
T2a
T2b
T2c
T3
T3a
T3b
T4

Primary tumour cannot be assessed
No evidence of primary tumour
Clinically inapparant tumor neither palpable nor visible
by imaging
Tumour incidental histologic finding in 5% or less of
tissue resected
Tumour incidental histologic finding in more than 5% of
tissue resected
Tumour identified by needle biopsy
Tumour confined within prostate#
Tumour involved one-half of one lobe or less
Tumour involved more than one-half of one lobe but not
both lobes
Tumour involved both lobes
Tumour extends thorough the prostate capsule##
Extracapsular extension (unilateral or bilateral) including
microscopic bladder neck involvement
Tumour invades seminal vesicles
Tumour is fixed or invades adjacent structures other then
seminal vesicles: bladder neck, external sphincter, rectum,
levator muscles, and/or pelvic wall

Regional Lymph Nodes (N)
NX
Regional lymph nodes cannot be assessed
N0
No regional lymph node metastasis
N1
Regional lymph node metastasis
Distant metastasis (M)
M0
No distant metastasis
M1
Distant metastasis
#: Tumour found in one or both lobes by needle biopsy, but not palpable or reliably
visible by imaging is classified as T1c.
##: Invasion into the prostatic apex or into (but not beyond) the prostatic capsule is
classified not as T3 but as T2.
** Srigley et al., 20099
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Table 1.2. Clinical stage classification of prostate cancer based on TNM criteria, PSA,
and Gleason score as defined by the Union for International Cancer Control (UICC)
Group
I

T
N
M
PSA
Gleason
T1a-c
N0
M0
PSA < 10
Gleason ≤ 6
T2a
N0
M0
PSA < 10
Gleason ≤ 6
T1-2a
N0
M0
PSA X
Gleason X
IIA
T1a-c
N0
M0
PSA < 20
Gleason 7
T1a-c
N0
M0
PSA ≥ 10 < 20
Gleason ≤ 6
T2a
N0
M0
PSA ≥ 10 < 20
Gleason ≤ 6
T2a
N0
M0
PSA < 20
Gleason 7
T2b
N0
M0
PSA < 20
Gleason ≤ 7
T2b
N0
M0
PSA X
Gleason X
IIB
T2c
N0
M0
Any PSA
Any Gleason
T1-2
N0
M0
PSA ≥ 20
Any Gleason
T1-2
N0
M0
Any PSA
Gleason ≥ 8
III
T3a-c
N0
M0
Any PSA
Any Gleason
IV
T4
N0
M0
Any PSA
Any Gleason
Any T
N1
M0
Any PSA
Any Gleason
Any T
Any N
M1
Any PSA
Any Gleason
Note: When either prostate specific antigen (PSA) or Gleason is not available, grouping
should be determined by T stage and/or whichever of either the PSA or Gleason is
available.
**Srigley et al., 20099
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1.1.2

Treatment options for prostate cancer
In most cases, PCa is a slow-growing disease and when caught early it is

highly treatable. In fact, PCa patients without distant spread show 5 year relative survival
rates of 100%. However, the relative survival rates of patients with distant spread of this
disease are significantly reduced, with only 31% surviving more than 5 years1. The
treatment options available for PCa patients depend on disease stage. The poor outcomes
observed for patients with distant disease are as a result of a lack of effective treatment
options in this disease setting.

1.1.2.1 Active surveillance
Due to the slow-growing nature of PCa, active surveillance is an option that is
often offered to men with low risk disease, older men who have a life-expectancy of less
than 10 years, and/or men with other significant health problems11–14. During active
surveillance, patients are routinely monitored every 3-6 months using PSA testing or/and
physical examination, including DRE. Repeat biopsies are usually performed every 1-2
years or as clinically indicated.

1.1.2.2 Surgical intervention: radical prostatectomy
Upon evidence of disease progression, PCa patients may be offered surgical
removal of the prostate via radical prostatectomy. This treatment option is most typically
offered to men with stage I and II disease, under the age of 75, and in good physical
health11,12. Although less common, radical prostatectomy may also be offered as a
treatment option for stage III patients15. Following surgical intervention, assessment of
the pathological tissue as well as monitoring via PSA testing can assist clinicians in
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determining if patients should be recommended for post-surgical radiation therapy
(RT)16,17.

1.1.2.3 Radiation therapy
Brachytherapy is an internal radiation therapy approach often offered to
patients with low or intermediate risk disease. This treatment option, utilized in place of
radical prostatectomy, relies on the strategic placement of small radioactive implants,
either permanent or temporary, into the prostate, thereby slowing killing the cancer cells
over time11. Brachytherapy may also be utilized in combination with external beam
radiation therapy for patients with intermediate or high risk disease18.
If surgical intervention is chosen, patients with adverse pathological results
(e.g., extracapsular extension [ECE], seminal vesicle invasion [SVI], and/or positive
margins) without a detectable PSA or patients with a detectable PSA, with or without
adverse pathology, may be recommended to undergo adjuvant or salvage external beam
radiotherapy respectively17. Additionally, external beam radiation therapy, often given in
combination with hormonal therapy, is often utilized for treatment of patients with stage
III disease19. It can also be used in earlier stage patients who are unfit or do not desire
surgery.

1.1.2.4 Hormonal therapy: androgen deprivation
In general, hormonal therapies are reserved for those individuals suffering with
stage III and IV disease. These therapies exploit PCa's requirement for androgen
(testosterone and dihydrotestosterone [DHT]) stimulation in promoting tumor growth. By
depriving tumor cells of these necessary androgens, hormonal therapies are able to slow
the growth of residual disease20,21.
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Currently, there are 5 classes of hormonal treatments available; (1) luteinizing
hormone-releasing hormone (LHRH) agonists, (2) LHRH antagonists, (3) anti-androgens,
(4) estrogens, and (5) orchiectomy21. Luteinizing hormone (LH) is released by the
pituitary gland, following stimulation by LHRH. LH then activates the testes to release
testosterone into the bloodstream thus enhancing tumor cell growth. LHRH agonists (e.g.,
Lupron [leuprolide acetate], Zoladex [goserelin], Suprefact [buserelin acetate], and
Trelstar [triptorelin pamoate]) result in excessive stimulation of the pituitary gland to
release LH. Ultimately, the pituitary will stop responding to LHRH thereby preventing
stimulation of the testes and reduced secretion of testosterone 22. In contrast, LHRH
antagonists (e.g., Firmagon [degarelix]) work by blocking the release of LH from the
pituitary gland, again resulting in reduced testosterone secretion23. Unlike LHRH-based
therapies which act at the level of androgen secretion, anti-androgen treatments (e.g.,
Euflex [flutamide], Casodex [bicalutamide], Anandron [nilutamide], Zytiga [abiraterone
acetate], and Xtandi [enzalutamide]) act by blocking androgen receptors expressed by
prostate cancer cells, thereby preventing cell stimulation24. Estrogen therapy is typically
reserved for cases in which patients are no longer responding to androgen deprivation.
The use of estrogens in these patients has been demonstrated to reduce androgen levels 25.
Finally, orchiectomy is a surgical procedure in which the testes are removed, thus
eliminating the primary source of androgen secretion. However, for many men, chemical
castration is preferred over this surgical intervention21. Unfortunately, although up to
85% of men initially respond well to hormonal treatments, these therapies are not
curative and patients will eventually no longer respond to androgen deprivation. This
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lethal stage of disease is commonly referred to as castration resistant or hormone
refractory PCa26.

1.1.2.5 Chemotherapy
Chemotherapy in PCa is typically only utilized during the castration resistant
phase of disease and its use is strictly palliative. Commonly utilized chemotherapy
regimens include treatment with Taxotere, Novantrone, or Jevtana in combination with
Prednisone. Although not curative, these combination treatments can be utilized to
prolong survival, reduce pain, and improve the quality of life for terminal patients 21.
More recently chemotherapy has been shown to be beneficial in select patients with
metastatic hormone sensitive prostate cancer (NIH Trial #:NCT00309985) and in those
with high risk disease (NIH Trial #:NCT00288080).

1.1.3

Prognostic biomarkers in prostate cancer
The advent of PSA screening for PCa in the early 1980s revolutionized the

management of this disease, allowing for earlier detection and subsequently earlier
treatment initiation for PCa patients. However, observed discrepancies between one's
lifetime risk of prostate cancer development (1 in 6, ~16%) and lifetime risk of death due
to this disease (~2%) has led to controversy regarding the potential for over detection and
over treatment of this slow-growing disease27,28. In addition to over detection and over
treatment, there is also the potential for false-positive results during the screening
process. As recently described in the multi-centre European Randomized Study of
Screening for Prostate Cancer trial, the false-positive rate is largely influenced by the
PSA threshold utilized, with 4.0 ng/ml resulting in 11.3% false-positives versus 3.0 ng/ml
resulting in 19.8%. Unfortunately no PSA value has been described that can conclusively
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discriminate patients with and without PCa. Therefore great controversy exists with
regards to the widespread utilization of PSA testing, especially when considering low- or
average- risk patients under the age of 55 or over the age of 70 29. Currently, aside from
the standard clinicopathologic parameters utilized in assessing patient risk (TNM stage,
PSA, and Gleason score) there are very few prognostic biomarkers available that are
helpful in differentiating indolent disease from aggressive disease. Oncotype DX ®, a
biopsy-based genomic test, has received prospective validation as a prognostic marker in
low-risk patients28,30,31. This test measures the expression levels of 17 genes across four
biological pathways to assess the anticipated aggressiveness of a given tumor. The results
are then reported as a number between 0 and 100, called the Genomic Prostate Score, in
which smaller numbers reflect lower risk. This test along with the results of other clinical
parameters aids clinicians in selecting better candidates for active surveillance as an
initial management strategy. Although concerns regarding over-treatment have received
increasing attention in recent years, under-treatment of men with aggressive disease is
also a concern. Prolaris® is a prognostic genomic assay that assesses increases in cell
cycle progression gene mutations that has been validated to aid in differentiating low-risk
and high-risk patient populations when used in combination with standard
clinicopathologic parameters28,30,32–34. Finally, Decipher®, a genomic based assay, has
been validated for predicting the probability of metastasis following surgical intervention
via radical prostatectomy, thus better identifying high-risk patients28,35,36.
However, in spite of the available clinicopathologic parameters and prognostic
biomarkers, PCa is still a highly lethal disease, claiming an estimated 4,100 lives this
year alone in Canada1. Therefore, there is a necessity for novel prognostic biomarkers
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that could better predict aggressive disease. Additionally, minimally invasive prognostic
biomarkers that could be repeatedly utilized, serving as "real-time biopsies" of ongoing
disease progression, would be especially valuable in the management of PCa.

1.2

Metastasis and circulating tumor cells (CTCs)
The majority of PCa cancer-related deaths occur as a result of metastasis. This

lethality is largely attributable to our current lack of effective treatments in the metastatic
setting37,38. One contributing factor to this is that metastatic lesions are highly
heterogeneous when compared to their primary tumor counterparts39–48; however, the
majority of treatment decision-making is currently based upon characteristics of the
primary tumor. Although disease outcome is ultimately determined by metastatic spread,
biopsy of metastatic lesions is often difficult to perform and can be a significant source of
morbidity for patients. Therefore, it is currently not clinically feasible to subject patients
to repetitive metastatic biopsies upon disease recurrence or progression, even if this
approach could provide information that might improve treatment of metastatic disease.
Unfortunately, this suggests that many patients are receiving sub-optimal treatment and
therefore techniques that could better assess the characteristics of metastatic disease
might enhance treatment efficacy and ultimately improve patient outcomes.
Metastasis has been demonstrated to correlate with the presence of cancer cells
in the peripheral blood circulation, hereafter referred to as circulating tumor cells
(CTCs)49–51. The existence of CTCs has been known since the mid-1800s, when they
were first reported by Thomas Ashworth, a resident physician at Melbourne Hospital.
Upon autopsy of a patient with numerous (~30) subcutaneous tumors, Ashworth described
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these cells as appearing “exactly in shape, size, and appearance” to those seen in the
primary lesions. Ashworth postulated that these tumor-like cells were cancer cells in the
blood and that their existence could shed light on the “mode of origin” of numerous
tumors in one individual52. Since the work of Ashworth in 1869, it has since been
confirmed that the blood is a major route of transport for disseminating cancer cells, and
it has been postulated that these CTCs might act as surrogate biomarkers of disease
spread and patient outcome49–51. However, only recently has technological advancement
allowed for detailed investigation of these cells and their consideration for use in the
clinic.

1.2.1

Clinical applications of CTCs
Thus far, the clinical uses of CTCs have focused mainly on enumeration. Due

to the rare nature of CTCs, this process typically requires both enrichment and detection
steps (Figure 1.1). For enrichment, approaches include size or density-based techniques
and/or immunomagnetic separation (i.e., positive selection using epithelial-specific or
tumor-associated markers; or negative selection using markers expressed by
contaminating cells such as leukocytes). For detection, approaches include nucleic acidbased techniques such as reverse transcription polymerase chain reaction (RT-PCR),
reverse transcription quantitative-PCR (RT-qPCR), microarray, or sequencing; and/or
protein-based techniques such as immunofluorescence or flow cytometry (FCM) using
antibody-mediated detection. The advantages and disadvantages of each of these
techniques have been extensively reviewed previously53–58 and therefore will not be
discussed here.
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Figure 1.1. An overview of the most commonly utilized techniques for the process
of CTC enrichment and detection. In general, four approaches currently exist for
CTC enrichment: (1) size-based; (2) density-based; (3) immunomagnetic separation; and
(4) microfluidic-based. Using size-based enrichment techniques, diluted whole blood is
passed through a filtration device with specific sized pores (typically 8 µm). CTCs are
captured based on differences in cell size between CTCs (typically >8 µm) and white
blood cells (WBCs; typically <8 µm). Density-based enrichment utilizes Ficoll (or
similar density gradient medium) to enrich for mononuclear cells (including CTCs)
from other blood components. Immunomagnetic separation involves the use of ironconjugated antibodies targeted toward CTCs (e.g., EpCAM; positive selection) or
contaminating blood cells (e.g., CD45; negative selection) and incubation in a
magnetic field. For microfluidic-based techniques, whole blood is slowly passed across a
chip-based surface and isolated using either CTC targeted antibody-coated microposts
and/or other chip surfaces (CTC Chip, Herringbone CTC Chip, iChip, graphene oxide
chip, and the OncoBean Chip59–63), or dielectrophoresis (DEPArray64,65). Current CTC
detection techniques use either a protein-based approach (i.e., immunofluorescence or flow
cytometry) expressed by whole cells or secreted proteins (EPISPOT assay66–68), or
nucleic acid-based approaches such as RT-PCR or RT-qPCR, applied at the level of
single genes or using a multiplex approach.
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Despite the development of numerous CTC platforms using various
combinations of the above enrichment and detection steps, capture of these cells is still
technologically challenging due to their rare nature (~1 CTC per 105–108 white blood
cells69–71), the potential presence of contaminating cells that can lead to false positive
identification (i.e., non-tumor epithelial cells, circulating endothelial cells), and the lack
of a globally accepted marker for capture of all CTCs (e.g., some CTCs may lose
EpCAM [epithelial cell adhesion molecule]/CK [cytokeratin] expression as they enter the
bloodstream via a process known as epithelial-to-mesenchymal transition [EMT]72). In fact,
currently, the only U.S. Food and Drug Administration (FDA) cleared system for CTC
detection and enumeration in the clinic is the CellSearch ® system (CSS; Janssen
Diagnostics, LLC, Raritan, NJ, USA), developed in the early 2000s. This platform
enriches for CTCs using positive immunomagnetic selection based on EpCAM, followed
by immunofluorescent staining for CK 8/18/19; CD45; and the DNA dye DAPI (4',6diamidino-2-phenylindole). Positive CTCs are identified, using semi-automated
fluorescence microscopy, as cells with a CK+/DAPI+/CD45− phenotype73. The CSS is
currently cleared for prognostic use in metastatic breast, prostate, and colorectal cancers,
where the presence of ≥5 (breast 73 and prostate74) or ≥3 (colorectal75) CTCs in 7.5mL of
blood is correlated with poorer prognosis compared to patients with fewer CTCs in the
same blood volume. Using this platform, CTC enumeration has been utilized not only to
assess CTC number at baseline but also throughout the course of treatment and/or
following completion of various treatment regimens. It has been demonstrated that CTCs
are correlated with patient outcome and that the change in CTC number during treatment
is predictive of therapy response, often sooner than currently utilized techniques such as
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imaging74,76–78. However, as described in the following sections, simple enumeration of
CTCs fails to capitalize on their full potential as biomarkers of metastatic disease.

1.2.2

CTCs as surrogate biomarkers of metastatic biopsy
As previously mentioned, although the biopsy and subsequent molecular

profiling of metastatic tissue would be ideal for determining appropriate interventional
treatments for cancer patients upon disease recurrence or progression, this approach is
typically not routinely feasible in the clinic. Therefore, molecular characterization of the
cells that seed these metastatic lesions has been proposed as a surrogate for metastatic
biopsy. For patients who have been heavily pre-treated with numerous lines of therapy, it
is highly likely that the cancer cells that persist in the body are significantly different
from those that originally existed in their primary tumor counterpart 39–48. In addition,
outside of the metastatic setting, CTCs may also demonstrate utility in circumstances
where no primary tumor is available for characterization, or where the collected tissue is
of poor quality and/or insufficient quantity. The molecular characterization of CTCs
therefore holds great promise in terms of assessing disease status and will likely better
represent the overall heterogeneity of disease at the time of necessary intervention.
Moving forward, molecular characterization of CTCs could provide an
attractive and powerful alternative to metastatic biopsies; acting as a minimally invasive
“real-time liquid biopsy” that can be repeatedly performed to allow assessment of genetic
drift, investigation of molecular disease evolution, and identification of actionable
genomic characteristics.
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1.3

Current CTC molecular characterization
approaches

1.3.1

Protein-based CTC characterization techniques

1.3.1.1 Immunofluorescence
Immunofluorescence is the primary means by which CTCs have been
interrogated at the protein level, using specifically targeted antibodies. A number of CTC
enrichment techniques have been employed prior to immunofluorescent staining
including immunomagnetic approaches (both positive and negative selection) 79–91,
density gradient centrifugation86, and microfluidic chip-based approaches59. Using
immunofluorescence, CTCs have been characterized for expression of many markers
including HER262,79,80,82–93, EGFR (epidermal growth factor receptor)79,94,95, androgen
receptor (AR)96,97, PSA59, estrogen receptor (ER)87,94, and progesterone receptor (PR)94.
Thus far in the literature, the gold standard CSS is the most highly utilized
system for CTC characterization at the protein level, using a single fluorescein
isothiocyanate (FITC) fluorescence channel not required for CTC identification.
Currently the CSS has three commercially available markers that can be used on-system
in combination with this platform to examine HER2, EGFR, or insulin-like growth factor
1 receptor (IGF-1R) expression on CTCs. In addition, the CSS is amenable to the
development of user-defined protein marker protocols for CTC characterization.
However, the CSS is a “closed” platform, with little flexibility in terms of fluorophore
selection and fluorescent channel availability, and on-system characterization is currently
limited to one additional marker. While this limitation in fluorophore availability is a
hurdle that must be overcome by all protein-based platforms, several groups have
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developed systems that are more “open” in nature and therefore more amenable to
extensive multi-marker CTC characterization.
A microfluidic chip-based assay known as the CTC Chip platform59, the next
generation CTC Chip platform, the iChip which combines microfluidic and magnetic cell
sorting technologies60, and a portable microfiltration platform98 developed recently are
excellent examples of “research-friendly” immunofluorescent techniques that allow
flexibility in CTC characterization. These two platforms utilize different CTC enrichment
methodologies to capture these rare cells, with the CTC Chip system relying on positive
selection using anti-EpCAM coated microposts as blood is passed over the chip surface,
versus the microfiltration system which utilizes size-based capture of CTCs. Thus far in
the literature these two platforms have been exploited for CTC characterization,
examining a variety of markers including PSA, M-30, thyroid transcription factor 1
(TTF1), Ki-67, and HER256,59,61,98.
The advantages of utilizing immunofluorescence for CTC characterization
include: (1) the ability to examine the presence or absence of expression, as well as
protein localization and co-localization with additional proteins; (2) the ability to
examine many proteins of interest simultaneously, limited only by the filter capacity of
the investigators’ microscope; (3) the ability to visually confirm that expression is in
CTCs and not contaminating cells; and (4) the ability to visualize variations in protein
expression levels (it is important to note that this may also be seen as a disadvantage if
not properly standardized). Several disadvantages also exist with regards to
immunofluorescence techniques including: (1) limitations in assay sensitivity (i.e.,
enough antigens need to be present to display a visible signal); (2) bleed-through from
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additional fluorescent channels can make interpretation of results confusing; and (3)
using this approach, result interpretation can be more difficult to standardize (i.e., what
constitutes a true positive or negative signal), although automated CTC analysis
approaches are evolving to help address this issue86,92.
In the clinic, the primary benefit of immunofluorescence-based CTC
characterization is the ability to identify the presence or absence of particular therapeutic
target molecules, thereby expanding the availability of targeted therapies to patients who
would previously be considered ineligible based solely upon the characteristics on their
primary tumor. An excellent example of a setting in which CTC characterization could
augment patient care is illustrated by the limited availability of HER2 targeted therapies
to breast cancer patients with HER2− primary tumors who may have HER2+ disease in
sites distant from the primary tumor (i.e., metastases). In particular, the detection of
HER2+ CTCs in a patient with a HER2− primary tumor could predict response to HER2
targeting agents and increase the availability of these personalized treatment options to
patients. In the future, we envision serial CTC assessment at the protein level as a tool for
predicting therapy response to specific targeting agents and facilitating evaluation of
emerging drug resistance based upon the loss/downregulation of target molecules.

1.3.1.2 Flow cytometry
Although immunofluorescence is a powerful tool for CTC characterization at
the protein level, its primary limitation is that the data obtained using this approach is
largely qualitative. Due to the highly heterogeneous nature of CTCs, quantitative analysis
of these rare cells may be advantageous. Quantifiable flow cytometry assays are therefore
an attractive alternative for protein-based characterization. In the clinic, FCM has been
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proven to be an extremely powerful technology, with clinical FCM being utilized in a
number of disciplines, including hematology and oncology99,100. In general, FCM has
primarily been utilized for CTC enumeration; however, this technique is also an attractive
method for multi-marker, on-system, molecular characterization of CTCs. Thus far in the
literature, this technology has been utilized to examine the expression of EGFR and its
phosphorylated counterpart, ALDH1 (aldehyde dehydrogenase 1), CD44, CD47, MET,
and heparanase (HPSE)101–104. Simultaneous to on-system characterization, FCM offers
the ability to easily sort and collect characterized CTCs using fluorescence activated
cell sorting (FACS) technology102,103. Additional advantages offered by flow cytometric
methods include: (1) the ability to examine not only the presence or absence of marker
expression but also to examine the level of expression in a measurable and quantifiable
fashion; (2) the ability to easily perform multi-marker analysis on a single sample, limited
only by laser and fluorescent filter set availability; and (3) ease of sorted sample collection
and downstream characterization using other approaches. However, disadvantages also exist
including: (1) limitations with regards to assay sensitivity even when combined with preenrichment steps105,106; and (2) the inability to visually confirm that results are from
CTCs and not due to leukocyte contamination.
Moving forward, the use of FCM for CTC characterization in the clinic could
provide similar benefits as those recognized for immunofluorescent techniques. In brief,
these techniques could provide valuable information regarding the expression of protein
markers for targeted therapies and the detection of drug resistant phenotypes, as well as
the added potential for performing multi-marker protein analysis with a quantifiable
readout. When utilized clinically, this approach would be better equipped (relative to
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immunofluorescence) for assessing overall CTC heterogeneity and for identifying distinct
CTC subpopulations. An example of this has recently been elegantly demonstrated by
Baccelli et al. (2013), who identified a CD44+CD47+MET+/− CTC subpopulation that is
enriched for metastasis-initiating cells102. In addition, FCM would also allow for these
subpopulations to be quantified, potentially providing information regarding patient
prognosis102. However it is important to highlight that current limitations with regards to
assay sensitivity restrict the use of this technique as a clinical assay at present, and
advances in technology are needed to address this.

1.3.2

Nucleic acid-based CTC characterization techniques

1.3.2.1 Fluorescence in situ hybridization
At the genomic level, fluorescence in situ hybridization (FISH) has been
utilized to interrogate CTCs for changes in individual genes, including gene copy
number, gene rearrangement, and/or gene deletion; as well as chromosomal changes,
such as select arm deletion or amplification79–81,92,93,107–113. Prior to FISH analysis, CTCs
are typically enriched from whole blood, with the exception of one group that
demonstrated FISH analysis of CTCs without prior enrichment 114. In the literature several
enrichment techniques have been employed, including the CSS 79–81,93,110,111,113, isolation
by size of epithelial tumor cells (ISET) 107,109, density gradient centrifugation79,108,113,115,
OncoQuick112, and microfluidic chip-based assays79,108,115. Following enrichment,
isolated CTCs from metastatic breast, prostate, and lung cancers have been examined by
FISH (either on-platform or after being cytospun onto charged glass slides) for several
common genomic aberrations and amplifications including HER2 79,80,92,93,108,110,115,
anaplastic lymphoma kinase (ALK)107,109, phosphatase and tensin homolog (PTEN)113,
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AR81,111,113, EGFR79,81, and TMPRSS2:ERG (transmembrane protease serine 2:ETSrelated gene) fusions112. FISH has previously been demonstrated to be a powerful tool in
assessing genomic aberrations in the clinic in primary and metastatic lesions116. Therefore
it is not surprising that this technique has several advantages with regards to CTC
characterization, including: (1) the ability to assess the genomic characteristics of
individual CTCs with visual confirmation; (2) the ability to assign easily defined cutoff/threshold values based on quantifiable ratios of mutation to parent chromosome; and
(3) the availability of automated FISH enumeration systems. As with all techniques,
FISH does present several limitations as well, including: (1) the underlying fact that FISH
interrogates CTCs at the genomic level and therefore results may not truly reflect CTC
phenotype at the functional protein level; and (2) FISH assessment does not provide
information regarding markers whose regulation and/or function rely on epigenetic
changes, phosphorylation, or appropriate protein localization.
Since the results of FISH analysis are not necessarily representative of cellular
phenotype and/or target molecule expression at the protein level, it is likely that FISH
technologies will demonstrate their greatest clinical benefit at the level of disease
prognosis. An example of this is illustrated by Attard et al. (2009), in their
characterization of CTCs for hetero- or homozygous deletion of PTEN113. PTEN is
involved in the phosphoinositide 3-kinase (PI3K) pathway, and inadequate inhibition of
this pathway is associated with high Gleason score and tumor progression in prostate
cancer117,118. Retrospective analysis has demonstrated that PTEN deletion in primary
tumors could stratify patients into different prognostic groups, with hetero- or
homozygous PTEN deletion resulting in shorter time to biochemical relapse following
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surgery and earlier recurrence of disease when compared to those patients without
deletion119. Although not investigated by Attard et al., presumably PTEN status on CTCs
could be utilized in the future for assessing disease progression throughout the course of
disease. By assessing PTEN deletion status in CTCs at baseline or changes in PTEN
status with repeated sampling, patients deemed at high risk of progression could be
recommended for more aggressive treatment options earlier, thereby sparing patients the
morbidity associated with ineffective therapies.

1.3.2.2 Reverse transcription polymerase chain reaction (RTPCR) and reverse transcription quantitative PCR (RTqPCR)
With regards to CTC analysis, RT-PCR has been utilized as a means to both
detect the presence or absence of CTCs as well as a means for specific molecular
characterization. The target transcripts or combinations of transcripts utilized for CTC
detection are predominantly of either epithelial- or tissue-specific origin (i.e., EpCAM,
prostate specific membrane antigen [PSMA], mucin-1 [MUC-1]), and therefore
presumably not transcribed by contaminating leukocytes. However, several groups in the
literature have also published the use of RT-PCR for additional molecular
characterization of these rare cells following CTC enrichment using the immunomagnetic
AdnaTest, including assessment of HER2120, ER120,121, and/or PR120,121, and the CTC chip
and herringbone CTC chip platforms for assessment of TMPRSS2:ERG gene
fusions61,122. One major disadvantage that limits the use of RT-PCR in the
characterization of CTCs is that, although assay sensitivity is high, specificity can be
reduced as a result of illegitimate transcription and false positives. It is because of this
limitation that many have chosen to utilize RT-qPCR in place of traditional RT-PCR for
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CTC characterization. The major advantage that RT-qPCR has over RT-PCR is the
ability to set defined cut-offs, in the form of Cq values, to reduce false positives based on
levels of illegitimate transcription observed in healthy donor blood samples. Utilizing this
approach results in an assay that is not only highly sensitive but also highly specific. As
with RT-PCR, this technique requires prior enrichment for CTCs, with the majority of
studies utilizing the CSS’s Profile Kit 123,124 or a similar immunomagnetic approach125,126
for this task, examining a multitude of prognostic markers including (but not limited to)
HER2, TWIST1, CD133, EGFR, MET and VEGFR2 (vascular endothelial growth factor
receptor 2)112,120,121,123–127. The ability to multiplex this approach and examine multiple
genes at once from a very small initial sample volume is a significant advantage that this
technique offers. In addition, very recent studies have demonstrated that novel PCR
approaches may also be useful in examining microRNA (miRNA) expression,
methylation status, and single nucleotide mutations on CTCs124127,128. However, RT-PCR
and RT-qPCR also have several well recognized disadvantages, including: (1) the
inability to visually confirm that signals obtained are from CTCs and not due to leukocyte
contamination; and (2) analysis of single CTCs is still technologically challenging using
this approach with few studies having published results from patient samples125.
Therefore the majority of studies in the literature rely on pooled samples, which limits the
ability to examine heterogeneity in marker expression across multiple CTCs in a single
sample.
Although both RT-PCR and RT-qPCR have been routinely employed for CTC
detection and characterization112,120,121,123–127, their widespread utility, especially with
regards to detailed molecular characterization of heterogeneous CTC populations, is
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currently restricted by their limited capacity for single-cell analysis. Based on this current
limitation and the availability of a number of other excellent single-cell analysis
techniques, at present we do not foresee this technique to be the primary CTC
characterization choice for predicting targeted therapy response, drug resistance
development, or prognosis in the metastatic setting. However one area in which we
anticipate that these approaches will be very advantageous is the clinical setting of
primary disease. In this clinical setting, blood analysis can yield very low numbers of
CTCs129, with the only way to combat this issue being the collection of larger blood
volumes. Therefore characterization of CTCs in patients with primary disease is
extremely challenging and extra care must be taken in obtaining the greatest amount of
information from this small sample size. PCR approaches are beneficial in this regard as
they allow for the amplification of these small samples and for multi-marker analysis
allowing for the assessment of many potential targets at once. For example, using this
approach, a pooled sample with isolated CTCs from a primary breast cancer patient could
be assessed for expression of HER2, EGFR, ER, PR, and cancer stem cell (CSC) markers
simultaneously, thereby increasing the likelihood of obtaining useful CTC
characterization information that could help direct patient care. Therefore, in the future
we anticipate that RT-PCR and RT-qPCR approaches will demonstrate their greatest
clinical benefit in the setting of early-stage/primary disease, with the potential for
widespread utilization in the metastatic setting based upon the optimization of single-cell
analysis protocols.
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1.3.2.3 Microarrays
Both gene expression arrays and comparative genomic hybridization arrays
(aCGH) have been used to characterize CTCs. Gene expression arrays provide
information about samples at the RNA level, in particular the up/down regulation of
suspected and novel transcripts; while aCGH provides information about samples at the
DNA level, including copy number variations, specific mutational variants, or global
genomic changes. Both techniques require that experimental samples be compared to
appropriate control samples. Depending upon the information that one wishes to obtain,
these controls will vary. For example, to obtain information regarding differences
between CTCs (experimental) and primary/metastatic lesions (control), samples of each
must be obtained and analyzed for differences using pre-determined cut-off values (i.e.,
1.5 fold change). Immunomagnetic enrichment 130–132 and density gradient
centrifugation133 have been the primary means utilized as upstream CTC enrichment
techniques prior to microarray analysis. In the literature, microarrays have been primarily
utilized to look for genetic signatures of aggressive disease and/or the identification of
prognostic/diagnostic biomarkers of disease131–133. In addition, gene or copy number
aberrations have been examined in CTCs130,131,134. The obvious advantages of array-based
analysis include: (1) automated analysis; (2) the ability to set pre-determined cut-off
values, thereby standardizing interpretation; (3) direct comparison of a multitude of
disease settings (e.g., CTCs to primary/metastatic tumors, CTCs in treatment responders
versus non-responders, CTCs at baseline versus following systemic treatment, etc.); and
(4) the potential for novel biomarker identification and/or CTC gene signatures. In
addition to the many advantages that this approach offers, several limitations also exist,
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including: (1) the necessity for specialized bioinformatics personnel for the analysis and
interpretation of the massive amount of data that can be generated using this approach;
(2) the necessity for validation of individually identified genes (gene expression arrays)
using RT-qPCR; (3) cost; (4) difficulty in assessing sample purity to determine if results
are from CTCs or contaminating leukocytes; and (5) limitations with regards to
sensitivity that can make single cell analysis difficult, with few studies reporting on
arrays using individual CTCs134.
In the future, we anticipate that the most useful application of microarraybased approaches for CTC analysis may be in the area of prognosis and patient treatment
stratification using CTC gene signatures. This approach has previously been
demonstrated to be feasible when examining primary tumor tissue in breast cancer using
the FDA approved MammaPrint ® Breast Cancer Test by Agendia (Irvine, CA,
USA)135,136. Using this assay, primary tumor tissue is collected and subjected to array
analysis to stratify patients into poor or good prognosis groups, and recommendations for
aggressive (hormone therapy plus chemotherapy with or without trastuzumab) or less
aggressive (hormone therapy alone) treatment, respectively, can be made based upon the
results. Although this level of personalized care has not yet been met using microarrays
on isolated CTCs, moving forward, microarray approaches may hold similar potential in
this regard.

1.3.2.4 Sequencing
Until recently, the use of sequencing in clinical cancer genomics has presented
significant logistical and economic challenges, due to the slow speed of sample
processing and the high cost of sequencing. However the development of novel, next-
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generation sequencing technologies has renewed enthusiasm in the field of clinical cancer
genomics137–140. Sequencing is an umbrella term that encompasses a number of different
methodologies including traditional gene sequencing approaches (Sanger sequencing;
pyrosequencing; MALDI-TOF sequencing; and targeted sequencing approaches such as
allele-specific RT-PCR and RT-qPCR melting curve analysis) and next-generation
sequencing platforms (Roche 454™ pyrosequncing, Life Technologies SOLiD™
sequencing and Ion Torrent™ sequencing, the Illumina HiSeq™, the Helicos
Heliscope™, Pacific Biosciences PacBioRS™, and Complete Genomics CGA™
platform), all of which have been reviewed previously138–145. Each technique has specific
advantages and disadvantages, with all resulting in the acquisition of the base-by-base
sequence information for a particular genome or target region within that genome.
Sequencing technology is a powerful tool for the analysis of specific genomic
aberrations, especially in the setting of cancer. It is important to note that this technique
can be applied to both genomic DNA and transcribed RNA sequences in the form of
cDNA (complementary DNA). With regards to CTC analysis, sequencing tends to be
applied more frequently at the level of RNA; however several studies have also
interrogated CTCs at the DNA level128,146–148. In general, for processing at the RNA level,
total RNA or mRNA is extracted from CTCs following enrichment using either
immunomagnetic methods149 including the CSS128,150, density gradient centrifugation151,
or microfluidic chip-based152 approaches. Isolated RNA is then reverse transcribed into
cDNA and PCR amplified using primers that are specific to the mutant/target region.
Amplified mutations can be detected using either gel electrophoresis for known length
transcripts, and/or analyzed with one of the several commercially available sequencing
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platforms mentioned above. For processing at the DNA level instead, total DNA is
extracted from CTCs, whole genome amplified using commercially available kits, and
subsequently amplified via PCR using primers that are specific to the mutant/target
region. As with RNA, the PCR product is then analyzed using either gel electrophoresis
or a sequencing platform. Many studies in the literature have utilized these approaches to
interrogate CTCs for a variety of single nucleotide changes in KRAS 128, BRAF128, p53149,
AR152, TMPRSS2:ERG152, PI3KCA (phosphatidylinositol-3-kinase, catalytic subunit
α)148, and EGFR146,147.
One of the first reported studies examining the utility of CTC sequencing was
reported by Maheswaran et al. (2008), in their examination of EGFR activating and drugresistant mutants in non-small-cell lung cancer patients153. Throughout the study this
group not only demonstrated the presence of the primary EGFR activating mutation in
CTCs but also the presence of a T790M mutation known to confer resistance to EGFRtargeted therapies. Using serial CTC analysis, it was additionally observed that the
genotype of captured CTCs evolved throughout treatment and that the prevalence of the
T790M resistance genotype increased throughout the course of therapy, suggesting that
CTCs may be representative of the current state of disease. In a recent report by Heitzer
et al. (2013), single CTCs from metastatic colorectal cancer patients were assessed for a
panel of 68 colorectal cancer-associated genes148. Using this approach, CTCs were
shown to harbor mutations found in both the primary and metastatic lesions, metastatic
lesions alone, and novel mutations not previously observed in either the primary or
metastatic sites (termed private mutations). Subsequent ultra-deep sequencing of primary
and metastatic sites often revealed the presence of these private mutations, previously
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missed by sequencing but captured by CTC analysis. In addition, many of the identified
mutations were for actionable targets, with FDA-approved drugs currently available or
being assessed for targeted treatment in ongoing clinical trials.
The utilization of sequencing for CTC analysis has several advantages over
other characterization techniques including: (1) the ability to identify single nucleotide
alterations, since minor aberrations such as these can result in significant phenotypic
changes and may be important for predicting response to select therapies; (2) results from
sequencing are presented as either positive or negative and do not appear as gradations as
with immunofluorescence; and (3) analysis can be automated to reduce interpreter bias.
Sequencing techniques also have several marked disadvantages including: (1) limitations
with regards to sensitivity that make single cell analysis difficult, with many groups
reporting the need for a minimum of 50 or more CTCs for adequate results128,149; and (2)
leukocyte contamination and the inability to visually confirm the source of amplified
transcripts can lead to false positive/negative results. However, several groups have
attempted to utilize single cell micromanipulation (selecting for CTCs based on
immunofluorescent staining prior to the collection of DNA/RNA) 146 and/or adapted PCR
protocols (e.g., nested PCR)128 to combat these issues with promising results.
When considering clinical cancer genomics moving forward, care must be
taken in discriminating driver mutations from so-called passenger mutations. As genomic
instability is an underlying characteristic of cancer 154,155 one cannot assume that all
mutations in a given sample are of equal importance. This is well exemplified by the
great clinical benefit of trastuzumab for HER2-amplication in breast and gastric cancers
but the lack of this benefit in ovarian and endometrial cancers137,156–158. In addition, the
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identification of actionable/druggable targets must be at the forefront of clinical cancer
genomics. There is concern in this field that the genotyping of tumor tissue biopsies
and/or CTCs may not be capturing functionally relevant information159,160. The reason for
this concern centers on the fact that the cellular genotype is not necessarily reflective of
the cellular phenotype and that sample contamination with normal tissue can lead to false
negative results. We anticipate that the molecular characterization of CTCs will help to
alleviate some of these concerns. Firstly, Heitzer et al. (2013), have described a CTC
sequencing approach for single-cell analysis, suggesting that contamination with normal
cells may be reduced. Secondly, although the sequencing of CTCs does not change the
fact that the readout is still at the level of the genome, we anticipate that, especially in
cases in which metastatic lesions are inaccessible, that CTC sequencing will strengthen
conclusions regarding mutations that are drivers versus those that are passengers as they
may be present not only in the primary/metastatic lesion but also in the cells that were
able to escape into the circulation. The conserved nature of these mutations may suggest
an important functional contribution to disease progression. In addition, as demonstrated
by Heitzer et al., the sequencing of CTCs may identify relevant private mutations, present
but not detected in tumor tissue148.
In the future we anticipate that the greatest clinical benefit of the genomic
sequencing of CTCs will be achieved when this approach is utilized to assess the
genomic evolution of disease within a patient over time, and to quickly identify
actionable target mutations that would make patients eligible for ongoing clinical trials,
as demonstrated by Heitzer et al.148. As it is still unclear if genomic sequencing will
provide functionally relevant information that can be applied for predicting targeted
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treatment response and overall patient outcomes, we foresee that this approach, at least in
the near future, will likely not be utilized in isolation and instead used in combination
with other phenotyping platforms such that firm conclusions can be drawn regarding
clinical treatment decision-making.

1.3.3

General considerations for CTC characterization
Although there are currently a number of exciting methodologies available for

CTC characterization and even more in development, careful consideration needs to be
placed on which technique will produce optimal results for the molecular characteristic(s)
under investigation, as it is likely that different aberrations will require different
approaches. For example, the presence or absence of a particular marker may be
sufficient for some targets, (e.g., estrogen/progesterone receptors) 161, however others may
require the presence of particular single nucleotide substitutions (e.g., BCR-ABL
mutations which confer drug resistance) 162, copy-number alterations (e.g., AR
amplification)163, aberrant localization (e.g., BRCA1 absent/reduced nuclear expression and
association with aggressive phenotypes)164, or specific functional activation (AKT
phosphorylation)165,166 in order to draw any conclusions regarding novel treatment
options or patient outcomes. As not all approaches can provide this information, care
must be taken in choosing the appropriate molecular characterization technique or
combinations of techniques for each target. In addition, once chosen, the appropriate
technique(s) needs to be validated and standardized before it can be considered for
routine use in the clinic. This standardization needs to be implemented at both the level of
procedure as well as at the level of interpretation. For example, data must be interpreted
to determine if analysis of single cells is necessary or if a pooled result from all CTCs in
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an individual will suffice. If a single cell approach is chosen, clear-cut criteria must be set
with regards to how many cells should be characterized with appropriate minimum or
maximum values set. In addition, what constitutes a positive or negative signal must be
appropriately defined; if the system is more graduated in nature (i.e., low, medium, or
high expression) these gradations need to be specifically defined, and if necessary
automated systems need to be implemented to ensure that results are the same across
laboratories. The considerations discussed in this section can all have a dramatic impact
on the results obtained from individual studies and clinical trials. Therefore when
comparing the current literature one must take into account the variety of approaches
utilized and the effect these approaches may have on the reported results. These
considerations and others have been extensively reviewed previously55,167–169.

1.3.4

Current limitations of CTC molecular characterization
The most prominent limitation that currently exists in the molecular

characterization of CTCs is the low number of CTCs collected, especially from those
patients with early-stage disease. These cells appear to be very delicate in nature and can
be easily lost or destroyed during processing110. Considering that CTC populations tend
to be quite heterogeneous, it is very difficult to draw conclusions about treatment if only
a small population of cells are available for analysis. To combat this issue, research has
begun to focus on the development of novel technologies for enhanced CTC capture as
well as focusing on CTC characterization on-system, thereby reducing CTC loss when
switching techniques. However, thus far the CSS continues to be the only platform that is
FDA-approved for use in the clinic.
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1.3.5

Clinical significance of CTC molecular characterization
Although a number of different molecular characteristics have been

investigated on CTCs across numerous epithelial cancers, the aberration that has been
most widely examined is HER2, an EGFR, known to be over-expressed in a subset of
cancer patients. Currently the expression of HER2 can be investigated on individual
CTCs captured by the CSS. Based on the results of such an investigation, it may be
possible for patients to get access to HER2 targeting therapies (e.g., Herceptin) that are
currently reserved for patients whose primary tumors express this protein170. In this way,
CTCs could act as a liquid biopsy, informing physicians of disease evolution earlier then
currently utilized methods, and thereby ultimately improving patient care (Figure 1.2). In
addition, the characterization of CTCs could identify new targets for novel therapies and
enable a better understanding of the mechanisms that allow these cells to escape into the
circulation, extravasate into distant tissue and form clinically relevant secondary
metastases.
Although promising from a research perspective, thus far data supporting the
clinical significance of the molecular characterization of CTCs is inconclusive. Several
retrospective studies examining treatment outcomes in patients with HER2- primary
tumors but with HER2+ CTCs who have received Her2-targeting agents have
demonstrated mixed results82,88,171,172. Thus far, only one prospective clinical trial
examining the utility of treatment stratification based on the HER2 status of CTCs has
been completed89. This multicentre phase II trial aimed to evaluate the use of single-agent
lapatinib (targeting both HER2 and EGFR) in metastatic breast cancer patients with
HER2− primary tumors and HER2+ CTCs. Of the seven patients enrolled, one
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experienced an adverse event during the treatment period and discontinued treatment.
The other six patients demonstrated signs of progressive disease and therefore also
discontinued treatment. Following these results the study was terminated. However,
several upcoming trials are set to continue to investigate the HER2 status of CTCs and
the use of CTCs as a liquid biopsy, including the TREAT CTC173, DETECT III174,
CirCé01175, and the COMETI P2176 trials177.
The inconclusive results described here raise questions about our current
understanding of the biology of these rare cells. CTC research is unique in that it has
largely utilized a bedside-to-benchtop approach. This method, unlike benchtop-to-bedside
research, which can often take years to impact patient care, has allowed CTCs quick entry
into the clinical setting. However, physicians are hesitant to use results from CTC
analysis in patient treatment decision-making due to a lack of understanding of their
underlying biology. Therefore appropriate pre-clinical mouse models of metastasis and
complementary CTC analysis techniques must be utilized in order to properly identify the
current limitations that exist with CTC detection, enumeration, and characterization
technologies and to further investigate these outstanding biological questions. In addition,
a better understanding of CTC biology may shed light on which CTCs are the most
important to study and characterize and therefore guide strategies on how to utilize CTCs
most effectively in a clinical setting.

1.4

Epithelial-to-mesenchymal transition (EMT)
It is curious to note that in up to 35% of patients with various metastatic

cancers, CTCs are undetectable despite the presence of widespread systemic disease178.
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Figure 1.2. An overview of the current and potential patient outcomes following
the incorporation of CTC molecular characterization into the clinic. The majority of
cancer-related deaths result from the development of metastatic disease. Although
metastatic lesions can be highly heterogeneous compared to their primary tumor
counterparts, current treatment decision making is typically based on characteristics of
the primary tumor, as routine metastatic biopsy is not clinically feasible. CTCs have
been suggested as a surrogate to metastatic biopsy. Characterization of therapeutic
target molecules such as HER2 on CTCs may increase the availability of targeted
therapies (i.e., the HER2 targeting agent Herceptin) to patients previously considered
ineligible based upon the characteristics of their primary tumor. Ultimately, utilization
of CTC analysis and characterization in the clinic may predict response to targeted
therapies and improve patient outcomes.
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This lack of detection has been proposed to be a result of the epithelial-to-mesenchymal
transition (EMT), a process first described for its essential role in embryo
development179. The process of EMT involves the conversion of epithelial cells to
mesenchymal cells via significant phenotypic changes resulting in the loss of cell-cell
adhesion, loss of cell polarity, and the acquisition of a highly invasive and motile
phenotype necessary for appropriate embryogenesis180–182. The acquisition of this
phenotype is only accomplished through significant remodeling of epithelial cells,
specifically via reduced expression of various epithelial markers (i.e., E-cadherin and
EpCAM) and a corresponding increase in mesenchymal markers (i.e., N-cadherin and
vimentin)72,182–185. This developmental process is thought to be reactivated in some
epithelial cancers, thus allowing for enhanced tumor motility and an increased ability to
invade and metastasize to distant organs (Figure 1.3)186,187. Once reaching a suitable
secondary site, it is believed that the reverse process, mesenchymal-to-epithelial
transition (MET), may be required to initiate tumor growth. In addition to this enhanced
migratory phenotype, EMT has also been associated with increased therapy resistance 188–
190

.
The mechanisms of EMT in cancer are extremely complex and involve a

number of identified and yet unidentified molecular players. In brief, it is believed that
the process of EMT can be greatly influenced by EMT-inducers in the tumor
microenvironment, including a number of growth factors such as epidermal growth factor
(EGF), hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), plateletderived growth factor (PDGF), fibroblast growth factor (FGF), and transforming growth
factor β (TGF-β)191–195. These paracrine (and sometimes autocrine) signals are then
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converted into intracellular signals that will eventually result in specific EMT-related
phenotypic changes (i.e., enhanced cellular migration, invasion, and cell survival). In
general, thus far three intracellular mechanisms have been recognized as controllers that
respond to EMT-inductive stimuli. Specifically, (1) signal transduction cascades (i.e.,
Wnt signaling pathway and AR signaling), (2) EMT-related transcription factors (i.e.,
Snail, Twist, and ZEB family members), and (3) epigenetic mechanisms (i.e., chromatin
remodeling, DNA methylation, and miRNA)191.

1.4.1

Clinical evidence and implications of EMT in prostate
cancer
Although EMT has been extensively recognized in in vitro and in vivo model

systems, due to the plastic nature of this process, it has been difficult to validate in
clinical samples. Evidence of EMT in PCa, however, has been demonstrated in a number
of studies. The aberrant expression and/or downregulation of the epithelial marker Ecadherin has been the most extensively studied and demonstrated to correlate with
advanced Gleason score, tumor grade, disease stage, and N-cadherin
overexpression191,196–200. In addition, reduction/aberrant expression of this marker is
prognostic, predicting for progression following radical prostatectomy, the presence of
metastases, and shorter overall survival199. Expression changes in various mesenchymal
markers and EMT transcription factors, such as N-cadherin, vimentin, Twist, Zeb1, have
also been demonstrated in clinical samples. Specifically, overexpression of N-cadherin,
Twist, and Zeb1 have been associated with increasing Gleason scores and shown to be
absent or reduced in normal and/or benign disease194,197,201,202. Additionally, vimentin has
been shown to be prognostic in primary PCa, predicting for shorter time to biochemical
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Figure 1.3. Contribution of the epithelial-to-mesenchymal transition (EMT) to
prostate cancer progression and metastasis. The developmental process of epithelialto-mesenchymal transition (EMT) has been proposed to be reactivated during cancer
progression and required for the intravasation of tumour cells through a basement
membrane into the circulation. The enhanced invasive phenotype exhibited by cells that
have undergone EMT is due, in part, to significant remodelling of the cytoskeleton,
including downregulation of various epithelial proteins (i.e., E-cadherin and EpCAM) and
upregulation of various mesenchymal proteins (i.e., N-cadherin and vimentin). This
process exists on a continuum from purely epithelial --> hybrid expression --> purely
mesenchymal, thereby potentially generating circulating tumour cells (CTCs) with highly
heterogeneous EMT phenotypes. Upon reaching an appropriate secondary site, CTCs may
extravasate from the bloodstream into the surrounding tissue. However it has been
proposed that disseminated tumour cells must undergo the reverse process of
mesenchymal-to-epithelial transition (MET) in order to establish micro- and macrometastases at secondary sites, during which cells downregulate expression of
mesenchymal proteins and upregulate expression of epithelial proteins.
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recurrence and has also been associated with the presence of bone metastases and poorly
differentiated tumors203,204.

1.4.2

Clinical evidence and implications of EMT in CTCs
Thus far the majority of EMT characterization in CTCs has been performed in

cells that have been enriched for, or detected using, epithelial-based strategies, likely due
to a lack of appropriate technologies for selecting highly mesenchymal CTCs. With this
in mind, several studies (especially in breast cancer) have detected the expression of
various mesenchymal markers in both early-stage (I-III) and metastatic disease.
Specifically, the expression (mRNA and/or protein) of vimentin205–209, fibronectin205,207,
Twist1206,210–214, AKT2211,212, PI3K211,212, Slug213, FoxC2213, Snail1214, Zeb162,214, Ecadherin215, N-cadherin209, and many others have been assessed in these patient cohorts.
A general trend that exists in the current literature is that CTCs with a hybrid EMT
phenotype are more likely to be detected in patients with metastatic disease and/or show
higher expression of mesenchymal markers compared to those in early-stage
disease205,206,210. Additionally, it has been demonstrated that in both early-stage and
metastatic patients that these hybrid CTCs are not rare, and represent a significant portion
of the detectable CTCs within an individual patients205–207,209–212,214–216. These hybrid
CTCs are also often co-expressed with various stem cell markers including
ALDH1205,210,211,214, CD44211, and CD133209,214,215. A small number of published studies
have also attempted to characterize CTCs that are undetectable by current epithelialbased capture techniques, by examining patients with CTC-negative disease205,207,214.
Although several studies have reported the detection of various mesenchymal markers in

40

these patients, without reliable mesenchymal CTC markers, these results are difficult to
interpret as they may represent false positives.
Of particular interest with regards to EMT characterization of CTCs is the
prognostic value of cells with a hybrid epithelial-mesenchymal phenotype. Thus far, only
a small number of studies have reported such information. Specifically, Gradilone et al.
(2011) noted that metastatic breast cancer patients with CTCs positive for the expression
of either vimentin and/or fibronectin (EMT +) showed worse prognosis compared to those
that did not (EMT-), and compared to patients with CK+EMT- disease207. Interestingly,
this study did not report differences in prognosis between patients with CK-EMT+ and
CK+EMT+ CTCs. In contrast, Pal et al. (2014), have reported that CTC fragments
(CK+DAPI+/-CD45- events) in a small group of high-risk localized prostate cancer
patients (n=35) isolated using the CSS and characterized for E-cadherin and/or CD133
positivity were prognostic of BCF at 1 year following radical prostatectomy215. Finally,
the relationship of EMT+ CTCs and treatment resistance is a growing area of research,
however thus far the results are only correlative in nature, with EMT phenotypes
appearing to be associated with disease progression and treatment response 216.

1.5

Overall Rationale
The CSS not only provides a minimally invasive means of patient sample

collection and CTC enumeration but also allows for limited molecular characterization
of CTCs. Characterization of isolated CTCs could lead to a better understanding of the
biological mechanisms that underlie metastasis, aid in the identification of novel targets
for new therapies, and ultimately help to direct patient care. In addition to exploring the

41

molecular characteristics of CTCs, we also aim to investigate several areas of research
that have been largely unexplored, including the potential role of CTCs in early-stage
disease and therapy response, as well as exploiting an in vivo model system to gain a
better understanding of the biology of CTCs and their contribution to the metastatic
cascade.

1.6

Overall Goal and Objectives
The overall goal of this thesis is to address the need for improved

understanding of the significance of CTCs in early stage prostate cancer, provide novel
tools for assessing CTC characteristics in the clinic, and develop a better understanding
of CTC biology and its contribution to metastasis.

In order to assess this goal, the specific objectives of this thesis are:
1. To investigate CTCs in post-surgery prostate cancer patients receiving adjuvant
and salvage radiotherapy.
2. To develop and optimize new techniques that would allow for molecular
characterization of CTCs on the regulatory-approved CSS.
3. To investigate the effects of epithelial-to-mesenchymal (EMT) on CTC
generation and metastasis.
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Chapter 2
Circulating tumor cells in prostate cancer patients
receiving salvage radiotherapy
A version of this chapter has been published:
Lowes LE, Lock M, Rodrigues G, D'Souza D, Bauman G, Ahmad B, Venkatesan V,
Allan AL, and Sexton T. Clin Transl Oncol. 2012;14(2):150-6.1111

Abstract
Within 10 years of radical prostatectomy (RP), up to 30% of prostate cancer
(PCa) patients will have a rise in prostate-specific antigen (PSA), requiring radiation
therapy (RT). However, with current technology, distinction between local and distant
recurrent PCa is not possible. This lack of an accurate test constrains the decision
whether to offer systemic versus local treatment. We hypothesize tests for detecting
circulating tumor cells (CTCs) within the blood may assist with clinical decision-making
and in this pilot study we investigated whether CTCs could be detected in this patient
population using the CellSearch® system (CSS). Blood samples were collected from PCa
patients (n=26) prior to RT and 3 months following completion of RT. Samples were
analyzed for PSA level via immunoassay and CTC number using the CSS. CTCs could
be detected in this patient population and following RT CTCs appeared to decrease.
However, no association was observed between a higher PSA and an increased number of
CTCs pre- or post-RT. Interestingly, patients who failed RT trended toward an
increased/unchanged number of CTCs following RT versus a decreased number in
patients with RT response. Our results demonstrate that CTCs can be detected in earlystage PCa, and suggest the possibility that post-treatment reduction in CTC levels may be
indicative of RT response . Future studies are aimed at evaluating CTCs in a larger cohort
of patients to validate our preliminary findings and further investigate the prognostic
value of CTCs in this patient population.
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2.1

Introduction
Prostate cancer (PCa) is the second most commonly diagnosed cancer and the

third leading cause of cancer-related death in men in Canada1. Upon diagnosis, one
common treatment option for men under the age of 70 with early-stage, localized disease
is surgical removal of the prostate via radical prostatectomy (RP)2. Following this
surgical intervention, prostate-specific antigen (PSA) testing is utilized to monitor
patients for signs of recurrence. Up to 30% of these early-stage patients will have a rise in
PSA within 10 years of surgery and require treatment for residual disease3,4. Based on
patient factors and tumor characteristics such as Gleason score, PSA doubling time
(PSADT), and time to biochemical recurrence following RP, patients are recommended
for surveillance, potentially curative radiation therapy (RT), or palliative hormonal
therapy5. Patients who experience a PSA recurrence following RP present a unique
problem to physicians, as current imaging technologies are unable to determine precisely
where recurrent PCa is located. If the recurrent disease is localized to the prostate bed,
salvage RT could potentially cure these patients. However, if the disease has spread
beyond the prostate bed and become systemic, local prostate bed radiation may not be
sufficient and systemic therapy, such as hormonal treatment may be warranted 5.
Therefore the ability to discriminate between these 2 patient cohorts is essential in order
to aid physicians in the effective treatment of patients who will benefit from RT, and
avoid unnecessary RT-associated morbidities in those patients for which treatment would
likely not provide benefit 6.
Systemic metastatic disease has been shown to correlate with the presence of
circulating tumor cells (CTCs) in the blood7. In metastatic PCa, de Bono et al. (2008)
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have shown that the presence of five or more CTCs in 7.5mL of blood correlates with a
significantly lower rate of overall survival, compared to those individuals who have less
than five CTCs in the same blood volume8. Several methods have been utilized to detect
CTCs, including polymerase chain reaction (PCR)-based assays, density-gradient
centrifugation, flow cytometry (FCM), and microchip techniques9. All of these
techniques have unique advantages and disadvantages, however one commonality they
all share is a lack of standardization; a necessity for use in the clinical setting. The
development of the the CellSearch® system (CSS; Janssen Diagnostics, Raritan, NJ)
provides a standardized method for the sensitive detection and quantification of these rare
CTCs in human blood using fluorescence microscopy and immunology based
techniques8,10,11.
The CSS has been approved by the U.S. Food and Drug Administration (FDA)
and Health Canada for diagnostic and/or prognostic use in metastatic breast, prostate, and
colorectal cancer. However, the role of CTCs and the use of the CSS in non-metastatic
PCa remains unclear. A study by Tombal et al. (2003) using a reverse transcriptionpolymerase chain reaction (RT-PCR) approach suggests that the presence of CTCs in the
blood of patients following RP is an indication of micrometastatic disease and may
predict a less favourable response to salvage RT 12. We hypothesize the use of the
clinically approved, standardized CSS to detect CTCs within the blood may act as a
clinically meaningful endpoint and be helpful for assisting with clinical decision-making
in this patient population. In the current pilot study, we utilized the CSS to determine if
CTCs are detectable in PCa patients with rising PSA levels post-prostatectomy, who have
consented to salvage RT.
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2.2

Materials and methods

2.2.1

Patient and control population
Studies were carried out under protocol # 15569E approved by the University

of Western Ontario’s Health Sciences Research Ethics Board (Appendix 1). Twenty-six
PCa patients with a rising PSA following RP who consented to salvage RT were enrolled
in this study following informed consent. To be included in this study, patients were
required to have a PSA value > 0.1 ng/mL and a minimum of three PSA values taken one
month apart, in order to calculate doubling time. Pre-RT bone scan and CT scan were
performed at the treating physicians’ discretion. Blood was drawn before radiation and
baseline PSA and CTC levels were determined using standard clinical immunoassay for
PSA and the CSS for CTC analysis as described below. Baseline characteristics of each
patient were noted, including pre-radiation PSA, Gleason score, pathologic T (pT) stage,
presence of extracapsular extension (ECE), presence of seminal vesicle invasion (SVI),
margin status, lymph node status, months free from relapse, and PSADT. All patients
were treated with radiation to the prostate bed as per Radiation Therapy Oncology Group
(RTOG) guidelines with 6600 cGy in 33 fractions using a 5 field intensity modulated
radiation therapy (IMRT) technique. Three months following the completion of RT, a
second set of blood samples were drawn and follow-up PSA and CTC levels were
determined.
Blood from 7 healthy individuals was also collected following informed
consent and analyzed for CTCs as a negative control. In addition, blood from 4
biochemically controlled patients with undetectable PSA for a minimum of 3 years was
collected following informed consent and assessed for PSA and CTC levels. This cohort
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consisted of two post-RP patients and two post-salvage RT patients. Blood was collected
at enrolment and at a 3 month follow-up visit for PSA and CTC analysis.

2.2.2

PSA determination
Blood samples were collected into a 6mL red topped Vacutainer® venous blood

collection tube and analyzed for total PSA concentration by the London Health Sciences
Centre Endocrinology Laboratory on the AutoDelfia using a time resolved
fluorimmunoassay from Perkin Elmer.

2.2.3

Circulating tumor cell enumeration
Blood samples were collected into CellSave Preservative tubes (Janssen

Diagnostics) and CTCs were enumerated using the CSS as per the manufacturer’s
directions within 96 hours of sample collection13. The CSS consists of two components,
(1) the CellTracks™ AutoPrep system, which automates the blood sample preparation,
and (2) the CellTracks™ Analyzer II, which scans the prepared samples. The AutoPrep
system uses an antibody mediated, ferrofluid-based magnetic separation technique and
differential staining with fluorescent particles to distinguish CTCs from contaminating
leukocytes in blood samples (Figure 2.1). Initially, an EpCAM (epithelial cell adhesion
molecule) selection is performed using anti-EpCAM antibodies conjugated to iron
nanoparticles incubated in a magnet. The only EpCAM+ cells in the blood should be the
tumor cells. The remainder of the fluid is then aspirated from the sample, selected tumor
cells are resuspended, and differential staining antibodies are added to the samples.
Samples are then incubated in a magnetic cartridge called a MagNest™ and scanned
using the CellTracks™ Analyzer II. Samples are scanned using three different filters,
each with the exposure time optimized to the appropriate fluorescent particle. CTCs are
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Figure 2.1. Schematic overview of the step-by-step processing of CTC blood
samples using the CellSearch® system (Source: Immunicon [adapted]). Following
sample collection into a CellSave tube, 7.5ml of blood is mixed with dilution buffer and
centrifuged (800g x 10 min) to collect blood and tumour cells. The centrifuged sample is
then loaded onto the CellSearch® AutoPrep, the plasma is aspirated, and anti-EpCAM
ferrofluid is added. Following a magnetic incubation, unlabelled cells are aspirated and the
remaining sample is permeabilized and incubated with the appropriate staining reagents
(CK/CD45/DAPI). The completed sample is then transferred to a MagNest® and
incubated for a minimum of 20 min (up to 24 hours). The MagNest device is then loaded
onto the CellSearch Analyzer for sample scanning and subsequent qualitative examination
by a trained operator (bottom panel).
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identified as events bound by anti-EpCAM and stained with anti-pan-cytokeratin (CK)phycoerythrin (PE) (CK 8, 18 and 19 are characteristic of epithelial cells), and the DNA
stain 4’, 6-diamidino-2-phenylindole (DAPI). Leukocytes are identified as events bound
by anti-CD45-allophycocyanin (APC) and DAPI. After the scan is complete, a gallery of
computer-defined, potential tumor cells is presented. These galleries were reviewed by 3
independent and blinded observers, and CTCs were confirmed via qualitative analysis
based on the differential staining criteria discussed above. If any discrepancies in the
number of selected events were noted between observers, these events were discussed
until a consensus was reached.

2.2.4

Statistical analysis
Mean and standard deviations were calculated for the following variables: age,

PSA, PSADT and Gleason score. The mean and standard deviations were compared with
CTC count (0 vs >0 and <2 vs ≥2) using the Independent-Samples t-test procedure.
Fisher’s Exact test was used to compare CTC count (0 vs >0 and <2 vs ≥2) with pT stage,
presence of ECE, SVI and margin status. In addition, the Pearson Correlation Coefficient
and the Spearman Correlation Coefficient were used to look for associations between
age, PSADT, Gleason score, change in PSA (pre-RT vs post-RT) and change in CTC
number (pre-RT vs post-RT). CTC cut-off values were chosen based on results
suggesting that CTC levels in early-stage PCa patients appear to be lower than those
observed in metastatic populations14.
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2.3

Results
Blood samples from 7 healthy control donors and 4 biochemically controlled

patients were processed for CTCs using the CSS. These biochemically controlled patients
all underwent a RP, 2 received RT a minimum of 3 years prior to study entry, and all had
undetectable PSA values for at least 3 years. Characteristics of these patients are
summarized in Table 2.1. All biochemically controlled patients had pT2 disease and the
two patients who received RT had positive margins. Blood sample analysis showed that
CTCs were not present in the circulation of healthy control donors. However,
interestingly, CTCs were detected in PCa patients with undetectable PSA, and CTC
levels appeared to fluctuate over time (Figure 2.2A).
Twenty-six PCa patients were enrolled in this pilot study with characteristics as
shown in Table 2.2. Sample analysis showed that CTCs could be detected in 73% of
patients in this population pre-RT (Figure 2.2B). pT stage, Gleason grade, ECE, SVI,
margin status, and PSADT did not appear to be statistically different between pre-RT
patients with negative (0 CTC) versus positive (≥1 CTC) CTC status (Table 2.3; p values
= 0.56, 0.51, 0.67, 0.63, 0.41, and 0.79 respectively).
Following RT there appeared to be a trend toward decreased CTCs, although
the difference from baseline was not statistically significant (Figure 2.2B). As seen with
pre-RT characteristics, pT stage, Gleason grade, ECE, SVI, margin status, and PSADT
were not statistically different between patients with negative versus positive CTC status
post-RT (Table 2.4; p values = 0.15, 1.0, 1.0, 0.08, 0.71, and 0.78 respectively).
Patients were subsequently divided into two groups, those who demonstrated
biochemical response to therapy (i.e. a decreasing or unchanged PSA value post-RT) and
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Table 2.1. Biochemically controlled population characteristics.
N (%)
pT Stage:
T2
4 (100)
T3a
0 (0)
T3b
0 (0)
Gleason Score:
6 (3+3)
2 (50)
7 (3+4)
1 (25)
7 (4+3)
0 (0)
8 (4+4)
0 (0)
8 (5+3)
1 (25)
9 (4+5)
0 (0)
Extracapsular Extension:
Negative
4 (100)
Positive
0 (0)
Seminal Vesicle Invasion:
Negative
4 (100)
Positive
0 (0)
Margins:
Negative (RP only)
2 (50)
Positive (RP and RT)
2 (50)
1
PSA Doubling Time :
≤ 10 Months
0 (0)
> 10 Months
1 (100)
CTC Detection Rate:
Day 0
4 (100)
Day 90
4 (100)
1: Only one patient's PSADT was measured as the rest of the patients were either in the
adjuvant setting or did not receive RT.
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Figure 2.2. CTC distribution in control donors and patient blood samples. (A)
CTC distribution of healthy donors at day 0 (n=7) and biochemically controlled
donors (n=4), at day 0 and 90. (B) CTC distribution of patients pre- and post-RT.
Circles and horizontal lines represent individual donors and medians respectively.
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Table 2.2. Study population characteristics.
N (%)
pT Stage:
T2
11 (42)
T3a
8 (31)
T3b
7 (27)
Gleason Score1:
6 (3+3)
4 (16)
7 (3+4)
10 (40)
7 (4+3)
8 (32)
8 (4+4)
1 (4)
8 (5+3)
1 (4)
9 (4+5)
1 (4)
Extracapsular Extension:
Negative
14 (54)
Positive
12 (46)
Seminal Vesicle Invasion:
Negative
20 (77)
Positive
6 (23)
Margins:
Negative
14 (54)
Positive
12 (46)
PSA Doubling Time:
≤ 10 Months
13 (50)
> 10 Months
13 (50)
CTC Detection Rate:
Pre-RT2
19 (73)
Post-RT3
14 (54)
1: One patient had a Gleason score of 7 with unknown primary and secondary scores and
therefore was not included in Gleason score percentage calculation.
2 :Due to poor blood draw 1 patient had 6.7 mL of blood for CTC
analysis.
3: Due to poor blood draw 2 patients had 4.6 mL or 7.1 mL of
blood for CTC analysis.
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Table 2.3. Patient characteristics pre-radiation therapy.
Pre-RT CTC Status
Negative
(0 CTC)
N (%)

Positive
(≥1 CTC)
N (%)

p value

pT Stage:
T2
2 (29)
9 (47)
0.56
T3a
2 (29)
6 (32)
T3b
3 (43)
4 (21)
1
Gleason Score :
6 (3+3)
0 (0)
4 (22)
7 (3+4)
3 (43)
7 (39)
7 (4+3)
3 (43)
5 (28)
0.512
8 (4+4)
1 (14)
0 (0)
8 (5+3)
0 (0)
1 (6)
9 (4+5)
0 (0)
1 (6)
Extracapsular Extension:
Negative
4 (57)
10 (53)
0.67
Positive
3 (43)
9 (47)
Seminal Vesicle Invasion:
Negative
5 (71)
15 (79)
0.63
Positive
2 (29)
4 (21)
Margins:
Negative (RP only)
2 (29)
12 (63)
0.41
Positive (RP and RT)
5 (71)
7 (37)
PSA Doubling Time:
≤ 10 Months
5 (71)
8 (42)
0.79
> 10 Months
2 (29)
11 (58)
Statistical analysis were performed using a t test (Gleason score and PSADT) or Fisher's
exact test (pT stage, ECE, SVI, Margins, CTC detection rate).
1: One patient (positive for CTCs pre-RT) had a Gleason score of 7 with unknown
primary and secondary scores and therefore was not included in Gleason score
percentage calculation.
2 :Analyzed as continuous variable.
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Table 2.4. Patient characteristics post-radiation therapy.
Post-RT CTC Status
Negative
(0 CTC)
N (%)

Positive
(≥1 CTC)
N (%)

p value

pT Stage:
T2
6 (59)
5 (36)
0.15
T3a
5 (42)
3 (21)
T3b
1 (8)
6 (43)
1
Gleason Score :
6 (3+3)
2 (18)
2 (14)
7 (3+4)
4 (36)
6 (43)
7 (4+3)
4 (36)
4 (29)
1.02
8 (4+4)
0 (0)
1 (7)
8 (5+3)
0 (0)
1 (7)
9 (4+5)
1 (9)
0 (0)
Extracapsular Extension:
Negative
6 (50)
8 (57)
1.0
Positive
6 (50)
6 (43)
Seminal Vesicle Invasion:
Negative
11 (92)
9 (64)
0.08
Positive
1 (8)
5 (36)
Margins:
Negative
7 (58)
7 (50)
0.71
Positive
5 (42)
7 (50)
PSA Doubling Time:
≤ 10 Months
5 (42)
8 (57)
0.78
> 10 Months
7 (58)
6 (43)
Statistical analysis were performed using a t test (Gleason score and PSADT) or Fisher's
exact test (pT stage, ECE, SVI, Margins, CTC detection rate).
1: One patient (negative for CTCs post-RT) had a Gleason score of 7 with unknown
primary and secondary scores and therefore was not included in Gleason score
percentage calculation.
2: Analyzed as continuous variable.
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those who demonstrated biochemical failure (BCF) to therapy (i.e. an increasing PSA
post-RT). Patients with biochemical response to therapy (n=21) were more likely to have
a decrease in CTC number following RT versus patients with BCF (n=5) who were more
likely to have an increase or no change in CTC number following RT (Figure 2.3),
although the differences did not reach statistical significance. Interestingly, of the patients
that demonstrated BCF following RT, 80% had a short PSADT (≤ 10 months) and/or
negative surgical margins, both of which are well established risk factors for systemic
failure and predict for failure post-RT. Furthermore, the pre-RT PSA did not appear to
predict for failure as the mean PSA value (0.43 ng/mL) was similar to that of the patients
who responded to radiation (0.53 ng/mL; Table 2.5)15.

2.4

Discussion
Current imaging technologies are unable to differentiate local from systemic

failure following RP. Regardless, these patients often receive RT because we currently
lack technology that can distinguish those who will benefit from this therapy versus those
who will not. However, in up to 30% of these patients the cancer will have spread beyond
the prostate bed and RT will not be beneficial. Therefore the ability to distinguish these
patient groups before the initiation of RT is essential. In this pilot study we sought to
investigate whether CTCs could be detected in this patient population prior to the
initiation of RT using the CSS.
Although this patient population had low pre-RT PSA values, we were
successful in detecting CTCs in over 70% of patients sampled and in all of our control
patients with undetectable PSA values. This indicated that the CSS is sensitive enough to
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Figure 2.3. Change in CTCs following radiation therapy in relation to treatment
response. Comparison of the change in CTCs following RT in patients with
biochemical response (decreasing or unchanged PSA following RT; n=21) and
biochemical failure (a rising PSA following RT; n=5).
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Table 2.5. Characteristics of patients with evidence of biochemical failure
N (%)
pT Stage:
T2
T3a
T3b
Gleason Score:
6 (3+3)
7 (3+4)
7 (4+3)
8 (4+4)
8 (5+3)
9 (4+5)
Extracapsular Extension:
Negative
Positive
Seminal Vesicle Invasion:
Negative
Positive
Margins:
Negative
Positive
PSA Doubling Time:
≤ 10 Months
> 10 Months
CTC Detection Rate:
Pre-RT
Post-RT

2 (40)
2 (40)
1 (20)
0 (0)
3 (60)
2 (40)
0 (0)
0 (0)
0 (0)
3 (60)
2 (40)
4 (80)
1 (20)
4 (80)
1 (20)
4 (80)
1 (20)
3 (60)
3 (60)
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detect very small numbers of CTCs, is more sensitive than PSA and could conceivably be
used as a prognostic tool and/or a clinically meaningful surrogate endpoint in PCa
patients with early recurrence or in patients with localized early disease. Tombal et al.
(2003) were also able to detect CTCs in a similar patient cohort using an RT-PCR
approach to analyze PSA mRNA as a marker of circulating prostate cells, although at a
lower frequency (34%) than that observed in our study12. This suggests that detection of
PSA mRNA may not be as sensitive and/or as accurate as detection with the CSS.
Although the CSS is able to detect 1 CTC in 7.5mL of blood, the majority of patients on
our study (73%) had 2 or less CTCs. Variability of CTC number between samples
increases significantly as the number of CTCs approaches zero, therefore larger patient
numbers or sample sizes may be required in order to properly enumerate CTCs in
samples with low CTC yields16. The presence of CTCs in patients with no clinical or
biochemical evidence of disease, as evidenced in our biochemically controlled patients,
makes one wonder about the biology of these CTCs and their metastatic potential. It is
also important to note that due to the epithelial-to-mesenchymal transition that often
occurs in invasive carcinomas17, it is highly likely that due to a lack of EpCAM
expression some tumor cells, potentially those with a more aggressive phenotype, will be
missed during CTC analysis using the CSS.
We were also interested in investigating if any associations existed between
CTC number and various patient and tumor factors. Unfortunately, we did not observe
any significant associations with pre-RT PSA, pT stage, ECE, SVI, margin status,
Gleason score or PSADT. However, Tombal et al. (2003) did observe a statistically
significant difference in therapy response between patients with and without CTCs prior
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to RT using RT-PCR12. This discrepancy could be explained by a number of factors in
this study including sampling variability, low patient numbers, patient characteristics, and
follow-up limited to one time point post-RT. These results however suggest the
possibility that with larger patient numbers and continued follow-up, similarly significant
results may be observed in our patient population.
Stephenson et al. (2007) described stratification of patients according to PSA
level at the time of salvage radiotherapy as well as Gleason score, margin status and
PSADT and noted rates of successful salvage radiotherapy ranging from 20-60%
depending on these factors15. Larger patient cohorts would allow evaluation of the
incremental prognostic significance (if any) of CTCs above the clinical factors noted by
Stephenson et al. We have undertaken a follow-up study (Chapter 3), which includes
patients not only from the salvage setting but also from the adjuvant setting. From these
patients we have collected serial PSA and CTC samples at baseline, and 6 months, 12
months, 18 months, and 24 months following the completion of RT. CTC values were
then correlated with response to RT, and overall survival. This study is aimed at
increasing statistical power in order to detect associations between variables.
Primarily the CSS has been utilized for the detection and enumeration of
CTCs8,10,11. However the system does allow for additional molecular characterization of
CTCs based on molecular markers of interest to researchers and physicians, via
differential staining. In prostate cancer, molecular markers such as PSA18, androgen
receptor (AR)19, PTEN deletion20, and TMPRSS2:ERG21 gene fusion have been shown to
be associated with poor prognosis and metastatic disease. Since CTC analysis represents
the opportunity to do a “real time” biopsy using a minimally-invasive blood test,
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examination of the molecular characteristics of these markers on prostate CTCs could
therefore enable a better understanding of the mechanisms that allow these cells to escape
into the circulation, extravasate into distant tissue and form clinically relevant secondary
metastases. These studies may also help us determine whether the CTCs being detected in
these assays are capable of metastasizing and thus allow for more individualized
treatment.
In summary, the novel results presented in this pilot study are the first to
suggest the possibility that CTC enumeration using the CSS could be utilized in clinicaldecision-making to determine who should receive salvage RT and who would benefit
more from palliative hormonal therapy. Validation studies examining the role of CTCs as
an independent predictive biomarker among larger cohorts of men with BCF post RP are
necessary and seem justified based on our preliminary results.
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Chapter 3
The significance of circulating tumor cells in prostate
cancer patients undergoing adjuvant or salvage
radiation therapy
A version of this chapter has been published:
Lowes LE, Lock M, Rodrigues G, D'Souza D, Bauman G, Ahmad B, Venkatesan V,
Allan AL, and Sexton T. In press, Prostate Cancer and Prostatic Diseases.

Abstract
Following radical prostatectomy, success of adjuvant and salvage radiation
therapy (RT) is dependent on the absence of micrometastatic disease. However, reliable
prognostic/predictive factors for determining this are lacking. Therefore, novel
biomarkers are needed to assist with clinical decision-making in this setting. Enumeration
of circulating tumor cells (CTCs) using the regulatory-approved CellSearch® System
(CSS) is prognostic in metastatic prostate cancer (PCa). We hypothesize that CTCs may
also be prognostic in the post-prostatectomy setting. Patient blood samples (n=55) were
processed on the CSS to enumerate CTCs at 0, 6, 12, and 24 months after completion of
RT. CTC values were correlated with predictive/prognostic factors and progression free
survival. CTC status (presence/absence) correlated significantly with margin status, and
trended toward significance with seminal vesicle invasion (SVI) and extracapsular
extension (ECE). CTC positive status at any point appears to be indicative of
disseminated disease, and in combination with other risk factors (margin+/SVI/ECE)
predicts for time to biochemical failure (BCF). Assessment of CTCs during RT may be
helpful in clinical decision-making to determine which patients may benefit from RT
versus those who may benefit more from systemic treatments.
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3.1

Introduction
In the United States in 2014, it is estimated that there will be 233,000 new

cases of prostate cancer (PCa) diagnosed and 29,480 deaths from this disease1. Upon
diagnosis, one commonly recommended treatment option is surgical resection of the
prostate via radical prostatectomy (RP) 2. Following surgical intervention, patients are
monitored using prostate-specific antigen (PSA) testing. However, within 10 years of RP,
up to 30% of early-stage patients will experience a rise in PSA levels and require
additional treatment for residual/recurrent disease3,4. Following relapse, evaluation of
time to biochemical recurrence, PSA doubling time, and pathological features (Gleason
score, margin status, seminal vesicle invasion [SVI], extracapsular extension [ECE]) can
assess the risk of PCa-specific mortality. Patients will then be recommended for either
surveillance, potentially curative radiation therapy (RT), or palliative hormonal therapy5.
Although these parameters provide a measure of disease aggressiveness, neither they, nor
available imaging technologies, can determine the precise location of recurrent PCa,
thereby presenting a unique problem. If recurrent disease is localized to the prostate bed,
RT could be curative. However, if the disease has become systemic, local radiation will
be insufficient and systemic therapy may be necessary. Therefore, novel biomarkers that
could discriminate patients with local recurrence versus those with systemic disease
would be of clinical benefit.
The presence of circulating tumor cells (CTCs) in the bloodstream of PCa
patients has been correlated with metastatic disease6. Additionally, CTC detection in the
metastatic setting is prognostic, correlating with significantly reduced progression freeand overall survival6. However, given that CTCs are rare and present in a high
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background of contaminating blood cells, detection and enumeration of CTCs requires
highly sensitive and clinically reproducible assays. Currently, the only CTC analysis
platform cleared by the U.S. Food and Drug Administration (FDA) and Health Canada
for prognostic use in metastatic breast, prostate and colorectal cancer is the CellSearch®
system (CSS) by Janssen Diagnostics7, thereby making it the current gold standard in
CTC technology in the metastatic setting for these disease sites.
Using this platform, the clinical value of CTCs in metastatic PCa has been
extensively explored6,8,9. Studies demonstrate that patients with ≥5 CTCs/7.5mL of blood
have significantly reduced progression free- and overall survival compared to patients
with <5 CTCs6. In addition, changes in CTC number throughout therapy may be a
surrogate endpoint for treatment efficacy in the metastatic setting 8. However, the clinical
value of CTCs in patients with localized PCa is less well described, with the majority of
studies focusing on the utility of CTCs in determining biochemical failure (BCF)
following RP. However few have explored the utility of CTCs in determining response to
intervention to treat residual disease (i.e. RT) 10–12.
Based on these initial reports we hypothesized that the presence of CTCs in the
blood of PCa patients undergoing adjuvant or salvage radiation may be an indicator of
disseminated disease and may ultimately assist with clinical decision-making in this
patient cohort. In this study, we specifically assessed whether the presence of CTCs
either before or following completion of RT (measured at baseline and 6, 12, and 24
months post-treatment) is indicative of treatment response. To our knowledge this is the
most extensive report in the literature examining the value of CTCs in this uniquely
challenging patient population, including serial CTC sampling following treatment
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completion and the longest period of follow-up to date (up to 3 years in some patients).
Additionally, we are the first to describe the utility of CTCs in adjuvant patients
undergoing RT.

3.2

Materials and methods

3.2.1

Patient population
All studies were carried out under protocol #16904E approved by Western

University's Health Sciences Research Ethics Board (Appendix 2). All patients were
enrolled following informed consent. Fifty-five PCa patients who had consented to
adjuvant or salvage RT following RP were enrolled. Inclusion criteria for adjuvant
patients included presence of any adverse pathological finding such as ECE, positive
margins, and/or SVI without the presence of a detectable PSA (<0.1ng/mL). Patients who
were enrolled with the intent of adjuvant radiation but who had detectable PSA levels
pre-radiation were categorized as adjuvant/salvage and analyzed separately. Inclusion
criteria for salvage patients included PSA value of >0.1 ng/mL13 and a minimum of three
PSA values taken one month apart, in order to calculate doubling time. Pre-RT bone scan
and CT scan were performed at the discretion of the physician. Blood was drawn before
the initiation of RT to determine baseline PSA and CTC levels. Additional baseline
characteristics were noted, including Gleason score, pathologic T (pT) stage, margin
status, lymph node status, presence of ECE, presence of SVI, months free from relapse,
mean PSA, and mean PSA doubling time (PSADT) where appropriate. All patients were
treated with radiation to the prostate bed as per Radiation Therapy Oncology Group
(RTOG) guidelines with 6600 cGy in 33 fractions using a 5 field intensity modulated
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radiation therapy (IMRT) technique14. Following completion of RT, PSA levels were
determined at 3, 6, 12, 18, 24, 30, and 36 months, while CTC levels were determined at
6, 12, and 24 months post-RT.

3.2.2

PSA determination and biochemical failure
Blood samples for PSA determination were analyzed by the London Health

Sciences Centre Endocrinology Laboratory on the AutoDelfia automatic immunoassay
system (Perkin Elmer) using a time resolved fluoroimmunoassay. BCF following RT was
defined as 3 consecutive rises in PSA during follow-up.

3.2.3

Circulating tumor cell enumeration
All blood samples for CTC analysis were drawn into CellSave tubes (Janssen)

and analyzed within 96 hours15. CTCs were identified as being selected by anti-EpCAM
(epithelial cell adhesion molecule), positive for cytokeratin (CK; 8/18/19) and the DNA
stain 4’, 6-diamidino-2-phenylindole (DAPI), >4 µm diameter, and with an intact cell
membrane. CTCs results were analyzed by 2 independent and blinded observers and
enumerated using the criteria described above. A positive CTC result was defined was ≥1
CTCs/7.5mL of blood.

3.2.4

Statistical analysis
Comparisons were made between patients with CTCs at baseline (CTCpos),

versus those without CTCs (CTCneg). A two-tailed Fisher's exact test was used to analyze
differences between CTCpos and CTCneg groups relative to Gleason score (>7), SVI,
margin status, ECE, radiation type (salvage, adjuvant, or adjuvant/salvage), and BCF at 2
years. Unpaired t-tests were used to assess age differences between CTCpos and CTCneg
groups. Log-rank tests were utilized to examine time to BCF.
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3.3

Results
Fifty-five PCa patients from the adjuvant or salvage settings were enrolled in

the study. Of these, 19 (34.5%) were classified as adjuvant, 33 (60%) as salvage, and 3
(5.5%) as adjuvant/salvage. The clinicopathological risk factors (CRFs) of study patients
are presented in Table 3.1. Mean pre-radiation PSA (and range) was observed to be 0.33
(0.11-1.37) (salvage setting) and 0.42 (0.11-1.0) (adjuvant/salvage setting). Mean PSA
doubling time (and range) was 16.4 (2-78) months (only measured in salvage patients).
No correlation was observed between PSA levels and CTC status (presence/absence).
To determine the relationship between CTCs at baseline and CRFs, patients
were characterized as either CTCneg (0 CTCs; [n=46]) or CTCpos (≥1 CTCs; [n=9])
(Figure 3.1 and Table 3.2). No significant differences were observed for patients with a
Gleason score of >7 and CTCneg (n=3) versus CTCpos (n=1) status at baseline (p>0.05). A
statistically significant difference was observed in relation to margin status (p=0.032),
with 63.0% of CTCneg patients presenting with positive margins (n=29) versus 22.2% of
CTCpos patients (n=2).
In addition to CTC status at baseline, analysis was also performed to determine
the relationship between detectable CTCs at any time point and CRFs. Patients were
characterized as either CTCneg (n=39) at all time points or CTCpos (n=16) at any time
point, including at baseline (Figure 3.2 and Table 3.3). No significant differences were
observed when considering ECE, SVI, or Gleason score of >7 and CTCneg (n=29, 4, and
3, respectively) versus CTCpos (n=9, 4, and 1, respectively) status (p>0.05). However, a
trend towards statistical significance was observed when considering margin status
(p=0.083). For CTCneg patients, there was a trend toward the presence of positive
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Table 3.1. Comparison of the clinicopathologic factors and CTC status of adjuvant,
salvage, and adjuvant/salvage patient populations.
Adjuvant
N (%)

Salvage
N (%)

Adjuvant
/Salvage
N (%)
3 (5.5)

Total
N (%)

19 (34.5)
33 (60)
55 (100)
Total
pT Stage:
T2
2 (11)
15 (45)
0 (0)
17 (31)
T3a
15 (79)
14 (42)
3 (100)
32 (58)
T3b
0 (0)
2 (11)
4 (12)
6 (11)
Gleason Score:
6
1 (5)
6 (18)
0 (0)
7 (13)
7
17 (89)
25 (76)
2 (67)
44 (80)
8-10
1 (5)
2 (6)
1 (33)
4 (7)
pos
17
(89)
18
(55)
3
(100)
38
(69)
ECE :
pos
2 (11)
5 (15)
1 (33)
8 (15)
SVI :
pos
12 (63)
17 (52)
2 (67)
31 (56)
Margins :
3 (16)
4 (12)
2 (67)
9 (16)
CTCpos (Baseline):
pos
1
5 (26)
9 (27)
2 (67)
16 (29)
CTC (Anytime) :
1: The number of CTCs detected in patients within each patient population are as follows,
1 (n=4) and 3 (n=1) [adjuvant]; 1 (n=6), 2 (n=1), 4 (n=1), and 5 (n=1) [salvage, with
one patients having CTCs at baseline (4 CTCs) and 12 months (1 CTC)]; 1 (n=1) and 2
(n=1) [adjuvant/salvage].
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Figure 3.1. CTC status at baseline correlates with previously recognized patterns
of disease recurrence of the clinicopathologic risk factors, extracapsular
extension, seminal vesicle invasion, and margin status. (A) Percentage of patients
with CTCs absent (CTCneg/-; n=34) versus CTCs present (CTCpos/+; n=4) at baseline
that presented with extracapsular extension. (B) Percentage of patients with CTCneg
(n=29) versus CTCpos (n=2) at baseline that presented with positive margins. (C)
Percentage of patients with CTCneg (n=5) versus CTCpos (n=3) at baseline that
presented with seminal vesicle invasion. (D) Percentage of patients with CTCneg (n=3)
versus CTCpos (n=1) at baseline that presented with a Gleason score of greater than 7.
* = significantly different (p ≤ 0.05).
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Table 3.2. Relationship of CTCs prior to radiation therapy with known clinicopathologic
risk factors and biochemical failure.
CTC Present
No
N = 46
N (%)

Yes
N=9
N (%)

p value

Gleason score >7

3 (6.5)

1 (11.1)

0.522

Seminal Vesicle Invasion

5 (10.8)

3 (33.3)

0.113

Positive Margins

29 (63.0)

2 (22.2)

0.032

Extracapsular Extension

34 (73.9)

4 (44.4)

0.116

Biochemical Failure at 2 yrs

7 (15.6)1

3 (33.3)

0.343
0.176

Time to Biochemical Failure:
One year

13.3%

22.2%

Two years

15.6%

33.3%

Three years

22.2%

46.7%

1: n=45; 1 patient was lost to follow-up and BCF could not be assessed at 2 years.
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margins, with 64.1% of CTCneg patients presenting with positive margins (n=25) versus
37.5% of CTCpos patients (n=6), similar to that observed for CTC status at baseline.
Ultimately, the usefulness of CTCs in this patient cohort depends on their
ability to determine who will experience BCF and who will not. Therefore, patients were
divided into those with CTCs absent (n=45) or present (n=9) at baseline and log rank
analysis was utilized to assess differences time to BCF in these patient subgroups (Figure
3.3A). Although there was a trend toward a decreased time to BCF in baseline CTC pos
patients, this trend was not significant (p=0.166). Similar analysis was then performed on
patients subdivided as CTCneg at all time points (n=38) versus those who were CTCpos at
any time point (n=16). The results demonstrated a significantly decreased time to BCF in
CTCpos patients (p=0.043; Figure 3.3B). No significant difference was observed in BCF
at 2 years in patients with CTC neg versus CTCpos disease at baseline (Table 3.2).
However, a significant difference was observed in BCF at 2 years when considering
patients with CTCneg versus CTCpos disease at any time point (p=0.049; Table 3.3). No
significant difference was observed in BCF at 2 years or time to BCF between adjuvant
and salvage patient groups (Table 3.4).
Although CTCs alone at baseline were not an independent predictor of time to
BCF, we investigated if combination with one or more of the known CRFs would
enhance this ability. This approach demonstrated that patients with the presence of ECE
(Figure 3.4A) or SVI (Figure 3.4C) in combination with a CTCpos status at baseline had a
decreased time to BCF (p=0.027 and p=0.043, respectively) versus those with the
presence of ECE or SVI alone. However, a significant difference was not observed when
comparing patients with the presence of positive margins and a CTC pos status versus
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Figure 3.2. CTC status at any time point correlates with previously recognized
patterns of disease recurrence of the clinicopathologic risk factor, margin status.
(A) Percentage of patients with CTCs absent (CTCneg/- ; n=29) at all time points versus
CTCs present (CTCpos/+; n=9) at any time point that presented with extracapsular
extension. (B) Percentage of patients with CTCneg (n=25) at all time points versus
CTCpos (n=6) at any time point that presented with positive margins. (C) Percentage of
patients with CTCneg (n=4) at all time points versus CTCpos (n=4) at any time point that
presented with seminal vesicle invasion. (D) Percentage of patients with CTCneg (n=3)
at all time points versus CTCpos (n=1) at any time point that presented with a Gleason
score of greater than 7.
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Table 3.3. Relationship of CTCs at any time point with known clinicopathologic risk
factors and biochemical failure.
CTC Present
No
N = 39
N (%)

Yes
N = 16
N (%)

p value

Gleason score >7

3 (7.7)

1 (6.3)

1.000

Seminal Vesicle Invasion

4 (10.3)

4 (25.0)

0.212

Positive Margins

25 (64.1)

6 (37.5)

0.083

Extracapsular Extension

29 (74.3)

9 (56.3)

0.213

Biochemical Failure at 2 yrs

4 (10.5)1

6 (37.5)

0.049
0.043

Time to Biochemical Failure:
One year

7.9%

31.3%

Two years

10.5%

37.5%

Three years

18.4%

43.8%

1: n=38; 1 patient was lost to follow-up and BCF could not be assessed at 2 years.
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Figure 3.3. CTCpos status at baseline and at any time point correlates with a
decrease in time to biochemical failure following adjuvant or salvage
radiotherapy. (A) Percentage of patients with CTCs absent (CTCneg/- ; n=45) versus
CTCs present (CTCpos/+; n=9) at baseline that are biochemical failure free over a 36
month period. (B) Percentage of patients with CTCneg (n=38) at all time points versus
CTCpos (n=16) at any time point that are biochemical failure free over a 36 month
period.
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Table 3.4. Observed differences in biochemical failure at 2 years and time to biochemical
failure in adjuvant versus salvage patient populations.
Disease Setting

Biochemical Failure at 2 yrs

Adjuvant
N = 19
N (%)

Salvage
N = 32
N (%)

p value

1 (5.3)

7 (21.9)

0.230
0.213

Time to Biochemical Failure:
One year

5.3%

18.8%

Two years

5.3%

21.9%

Three years

21.1%

25.0%
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those with the presence of positive margins alone (p=0.250; Figure 3.4B). Since the
presence of negative margins in this patient population suggests that patient’s disease
may no longer be confined to the prostate bed, time to BCF analysis was performed to
determine if a relationship existed between CTC status at baseline and negative margins.
Based on this analysis no significant difference was observed between patients with
CTCneg marginneg disease and those with CTCpos marginneg disease (data not shown).
Similar analysis was then performed on the ability CTC status at any time point
in combination with one or more of the known CRFs to determine time to BCF. Patients
that presented with of one or more CRFs were subdivided into those who were either
CTCpos versus CTCneg at any time point. This further demonstrated the relationship
between the ability of CTCs to determine time to BCF in patients in combination with the
presence of ECE (p=0.025; Figure 3.5A), although the same was not observed in
combination with the presence of SVI (p=0.128; Figure 3.4C). However, a significant
relationship was observed when comparing patients with the presence of positive margins
and CTCpos status at any timepoint versus those with the presence of positive margins
alone (p=0.001; Figure 3.5B). Additionally, a very strong relationship was observed with
the combination of presence of positive margins and ECE and CTCpos status at any time
point versus those with the presence of positive margins and ECE alone (p<0.0001;
Figure 3.5D).

3.4

Discussion
Current imaging technologies cannot differentiate local from systemic failure

following RP. Regardless, RT is a common treatment option, as biomarkers that can
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Figure 3.4. Combination of CTC status at baseline and known clinicopathologic
risk factors, extracapsular extension or seminal vesicle invasion, can predict for
time to biochemical failure following adjuvant or salvage radiotherapy. (A)
Percentage of patients that are biochemical failure free over a 36 month period that
presented with extracapsular extension (ECE), but without CTCs (CTC neg/-; n=34)
versus patients with ECE, but with CTCs (CTCpos/+; n=4) at baseline (p=0.027). (B)
Percentage of patients that are biochemical failure free over a 36 month period that
presented with positive margins (margins), but CTCneg (n=29) versus patients with
positive margins, but CTCpos (n=2) at baseline (p>0.05). (C) Percentage of patients
that are biochemical failure free over a 36 month period that presented with seminal
vesicle invasion (SVI), but CTCneg (n=5) versus patients with SVI, but CTCpos (n=3) at
baseline (p=0.043).
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Figure 3.5. Combination of CTC status at any time point and known
clinicopathologic risk factors, extracapsular extension and/or margin status, can
predict for time to biochemical failure following adjuvant or salvage
radiotherapy. (A) Percentage of patients that are biochemical failure free over a 36
month period that presented with extracapsular extension (ECE), but without CTCs
(CTCneg/-; n=29) at all time points versus patients with ECE, but with CTCs (CTC pos/+;
n=9) at any time point (p=0.025). (B) Percentage of patients that are biochemical
failure free over a 36 month period that presented with positive margins (margins), but
CTCneg (n=25) at all time points versus patients with positive margins, but CTC pos
(n=6) at any time point (p=0.001). (C) Percentage of patients that are biochemical
failure free over a 36 month period that presented with seminal vesicle invasion (SVI),
but CTCneg (n=4) at all time points versus patients with SVI, but CTCpos (n=4) at any
time point (p=0.128). (D) The percentage of patients that are biochemical failure free
over a 36 month period that presented with positive margins and ECE, but CTC neg
(n=15) at all time points versus patients with positive margins and ECE, but CTC pos
(n=2) at any time point (p<0.0001).
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distinguish those who will benefit from RT versus those who will not are unavailable.
Unfortunately, for patients whose cancer has become systemic, RT will not provide
benefit, resulting in up to 30% of patients experiencing disease recurrence. Therefore,
novel biomarkers that could distinguish these patient groups before initiation of RT are
essential. To the best of our knowledge, only two published studies have explored CTCs
in this patient population. The first was performed in a small number of patients (n=15)
using a non-standardized reverse-transcription polymerase chain reaction (RT-PCR)
approach examining the detection of PSA mRNA in the blood 12. This study suggested
that the presence of PSA mRNA following RP was indicative of micrometastatic disease
and may predict poor response to salvage RT. The second study, published by our group,
was the first to explore the detection and enumeration of CTCs using the U.S. FDA and
Health Canada-cleared CSS15. This study demonstrated that CTCs were detectable in
salvage patients (n=26) using the CSS, and that, similar to metastatic disease, changes in
CTC number following RT may be indicative of treatment response. In the current study
we sought to determine if detection of CTCs before initiation of RT could be utilized as a
surrogate biomarker for disseminated disease and therefore an indicator of treatment
failure in this patient cohort.
Despite having only a small number of CTCpos patients prior to RT, strong
correlations were observed with regards to CTC status at baseline and known CRFs.
Interestingly, CTCneg disease was most highly correlated with CRFs associated with local
recurrence, including ECE and positive margins16. However, when considering SVI, a
CRF associated with systemic relapse16, a correlation with CTCpos disease was observed.
These correlations, although in opposite directions, are consistent with the clinical
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observations of local versus systemic relapse associated with these CRFs. Based on the
propensity for local relapse in ECE + and margin+ patients, we would anticipate that these
patients would exhibit a tendency toward non-disseminated and therefore CTCneg disease
versus SVI+ patients, known to have a propensity for systemic relapse, whom we would
anticipate would exhibit a tendency toward disseminated and therefore CTC pos disease.
Therefore, CTC status appears to be in agreement with existing CRFs, suggesting that
CTCs may relate to disease localization in these patients.
Although these associations suggest a relationship between CTCs and disease
spread, the value of CTCs in this patient cohort will depend on their ability to predict RT
success. Upon examination of BCF at 2 years and time to BCF, we noted a strong trend
toward reduced time to BCF in CTCpos versus CTCneg patients at baseline. However, this
trend was statistical significant when considering patients with CTCs at any time point
for both measures (BCF at 2 years and time to BCF) . These promising results suggest
that the detection of CTCs at any time may be a surrogate biomarker of metastatic
disease, and support a recommendation for early initiation of systemic treatment in this
patient cohort.
However, this study also aimed to determine if CTCs could predict the
outcome of RT before treatment initiation, thereby reducing radiation-induced morbidity
in patients for which benefit would not be achieved. Therefore CTC status at baseline
was examined in combination with known CRFs to determine if this approach could
improve our ability to discriminate these patient subsets. We have demonstrated that the
presence of ECE or SVI in association with CTC pos status at baseline is predictive of
poorer response to RT. However, as this study was not powered appropriately to
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determine definitive associations between combinations of CRFs and CTCs, not all
significant associations observed at baseline were significant when considering CTC
status at any time point and vice versa. Additionally, not all CRF combinations,
especially multiple CRFs (e.g., ECE + SVI + CTC), could be effectively examined.
However, the results presented here, specifically with regards to ECE and CTC status,
demonstrate consistently poorer outcomes following RT, further strengthening the
existence of a relationship between the presence of CTCs and disease spread. This
suggests that the addition of CTCs to a patient’s clinicopathologic "risk profile" (ECE,
SVI, and margin status) may further enhance our ability to discriminate patients with
localized versus systemic recurrence. Further studies that could elucidate such risk
profiles are justified.
The sample size for this study was chosen based on our pilot studies, which
demonstrated that over 70% of salvage patients presented with CTCs at baseline using
the CSS15. Unfortunately, in the current study only 16% of salvage patients and 12% of
adjuvant patients presented with CTCs. Interestingly, for patients in the adjuvant/salvage
group, 67% had detectable CTCs at baseline and all demonstrated treatment failure
within 18 months, suggesting that CTCs may be more readily detectable and particularly
valuable in these rapidly progressing patients. However, these results would require
confirmation in a larger follow-up study. In agreement with our pilot analysis15, the
majority of patients with detectable CTCs at baseline presented with <2 CTCs (67%), and
no patient had >5 CTCs at any point. Although the CSS can detect as few as 1
CTC/7.5mL of blood, variability increases significantly as the number of CTCs
approaches 0, and with such low rates of detection the potential for false
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negative/positive results cannot be discounted as a confounding factor of this study.
Therefore proper enumeration of CTCs in these patients may be difficult and likely
contributed to the high number of CTCneg patients at baseline that failed RT (66%). The
low number of CTCs observed throughout the course of this study presents a statistical
challenge that can be overcome by either increasing sample size, increasing CTC capture
by collecting additional blood for analysis (>7.5mL), or utilizing new emerging CTC
technologies with increased sensitivity17. In doing so analysis of changes in CTC number
at baseline compared to a subsequent post-treatment time points may be possible. This
measure may also be valuable in determining the origin of disseminating disease (i.e.,
CTCs). For example, if CTCs number decrease following RT this may indicate that the
residual disease was localized to the prostate bed and effectively treated using RT.
However, should CTC numbers remain unchanged or increase following RT this may be
an indicator of metastatic disease.
In summary, the results presented here are the first to demonstrate that CTC
enumeration using the clinical gold standard CTC analysis CSS platform may be valuable
in clinical decision-making to determine which patients should receive RT versus those
who would benefit more from systemic therapy. Validation studies using larger patient
cohorts to examine the clinicopathologic "risk profiles" outlined in this manuscript are
necessary and justified based on these novel results.
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Chapter 4
User-defined protein marker assay development for
characterization of circulating tumor cells using the
CellSearch® system
A version of this chapter has been published:
Lowes LE, Hedley BD, Keeney M, and Allan AL. Cytometry A. 2012;81(11):983-95.

Abstract
The majority of cancer-related deaths result from metastasis, which has been
associated with the presence of circulating tumor cells (CTCs). It has been shown that
CTC cut-off values exist that predict for poorer overall survival in metastatic breast (≥5),
prostate (≥5), and colorectal (≥3) cancer based on assessment of 7.5mL of blood.
Development of the CellSearch® system (CSS; Janssen Diagnostics) has allowed for
sensitive enumeration of CTCs. In the current study, protocols were developed and
optimized for use with the CSS to characterize CTCs with respect to user-defined protein
markers of interest in human blood samples, including the cancer stem cell (CSC) marker
CD44 and the apoptosis marker M-30. Flow cytometry (FCM) experiments were initially
carried out to assess expression of CD44 and M-30 on MDA-MB-468 human tumor cells.
Human blood samples were then spiked with MDA-MB-468 cells and processed with the
appropriate antibody (CD44/M-30) on the CSS. Detailed optimization of CD44 was
carried out on the CSS using various antibody concentrations, exposure times, and cell
lines with varying CD44 expression. Troubleshooting experiments were undertaken to
explain observed discrepancies between FCM and the CSS results for the M-30 marker.
After extensive optimization, the best CD44/M-30 concentrations and exposure times
were determined to be 1.5/3.5 μg/mL and 0.2/0.8 s, respectively. The percentage of
CD44+ tumor cells was 99.5 ± 0.39% by FCM and 98.8 ± 0.51% by the CSS. The
percentage of M-30+ tumor cells following paclitaxel treatment was 17.6 ± 1.18% by
FCM and 10.9 ± 2.41% by the CSS. Proper optimization of the CD44 marker was
achieved; however, M-30 does not appear to be a suitable marker for use in this platform.
Taken together, the current study provides a detailed description of the process of userdefined protein marker development and optimization using the CSS, and will be an
important resource for the future development of protein marker assays by users of this
platform.
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4.1

Introduction
It has been estimated that 1,658,370 new cases of cancer will be diagnosed in

the United States and 589,430 individuals will die from this disease in 20151. The
majority of these deaths are as a result of the development of metastases2. These deaths
are due mainly to the ineffectiveness of current therapies in treating metastatic disease
and a general lack of understanding of the metastatic cascade. Metastatic disease has been
correlated with the presence of circulating tumor cells (CTCs) in the blood 3. Detection of
very small numbers of these rare cells has been shown to be predictive of overall survival
in metastatic breast 4, prostate5, and colorectal6 cancer, where patients with ≥5 (breast and
prostate) or ≥3 (colorectal) CTCs in 7.5mL of blood have a poorer prognosis then those
with fewer or no detectable CTCs.
Several methods have been utilized to enrich and detect CTCs, including
density-gradient centrifugation7,8, immunomagnetic selection9,10, polymerase chain
reaction (PCR)-based assays11,12, and flow cytometry (FCM)13,14 techniques. All of these
approaches have unique advantages and disadvantages; however, one commonality they
all share is a lack of standardization; a necessity for use in the clinical setting. The
development of the U.S. Food and Drug Administration (FDA) and Health Canada
cleared CellSearch® system (CSS) by Janssen Diagnostics provides a standardized
method for the sensitive detection and quantification of these rare CTCs in human blood
using fluorescence microscopy and immunology based techniques4–6. This system is
currently considered the gold standard in CTC enumeration and is the only CTC platform
approved for in vitro diagnostic (IVD) use in the clinic at the present time. The CSS
consists of two components, (1) the CellTracks™ AutoPrep system, which automates the
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blood sample preparation, and (2) the CellTracks™ Analyzer II, which scans the
prepared samples (described in Chapter 2 and Figure 2.1). The CellTracks™ Analyzer
II® utilizes a 10X objective lens to scan samples using different filters, each with the
exposure time optimized to the appropriate fluorescent particle. The CSS has been
primarily utilized for the detection and enumeration of these rare cells. However, this
platform does allow for single-cell characterization of CTCs for user-defined markers of
interest, using an additional fluorescein isothiocyanate (FITC) fluorescence channel not
required for CTC identification and enumeration15. However, the detailed process for
user-defined protein marker assay development and optimization using this platform is
not well-defined.
Tumor profiling of metastatic lesions is not routine practice in the clinic. In
fact, this profiling is often impractical or even impossible depending on the location and
size of the metastatic tumors. Therefore CTCs could act as a real-time, minimally
invasive liquid biopsy, and the characterization of these rare cells could inform clinical
decision-making. For example, human epidermal growth factor receptor 2 (HER2) is
over-expressed in a subset of breast cancer patients, and has been exploited as a marker
for targeted therapy using the HER2 receptor interfering monoclonal-antibody
Herceptin®16. However, this therapy has only been shown to be effective in patients
whose primary tumor expresses sufficient levels of HER2. Fehm et al., demonstrated that
approximately one third of breast cancer patients with metastases whose primary tumors
were HER2- had HER2+ CTCs17,18. Whether or not these patients with HER2+ CTCs
would benefit from treatment with Herceptin® still requires investigation; however, CTCs
hold great promise for improving personalized cancer treatment.
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Two general categories of protein markers are available for exploration on
CTCs; markers that reflect tumor biology (tumor phenotyping) and may act as target
molecules for therapy, and those that reflect cellular response to therapy. Currently,
Janssen Diagnostics has developed and optimized three tumor phenotyping reagents for
assessing well characterized therapeutic targets, and these are commercially available for
research use only (RUO) applications on the CSS. Using these reagents, CTCs can be
analyzed for expression of either HER2/neu, epidermal growth factor receptor (EGFR),
or insulin-like growth factor 1 receptor (IGF-1R). The development and optimization of
CSS assays for other user-defined markers of interest on tumor cells could identify new
targets for novel therapies and enable a better understanding of the mechanisms that
allow these cells to escape into the circulation, extravasate into distant tissue and form
clinically relevant macrometastases.
The aim of this study was therefore to develop and optimize protocols for
characterization of CTCs on the CCS for two proteins of interest, CD44 and M-30. CD44
has been associated with metastasis and has shown to be expressed by “cancer stem cells”
(CSCs), a subpopulation of tumor cells that are believed to be the cells responsible for
tumor initiation and metastasis19. The ability to characterize and track CD44+ cells would
therefore be an important tool for understanding the metastatic cascade. The M-30
CytoDeath antibody recognizes a neoepitope of CK18 that is exposed following caspase
cleavage at residue 396 during the early events of apoptosis20. This marker could be
utilized as a measure of therapy effectiveness, and potentially indicate the necessity for a
change in treatment much earlier than standard clinical evaluation techniques such as
imaging. For the first time in the literature, the current study provides a detailed
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description of the process of user-defined protein marker development and optimization
using the CSS, and will be an important resource for the future development of protein
marker assays by users of this platform.

4.2

Materials and methods

4.2.1

Cell culture and reagents
The MDA-MB-468 human breast cancer cell line was obtained from Dr. Janet

Price (M.D. Anderson Cancer Center, Houston, TX, USA21). The 21NT human breast
cancer cell line was obtained from Dr. Vimla Band (Dana Farber Cancer Institute,
Boston, MA22). The LNCaP human prostate cancer cell line was obtained from Dr. John
Lewis (London Regional Cancer Program, London, ON, Canada 23). MDA-MB-468 cells
were maintained in αMEM + 10% FBS. 21NT cells were maintained in αMEM + 10%
FBS, 3.32µg/mL of HEPES, 1% non-essential amino acids (10mM), 96.02µg/mL of
sodium pyruvate, 0.25mg/mL of L-glutamine, 43.63µg/mL of gentamicin, and
0.87µg/mL of insulin (Sigma-Aldrich, St. Louis, MO, USA). LNCaP cells were
maintained in RPMI-1640 + 10% FBS. All growth media and supplements were obtained
from Invitrogen (Carlsbad, CA, USA). FBS was obtained from Sigma-Aldrich (St. Louis,
MO, USA). For induction of apoptosis, MDA-MB-468 human breast cancer cells were
grown to ~65% confluency at which time cells were treated with fresh growth media
(αMEM + 10% FBS) or 0.1μg/mL of paclitaxel (Biolyse Pharma Corporation, St.
Catherines, ON, CAN) in αMEM + 10% FBS. Both the treated and untreated cells were
then grown for an additional 48 hours before they were harvested and analyzed as
described below.
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4.2.2

Flow cytometry sample preparation
For comparison of FITC mean fluorescence intensity (MFI), measured on a 4

decade log scale, MDA-MB-468 cells were spiked into whole blood at a concentration of
~0.01% (equivalent to ~200 MDA-MB-468 cells) of the total white blood cell (WBC)
count determined by analysis of whole blood using an LH 780 hematology analyzer
(Beckman Coulter, Hialeah, FL, USA). The 0.01% spiked solution was then incubated
with fluorescently conjugated antibodies for 20 min at room temperature, including 5µL
of anti-CD45-PC5 (clone J33; Beckman Coulter/Immunotech, Marseille, France) and
either 150µL of anti-EGFR (epidermal growth factor receptor)-FITC (Janssen
Diagnostics, Raritan, NJ, USA) or various amounts (0.05µg – 0.5µg) of anti-CD44-FITC
(clone G44-26; BD Biosciences). Following incubation, red blood cells were lysed using
1x ammonium chloride (NH4Cl) lysing solution (Beckman Coulter/Immunotech) for 10
min at room temperature. Samples were then analyzed using a Beckman Coulter EPICS
XL-MCL flow cytometer.
For analysis of differential CD44, EpCAM, and CK expression in the three cell
lines, MDA-MB-468, 21NT, and LNCaP tumor cells (5x105) were resuspended in flow
buffer (PBS + 2% FBS), fixed and permeabilized, as necessary (CK), using the
IntraPrep™ Fix/Perm kit (Beckman Coulter, Fullerton, CA, USA), and incubated with
either 150µL of anti-EGFR-FITC (Veridex; 20 min), 0.5µg of anti-CD44-FITC (clone
G44-26; BD Biosciences; 20 min), 0.0075µg of anti-EpCAM-PE (clone EBA-1; BD
Biosciences; 20 min), or 25µL of anti-CK-8/18/19-PE (Veridex; 30 min). Following two
washes with an excess volume (≥2ml) of flow buffer, samples were analyzed using a
Beckman Coulter EPICS XL-MCL flow cytometer. PBS and 5.0µg of FITC-conjugated
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mouse IgG2bĸ (clone MPC-11; BD Biosciences) or 0.0625µg of PE conjugated mouse
IgG2bĸ (clone 27-35; BD Biosciences) were used as negative controls.
For analysis of M-30, paclitaxel-treated and untreated MDA-MB-468 cells
(5x105) diluted in flow buffer were fixed and permeabilized using the IntraPrep™
Fix/Perm kit (Beckman Coulter) and subsequently incubated with 0.1µg of anti-M-30FITC (Alexis Biochemicals, Lausen, Switzerland; 30 min) and either 0.0075µg of antiEpCAM-PE (clone EBA-1; BD Biosciences; 20 min), 25µL of anti-CK-8/18/19-FITC
(Veridex; 30 min), or 0.07µg of DAPI (Sigma-Aldrich; 15 min). Following 2 washes
with an excess volume (≥2ml) of flow buffer, samples were analyzed using either a
Beckman Coulter EPICS XL-MCL flow cytometer (EPCAM/CK) or a Beckman Coulter
Navios flow cytometer (DAPI).
It is important to note that FCM was used throughout this study as a method to
determine the percentage of cells within any given cell population that were positive for
our marker of interest (i.e., EGFR, CD44, M-30) and not as a method by which to
compare the CSS. Although FCM would seem like an ideal method for CTC
characterization based on the results presented in this study, its lower sensitivity for rareevent detection make it less ideal for use in a clinical setting, which further highlights the
need to optimize appropriate protocols for CTC characterization on the gold standard
CSS.

4.2.3

Flow cytometry analysis and gating strategy
The flow procedures were performed on either a single laser (488nm Argon

Laser) four-color Beckman Coulter XL-MCL flow cytometer or a three laser (405 Violet,
488 Argon, 633 Helium-Neon Laser) 10 colour Beckman Coulter Navios flow cytometer.
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Alignment and calibration checks were performed daily on both flow cytometers using
FlowCheck/FlowSet (for XL-MCL flow cytometer) and FlowCheckPro/FlowSetPro
(Beckman Coulter Navios flow cytometer). Fluorochrome emission on the Beckman
Coulter XL-MCL was captured for FITC conjugates using a 525/40nm Band Pass (BP)
filter and for PE conjugates using 575/25 nm BP filter. Emissions on the Beckman
Coulter Navios cytometer for FITC, PE and DAPI were collected using 525/40nm,
575/30nm, and 450/40nm BP filters (respectively). Antibody combinations are detailed
elsewhere in the Materials and Methods.
For all assays, forward and side scatter was used for gating to eliminate cellular
debris and cell doublets from analysis. A minimum of 10,000 events were acquired for all
analyses. For single-colour assays, gates were set based on either FMO (fluorescence
minus one) or appropriate IgG controls. For 2 colour assays, an FMO strategy was used
to determine compensation coefficients. Gating for blood samples spiked with tumor cells
was set up using 10% tumor cell spiked samples (compared to WBC count). Tumor cells
were defined as CK+CD45- and/or EGFR+/CD44+, whereas WBCs were defined as CKCD45+ and/or CD44-/EGFR-. Relative MFI was determined based on IgG isotype or
FMO controls (as appropriate) in order to demonstrate changes in expression of the
specific marker in question. Populations of interest were observed to be single
populations (i.e. similar to what is seen in Figure 4.1A), and means were observed to be
comparable to medians. Therefore the mean was taken as the value for determining MFI.
All data were analyzed offline using the Kaluza™ Beckman Coulter analysis software.
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Figure 4.1. Initial validation of the CellSearch® system using EGFR. (A) FCM
analysis of MDA-MB-468 human breast cancer cells incubated with anti-EGFR-FITC
(red) and an IgG isotype control sample (blue). (B) Representative CellSearch®
system gallery images of 7.5ml of healthy donor blood spiked with 1000 MDA-MB468 human breast cancer cells, incubated with 450µl of anti-EGFR-FITC and standard
Veridex CTC reagents (CK-PE, CD45-APC, DAPI), and analyzed at an exposure time
of 0.8s as recommended by the manufacturer. Orange squares indicate EGFR+ CTCs,
identified as CK+/DAPI+/CD45–/EGFR+. Images acquired at 10x objective
magnification. (C) Percentage recovery of EGFR+ cells as determined by FCM and the
CellSearch® system (n=3). Data are presented as the mean ± SEM.
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4.2.4

CellSearch analysis
Blood from healthy volunteer donors was drawn into 10ml CellSave

preservative tubes (Janssen Diagnostics) containing EDTA (ethylenediaminetetraacetic
acid) and a proprietary cellular preservative. Blood in excess of 7.5ml (the standard blood
volume for use with the CSS) was removed from each CellSave preservative tube and
discarded. One thousand (EGFR/CD44) or 4000 (M-30) cultured human tumor cells from
the appropriate cell line, diluted in 100µL of flow buffer, were spiked into each CellSave
preservative tube. To avoid sample degradation, spiked blood was processed on the CSS
within 96 hours of blood collection as per the manufacturer’s guidelines. Following
thorough mixture by inversion, 7.5mL of spiked blood was collected from each CellSave
preservative tube and mixed with 6.5mL of dilution buffer (Janssen Diagnostics). Spiked
blood samples were mixed by inversion 5 times and then centrifuged at 800xg with the
brake off for 10 minutes at room temperature. Prepared blood samples were loaded into
the CellTracks™ AutoPrep system as per the manufacturer’s guidelines and processed
using the CellSearch CTC kit as described in the introduction.
Undiluted anti-EGFR-FITC (Janssen Diagnostics) was added to manufacturersupplied reagent cups in the CellSearch kit cartridge for processing on the CellTracks™
AutoPrep system. Anti-CD44 antibodies conjugated to either FITC (clone G44-26; BD
Biosciences) or PE (clone G44-26; BD Biosciences) and FITC-conjugated M-30
CytoDeath antibodies (Alexis Biochemicals) were diluted according to Janssen
Diagnostics recommendations24 in 1X ultrapure PBS (Invitrogen) to obtain the desired
working concentration. Ultrapure PBS and PE conjugated mouse IgG2bκ (clone 27-35;
BD Biosciences) diluted in ultrapure PBS at the corresponding working concentration of
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anti-CD44-PE were used as negative controls. For optimization, two variables were
altered: the antibody concentration utilized on the CellTracks™ AutoPrep, and the length
of time the FITC/PE fluorophore was exposed to the laser (altered using the “Research
Protocol” option under the “Set Up” tab, on the CellTracks™ Analyzer II).

4.2.5

Statistical analysis
Statistical analysis was performed using GraphPad Prism© 5.0 (La Jolla, CA,

USA). When analyzing two groups of data, the differences between the means was
determined using a Student’s t test. M-30 samples run in parallel were analyzed using a
paired Student’s t test. When analyzing three or more groups of data, two-way ANOVA
followed by a Bonferroni post-test was used. In all cases P<0.05 was considered to be
statistically significant.

4.3

Results

4.3.1

Initial CellSearch® system validation with a commercially
available optimized marker
To first determine the sensitivity and specificity of the CSS to detect an

optimized marker in the FITC channel, a commercially available marker from Janssen
Diagnostics, anti-EGFR-FITC, was processed with blood spiked with MDA-MB-468
human breast cancer cells on the CSS. MDA-MB-468 cells alone were first analyzed by
FCM to determine the percentage of the cell population that was EGFR +. These cells
were found to be highly EGFR+, with >99.9±0.03% of cells expressing EGFR (Figure
4.1A,C). Blood from a healthy volunteer donor was then spiked with MDA-MB-468
cells and processed on the CSS with the commercially available anti-EGFR-FITC
antibody. The CSS was able to characterize 95.1±2.34% of spiked cells as EGFR +
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(Figure 4.1B,C). Comparison of the ability of these two techniques for analyzing the
percentage of the cell population that was EGFR+ demonstrated that markers that have
been properly optimized for use with the CSS are not significantly different from results
obtained by FCM (Figure 4.1C).

4.3.2

CD44 protocol development for use with the CellSearch®
system
FCM experiments were next performed to determine the optimal concentration

of anti-CD44-FITC required for initial testing on the CSS. Blood samples spiked with
MDA-MB-468 cells at a concentration equivalent to equivalent to ~0.01% of the WBC
count (equivalent to ~200 MDA-MB-468 cells) were incubated with anti-EGFR-FITC
and analyzed by FCM. To ensure appropriate gating of tumor cells, 1% (compared to
WBC count) spiked samples were utilized. The sample showed a signal-to-noise ratio of
268.5. Several concentrations of anti-CD44-FITC were then analyzed, and based on the
FITC MFI values, the anti-CD44-FITC concentration that gave the closest signal-to-noise
ratio to that of the anti-EGFR-FITC was 3.5µg/mL, with a signal-to-noise ratio of 257.5
(Table 4.1 and Figure 4.2).
Based on these results, anti-CD44-FITC diluted in 1x ultrapure PBS at a
working concentration of 3.5µg/mL was chosen as the initial concentration to use with
the CSS. As in Figure 4.1, MDA-MB-468 cells were first analyzed by FCM to determine
the percentage of the cell population that were CD44+. These cells were found to be
highly CD44+ with 98.4±0.90% of cells expressing CD44 (Figure 4.3A,C). Blood
samples spiked with MDA-MB-468 cells were then analyzed using various exposure
times and increasing amounts of anti-CD44-FITC on the CSS using the CTC kit. After
extensive optimization, the highest percentage of CD44+ cells that could be obtained on
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Table 4.1. Optimization of CD44 antibody concentration by flow cytometry.
µg/ml of CD44-FITC

µl of EGFR-FITC

Signal to Noise Ratio

5.0

-

310.5

3.5

-

257.5

2.0

-

211.5

0.5

-

178.5

-

150

268.5
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Figure 4.2. Flow cytometry analysis of CD44-FITC titration. MDA-MB-468 tumor
cell spiked blood samples (equivalent to 1% of the white blood cell count) were
utilized to ensure appropriate tumor cell gating. MDA-MB-468 tumor cells spiked at a
concentration equivalent to 0.01% white blood cells (200 MDA-MB-468 cells)
were then incubated with various CD44-FITC volumes to MDA-MB-468 tumor cells
incubated with 150μl of EGFR-FITC to determine the FITC mean fluorescence
intensity, measured on a 4 decade log scale, signal-to-noise ratio that best matched that
observed when analyzing 150μl of EGFR-FITC. Tumor cells were defined as
CD44+CD45- or EGFR+CD45-.
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Figure 4.3. Protocol development for the CD44 marker using the CellSearch®
CTC and CXC kits. (A) FCM analysis of MDA-MB-468 human breast cancer cells
incubated with anti-CD44-FITC (red) and an IgG isotype control sample (blue). (B)
Representative CellSearch® gallery images of 7.5ml of blood from a healthy volunteer
donor, spiked with 1000 MDA-MB-468 human breast cancer cells, incubated with
4.0µg/ml of anti-CD44-FITC and standard Veridex CTC reagents (CK-PE, CD45APC, DAPI), and analyzed with the CellSearch® CTC kit and an exposure time of
0.5s. Orange squares indicate CD44+ CTCs, identified as CK+/DAPI+/CD45–/CD44FITC+. Images acquired at 10x objective magnification. (C) Percentage recovery of
CD44+ cells as determined by FCM and the CellSearch® system using the CTC kit
(n=3). Data are presented as the mean ± SEM. *** = significantly different than
respective FCM control (P < 0.0005). (D) FCM analysis of MDA-MB-468 human
breast cancer cells incubated with anti-CD44-PE (red) and an IgG isotype control
sample (blue). (E) CellSearch® gallery image of 7.5ml of blood from a healthy
volunteer donor, spiked with 1000 MDA-MB-468 human breast cancer cells,
incubated with 1.0µg/ml of anti-CD44-PE and standard Veridex CXC reagents (CKFITC, CD45-APC, DAPI), and analyzed using the CellSearch® CXC kit and an
exposure time of 0.6s. Orange squares indicate CD44+ CTCs, identified as
CK+/DAPI+/CD45–/CD44-PE+. Images acquired at 10x objective magnification. (F)
Percentage recovery of CD44+ cells as determined by FCM and the CellSearch®
system using the CXC kit (n=3). Data are presented as the mean ± SEM.
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the CSS was 69.3±2.67% at a concentration of 4.0µg/mL and an exposure time of 0.5s
(Figure 4.3B,C), and this was still significantly different (p=0.0005) than the CD44
positivity results obtained by FCM (Figure 4.3C), and thus were not considered to be
suitably optimized. The discrepancy observed between CD44+ cells identified by FCM
and the CSS was thought to be a result of either (1) the FCM assay not taking into
account the EpCAM and CK8/18/19 expression of the cells; and/or (2) the CSS not
detecting cells expressing lower levels of CD44. Upon analysis by FCM, lack of EpCAM
and/or CK 8/18/19 expression did not appear to contribute to the observed discrepancy,
since 99.5±0.47% and 99.0±0.70% of cells were EpCAM+ and CK8/18/19+, respectively
(Figure 4.4A,C and 4.5A,C). Therefore the CellSearch® CXC kit, optimized for use with
lower antigen density markers, was investigated.

4.3.3

CD44 protocol optimization using the CellSearch® CXC
kit
The CellSearch® CXC kit differs from the U.S. FDA and Health Canada-

cleared CTC kit in that the fluorescence detection of CK8/18/19, normally represented in
the PE channel, and the user’s marker of interest, normally represented in the FITC
channel, are reversed. Therefore the PE channel represents the user’s marker of interest
and the FITC channel represents CK8/18/19. This change allows for better visualization
of lower antigen density markers, ~50,000 antigens/cell on the CXC kit versus ~100,000
antigens/cell using the CTC kit 25. MDA-MB-468 cells were analyzed by FCM for CD44
positivity using an anti-CD44-PE antibody and were again found to be highly CD44+,
with 99.5±0.39% positive for CD44 (Figure 4.3D,F). Blood samples spiked with MDAMB-468 cells were then analyzed using 1.0µg/mL of anti-CD44-PE (equivalent to the
volume used for 4.0µg/mL of anti-CD44-FITC) and an exposure time of 0.6s, the
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Figure 4.4. Cell line comparison of EpCAM expression by flow cytometry (FCM).
(A) EpCAM expression of the MDA-MB-468, 21NT and LNCaP cell lines (n=3). (B)
PE mean fluorescence intensity (MFI), measure on a 4 decade log scale, as an
indicator of EpCAM antigen density, on the MDA-MB-468, 21NT and LNCaP cell
lines (n=3). (C) FCM analysis of MDA-MB-468, 21NT and LNCaP cell lines
incubated with anti-EpCAM-PE (red) and an IgG isotype control sample (blue).
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Figure 4.5. Cell line comparison of CK8/18/19 expression by FCM. (A) CK8/18/19
expression of the MDA-MB-468, 21NT and LNCaP cell lines (n=3). (B) PE mean
fluorescence intensity (MFI), measure on a 4 decade log scale, as an indicator of
CK8/18/19 antigen density, on the MDA-MB-468, 21NT and LNCaP cell lines (n=3).
(C) FCM analysis of MDA-MB-468, 21NT and LNCaP cell lines incubated with antiCK8/18/19-PE (red) and a cells only control sample (blue).
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maximum recommended by Janssen Diagnostics for the PE channel, as a starting point.
Using these parameters, 98.8±0.51% of cells were observed to be CD44+, a value not
significantly different from that obtained by FCM (Figure 4.3E,F).
After demonstrating that our developed marker was capable of identifying
CD44+ cells to an acceptable degree using the CellSearch® CXC kit, additional
optimization was required before the assay could be considered for use in a clinical
setting. Three cell lines with varying CD44 expression levels were chosen for this
purpose: MDA-MB-468 human breast cancer cells (high expression), 21NT human breast
cancer cells (low expression), and LNCaP human prostate cancer cells (no expression)
(Figure 4.6A). As with the MDA-MB-468 cells, the 21NT cells and LNCaP cells were
analyzed for EpCAM and CK8/18/19 positivity to ensure suitable identification by the
CSS (Figure 4.4A,C and 4.5A,C). All three lines were highly EpCAM+ and CK8/18/19+,
99.5±0.47%/99.0±0.70% (MDA-MB-468), 87.2±7.35%/98.6±0.67% (21NT), and 98.4±
0.97%/99.2±0.20% (LNCaP), respectively, with varying antigen densities represented as
EpCAM and CK8/18/19 MFI, measured on a 4 decade log scale, 24.7±4.49/69.0±19.7
(MDA-MB-468), 11.5±3.05/70.7±15.8 (21NT), and 16.4±1.97/37.5±3.22 (LNCaP),
respectively (Figure 4.4B and 4.5B). All three cell lines spiked into healthy volunteer
blood samples were initially processed using the CellSearch® CXC kit along with 1X
ultrapure PBS to determine the level of background noise at various exposure times
(0.05–0.6s) and compared to their respective FCM results. At all exposure times tested,
no significant differences were observed between the positivity levels obtained on the
CSS and those obtained by FCM (Figure 4.6B-D). However, background noise does
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Figure 4.6. CD44 marker optimization using the CellSearch® CXC kit. (A) FCM
analysis of MDA-MB-468 human breast cancer cells (high CD44-expression), 21NT
human breast cancer cells (low CD44-expressing), and LNCaP human prostate cancer
cells (CD44- cell line) incubated with anti-CD44-PE (red) and an IgG isotype control
sample (blue). (B-D) Comparison of the percentage recovery of CD44+ cells as
determined by FCM and the CellSearch® CXC kit incubated with either PBS, IgG-PE,
or anti-CD44-PE at stated concentration(s) of the MDA-MB-468 (high CD44expressing), 21NT (low CD44-expressing), and LNCaP (CD44- cell line), respectively
(n=3). Data are presented as the mean ± SEM. *** = significantly different than
respective FCM control (P<0.05). Representative CellSearch® gallery images of 7.5ml
of blood from a healthy volunteer donor, spiked with 1000 cells from the respective
cell line, incubated with 1.5µg/ml of anti-CD44-PE, and analyzed at an exposure time
of 0.2s are presented below their respective graph. Orange squares indicate CD44+
CTCs, identified as CK+/DAPI+/CD45–/CD44-PE+. Images acquired at 10x objective
magnification.
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appear to increase, although not significantly, with increasing exposure time, and
therefore exposure time should be kept to a minimum.
As demonstrated, MDA-MB-468 cells spiked into blood and processed with
1.0µg/mL of anti-CD44-PE on the CSS (CXC kit) at an exposure time of 0.6s resulted in
a similar percentage of CD44+ cell detection to that observed by FCM (Figure 4.3F).
However, with the goal of keeping exposure times to a minimum, various additional
exposure times were investigated. Results demonstrate that 1.0µg/mL of anti-CD44-PE
was adequate for identifying CD44 positivity in MDA-MB-468 cells (high CD44expressing cell line) at all exposure times except 0.05s (Figure 4.6B). However, using
1.0µg/mL of anti-CD44-PE in 21NT cells (low CD44-expressing cell line), we observed
that only exposure times of 0.4s and 0.6s were adequate for identifying CD44 + cells
(Figure 4.6C). Therefore, the concentration of anti-CD44-PE was increased to 1.5µg/mL.
Upon analysis of both the MDA-MB-468 and 21NT cells on the CSS (CXC kit) at this
increased antibody concentration, CD44 positivity of MDA-MB-468 cells was adequate
at all exposure times except 0.05s, and CD44 positivity of 21NT cells was now deemed
to be adequate at 0.2s and 0.4s (Figure 4.6B, C). A higher percentage of cells were
detected at 0.6s, however, this was accompanied by an increase in false positive cells in
the CD44 negative LNCaP cell line control sample using 1.5µg/mL (Figure 4.6D). Based
on these results, an antibody concentration of 1.5µg/mL was determined to be optimal for
CD44 visualization as it allowed the use of lower exposure times, thereby minimizing
background noise and false positive results. Finally, spiked blood samples for all three
cell lines were processed with appropriate IgG controls on the CSS and analyzed at
various exposure times to ensure antibody specificity (Figure 4.6B-D). Based upon these
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results, an antibody concentration of 1.5µg/mL and an exposure time of 0.2s were chosen
as the optimized parameters for this marker. Additional CellSearch® gallery images for
each cell line under optimized conditions can be found in Figure 4.7.

4.3.4

M-30 protocol development for use with the CellSearch®
system
Next, we chose to investigate M-30, a marker of cellular death. FCM

experiments were initially performed to determine the optimal concentration of paclitaxel
(0.1µg/mL) to use for apoptosis induction of the MDA-MB-468 cells (data not shown).
Paclitaxel-treated and untreated cells were then processed in parallel on the flow
cytometer and the CSS to control for various confounding factors (i.e., confluency of the
cells at time of treatment, slight variations in drug dilution, etc.) that would make direct
comparison of the M-30+ cells difficult. It should be noted that, during the development
and optimization of the M-30 protocol, images in the FITC channel were observed to be
clear, bright, and easily identifiable as M-30+ cells. This was not the case, however, with
CD44, where many images showed a faint signal in the FITC channel, but appeared
grainy in nature and were therefore not clear and bright enough to be classified as CD44 +
Based on these results, the CXC kit was not utilized in the development of the M-30
protocol as the images generated using the CellSearch® CTC kit were of the same quality
as those shown using the CellSearch® CXC kit for CD44 and therefore use of this kit
would likely not have significantly increased the number of M-30+ CTC. (Figure 4.8).
By FCM, untreated cells showed very low levels of M-30 positivity, with
0.8±0.13% being M-30+, and a small proportion of the paclitaxel treated cells
(17.6±1.18%) were classified as apoptotic (M-30+), based on gates set at the outermost
limits of an untreated control incubated with equivalent volumes of M-30 antibody
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Figure 4.7. Additional representative CellSearch® gallery images of optimized
CD44-PE protocol from Figure 3. Representative CellSearch gallery images of
7.5ml of blood from a healthy volunteer donor, spiked with 1000 cells from the
respective cell line, incubated with 1.5μg/ml of anti-CD44-PE, standard Veridex CXC
reagents (CK-FITC, CD45-APC, DAPI), and analyzed at an exposure time of 0.2s.
Orange squares indicate CD44+ CTCs, identified as CK+/DAPI+/CD45–/CD44-PE+.
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Figure 4.8. Observed staining differences between CD44-FITC and M-30-FITC
with the CellSearch® CTC kit. (A) Representative CellSearch® gallery images of
7.5ml of blood from a healthy volunteer donor, spiked with 4000 MDA-MB-468
human breast cancer cells treated with 0.1μg/ml of paclitaxel and subsequently
incubated with 3.5μg/ml of anti-M-30-FITC. Orange squares indicate M-30+ CTCs,
identified as CK+/DAPI+/CD45–/M-30+. (B) Representative CellSearch gallery images
of 7.5ml of blood from a healthy volunteer donor, spiked with 1000 MDA-MB-468
human breast cancer cells, incubated with 4.0μg/ml of anti-CD44-FITC and standard
Veridex CTC reagents (CK-PE, CD45-APC, DAPI), and analyzed with the CellSearch
CTC kit and an exposure time of 0.5s. Orange squares indicate CD44 + CTCs,
identified as CK+/DAPI+/CD45–/CD44-FITC+ (C) Representative CellSearch gallery
images of 7.5ml of blood from a healthy volunteer donor, spiked with 1000 MDAMB-468 human breast cancer cells, incubated with 1.5μg/ml of anti-CD44-PE and
standard Veridex CXC reagents (CK-FITC, CD45-APC, DAPI), and analyzed with the
CellSearch CXC kit and an exposure time of 0.2s. Orange squares indicate CD44+
CTCs, identified as CK+/DAPI+/CD45–/CD44-PE+.
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(Figure 4.9A,C). After extensive optimization on the CSS (CTC kit) 3.5µg/mL of anti-M30-FITC and an exposure time of 0.8s produced the highest percent of M-30+ treated
cells, with 10.9±2.42% being M-30+. In addition, this concentration and exposure time
when processing blood spiked with untreated cells showed M-30 positivity that was not
significantly different from the FCM results (Figure 4.9B,C).
In an attempt to explain this observed discrepancy, it was necessary to
determine if paclitaxel treatment would affect the ability of the CSS to detect the treated
CTCs by decreasing the MFI of EpCAM, CK8/18/19, and/or DAPI. Following 48 hours
of treatment with 0.1µg/mL of paclitaxel, treated and untreated cells were incubated with
anti-M-30-FITC and either anti-EpCAM-PE, anti-CK8/18/19-PE, or DAPI and analyzed
by FCM. Following paclitaxel treatment, there was no significant loss of EpCAM or CK
positivity, with 97.5±1.51% and 97.7±0.49% of cells observed to be EpCAM+ and CK+
respectively in untreated samples versus 89.6±5.89% and 91.5±3.88% respectively in
paclitaxel-treated samples. In addition, following treatment the vast majority of cells that
were apoptotic (M-30+) also appeared to be EpCAM+ (22.7±3.41% [M-30+] versus
19.9±4.62% [M-30+EpCAM+]) and CK+ (24.6±3.13% [M-30+] versus 24.9±2.26% [M30+CK+]) and therefore a significant population of M-30+/EpCAM- or M-30+/CK- cells
(that would not be captured by the CSS) was not found (Figure 4.10A,B). However,
following paclitaxel treatment there was a significant decrease in DAPI MFI relative to
untreated cells, 60.4±1.10% versus 96.9±0.46%, respectively, and there was a significant
difference between the apoptotic (M-30+) cells and those that were both apoptotic (M30+) and DAPI+, 17.6±1.18% versus 8.7±0.79%, respectively (Figure 4.10C). It is
important to note that this decrease in DAPI MFI did not necessarily constitute cells
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Figure 4.9. M-30 protocol development for use with the CellSearch® CTC kit. (A)
FCM analysis of M-30 expression in untreated MDA-MB-468 human breast cancer
cells (blue) and cells treated with 0.1µg/ml of paclitaxel (green), and a cells only
control sample (red). (B) Representative CellSearch® gallery images of 7.5ml of blood
from a healthy volunteer donor, spiked with 4000 MDA-MB-468 human breast cancer
cells treated with 0.1µg/ml of paclitaxel and subsequently incubated with 3.5µg/ml of
anti-M-30-FITC and standard Veridex CTC reagents (CK-PE, CD45-APC, DAPI).
Orange squares indicate M-30+ CTCs, identified as CK+/DAPI+/CD45–/M-30+. (C)
Percentage of M-30+ cells for treated and untreated samples as determined by FCM
and the CellSearch® system (n=3). Data are presented as the mean ± SEM. * =
significantly different than respective FCM control (P<0.05).
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Figure 4.10. Assessment of potential sources of M-30 loss using the CellSearch®
system. (A) Percentage of EpCAM+, M-30+, and dual stained M-30+/EpCAM+ cells in
the presence or absence of paclitaxel treatment (0.1 µg/ml for 48 hours; n=3). (B)
Percentage of CK+, M-30+, and dual stained M-30+/CK+ cells in the presence of
absence of paclitaxel treatment (0.1 µg/ml for 48 hours; n=3). (C) Percentage of
DAPI+, M-30+, and dual stained M-30+/DAPI+ cells in the presence or absence of
paclitaxel treatment (0.1 µg/ml for 48 hours; n=3). Data are presented as the mean ±
SEM. * = significantly different than respective untreated control (P < 0.05). a =
significantly different than paclitaxel-treated M-30+ sample.
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becoming DAPI-. Instead cells that demonstrated high levels of DAPI staining (DAPI hi
phenotype) prior to treatment appeared to exhibit decreased DAPI staining following
treatment (DAPIlo phenotype), which could therefore affect adequate visualization of
DAPI positivity on the CSS. This decrease in DAPI MFI lead us to further investigate the
percentage of cells that were M-30+DAPIhi by FCM compared with those that were M30+DAPI+ by the CSS (since DAPI positivity is a requirement to classify an event as a
CTC on the CSS). This comparison appeared to rectify the observed difference.
However, to validate this observation, reanalysis of the CSS data was necessary, to
determine if inclusion of those cells that were not originally classified as a CTC due to
poor DAPI staining would increase the number of M-30+ cells to that originally observed
by FCM (17.6±1.18%). However, upon reanalysis the percentage of M-30+ cells
increased only marginally and this increased value was still significantly different (paired
t-test) from the M-30+ data obtained by FCM (data not shown).

4.4

Discussion
The majority of cancer-related deaths are due to ineffective treatment of

metastatic disease and an incomplete understanding of the biology of metastasis.
Advances in the area of CTC detection and enumeration allows for investigation of the
early-stages of metastasis that until recently was limited by technological challenges. The
characterization of CTCs could be a powerful clinical tool, acting as a real-time,
minimally invasive liquid biopsy that would inform clinical decision-making and help
direct tailored, individualized therapy. In the present study, our aim was therefore to
develop protocols that would allow for the characterization of CTCs using the U.S. FDA

137

and Health Canada-cleared CSS. To the best of our knowledge, this is the first study in
the literature to describe the detailed process of protocol development and optimization
using this platform. We have demonstrated the appropriate steps that must be taken for
proper optimization of user-defined protein marker assays on this system, including
comparison of results with a well validated protein expression technology (FCM);
appropriate troubleshooting; and detailed optimization techniques using cell lines with
various target marker antigen densities. In addition, we have demonstrated that not all
markers are ideal candidates for use with the CSS.
Although previous studies have examined CTCs for the expression of CD44,
none of these previous studies have utilized the CSS to do so25–27. As this system is still
the gold-standard and the only U.S. FDA and Health Canada-cleared instrument for CTC
enumeration and clinical decision-making, the ability to characterize CTCs in
combination with enumeration using this particular platform is more clinically applicable
then the ability to do so using other techniques. Additionally, Rossi et al., 2010, is the
only published study (to our knowledge) that has utilized user-defined, non-Janssen
optimized protein markers assays (specifically M-30), on the CSS. However, this
manuscript fails to provide details of proper optimization of the protocol for the use of
this protein marker on the CSS28. This highlights the necessity for the current study,
which provides a detailed description of the process of protein marker optimization in
order for users of this instrument to develop properly optimized protein marker protocols
that could be utilized in a clinical setting.
The advantages of utilizing the CSS platform include system standardization;
clearance by the U.S. FDA and Health Canada for assessment of prognosis in metastatic
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breast, prostate, and colorectal cancer; and the ability to examine CTC heterogeneity at
the single cell level. However, the CSS does have a number of disadvantages, including
the use of the epithelial marker EpCAM for CTC enrichment. Others have shown that
many of the tumor cells found in the circulation are actually mesenchymal in phenotype
and are therefore potentially undetectable by this system due to a lack of EpCAM
expression29–32. In addition, it has been demonstrated that the epithelial-to-mesenchymal
transition (EMT), which may produce these undetectable CTCs, is associated with
enhanced cancer cell aggressiveness33,34. Therefore metastatic cells that may potentially
form metastatic lesions and are of great interest for characterization may be missed by the
CSS. New CTC platforms are currently under development, and hold great promise for
enhanced CTC detection and characterization35,36. However, the CSS, although not a
perfect detection and characterization platform, is currently the clinical gold standard for
CTC analysis, and for this reason we explored the development of additional CTC
characterization assays using this system.
We initially began protocol development for the CD44 marker using the
CellSearch® CTC kit, with limited success. We hypothesized that the low CD44
positivity results might be due to contamination with leukocytes expressing CD44,
thereby simulating a situation in which cells appear to have a lower than expected antigen
density. We tested this hypothesis by utilizing the CellSearch® CXC kit, which is
optimized for the visualization of lower antigen density markers. Utilization of this kit
resolved this observed discrepancy, showing levels of CD44 expression that were not
significantly different from those observed by FCM. Three cell lines with various CD44
expression levels were then chosen to optimize this protocol. This was a necessary step in
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the optimization process as the CD44 antigen density in patient CTCs is unknown, and
likely to be quite variable across patient samples. As demonstrated, the 21NT cell line
(low CD44-expressing) was unable to be adequately visualized at a low exposure time
using 1.0µg/mL of anti-CD44-PE, and therefore the concentration had to be increased to
1.5µg/mL to ensure adequate sensitivity. In addition, the LNCaP cell line (CD44
negative) was utilized to ensure specificity of the assay protocol.
As with all assays, limitations do exist when utilizing the CSS for the
visualization of CD44. CD44 is a marker of cancer stem cells (CSCs)19, a phenotype that
has been associated with EMT37. There is always the possibility that CTCs from patient
samples may express CD44, but largely by those cells that are undetectable by the CSS,
due to a lack of or low level of EpCAM expression. In addition, we have demonstrated
that leukocytes can affect adequate CD44 visualization. Therefore this assay could be
compromised in patients with exceptionally high levels of contaminating leukocytes.
However, we are confident that this assay is appropriately optimized for use in future
clinical studies of metastatic cancer patients.
Next we investigated a different type of marker, one that measures cellular
death in response to therapy. We attempted to optimize the integration of the early
apoptosis marker M-30 with the CSS. However, after extensive experimentation, we have
demonstrated that this marker is unlikely to ever capture all early apoptotic cells in
patient samples, as these results were unachievable even under highly controlled
conditions. The lack of optimal M-30 positivity on the CSS did not appear to be as a
result of a decrease in either EpCAM or CK MFI in our paclitaxel-treated cells. However,
when nuclear staining using DAPI was investigated by FCM, there did appear to be a
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significant decrease in the percentage of overall DAPI hi and M-30+DAPIhi cells, which
could affect adequate visualization of DAPI positivity, and therefore CTC classification,
on the CSS. When only the M-30+DAPIhi FCM results were compared to our M30+DAPI+ CellSearch® data this appeared to rectify the observed difference. To validate
this observation, re-analysis of the CellSearch® data was performed to determine if
inclusion of those cells that were not originally classified as a CTC due to poor DAPI
staining would increase the number of M-30+ cells to that originally observed by FCM.
However, re-analysis only marginally increased the percentage of M-30+ cells on the
CSS. This increased value was still significantly different from the M-30+ data obtained
by FCM and therefore could not be a plausible explanation for why M-30 positivity using
the CSS was lower than that observed by FCM. It is possible that spiking cells that are in
the process of cell death could reduce CTC recovery as some of these cells may be
damaged during the pre-spiking preparation and others during CellSearch® sample
processing. Therefore, experiments would need to be performed to determine M-30+ CTC
recovery, using spiked samples with high, medium, and low numbers of M-30+ CTCs,
and to demonstrate that these recovery results are reproducible across laboratories before
this protocol could be considered for clinical use. However, based on the results obtained
in our study and our primary aim of demonstrating proper protocol development and
troubleshooting, we will not be moving forward with this marker as we believe that there
are other markers that are likely better suited to identifying therapy response.
In previous work by Rossi et al. (2010), attempts were made to utilize the M30 assay on the CSS28. However, direct comparison between M-30 positivity by FCM
and the CSS was never performed; instead CellSearch® results were compared to
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Annexin V positivity, with somewhat discordant results. The authors attempt to explain
this difference as a result of non-classification of some events as CTCs on the CSS;
however experimentation was not undertaken to confirm this hypothesis. In addition,
optimal M-30 antibody concentration (2µg/mL) and exposure time (0.4s) were chosen
based on results from 3 patients with probable M-30+ CTCs, not in treated control spiked
blood samples, as shown in this study.
The M-30 assay has potential for utilization as a measure of therapy
effectiveness and as an early indicator of the necessity for a change in treatment.
However, this assay is only able to identify apoptosis, one of many known mechanisms
of cellular death (necrosis, autophagy, mitotic catastrophe)20. This presents a potential
problem when examining CTC death as a marker of therapy effectiveness, as it is likely
that not all therapy-induced cellular death will be apoptotic38–40. Therefore the
discrepancies observed in the visualization of this marker in the present study could be a
result of the overall complexity and lack of a complete understanding of cellular death in
response to therapy.
Research in this area has led many in the field to believe that there is much
overlap in the mechanisms that underlie these cellular death processes38–40 but that many
different pathways exist that may result in cell death (e.g., apoptosis, necrosis,
autophagy). Therefore many cells undergoing cellular death may be missed by relying on
an assay that only measures apoptosis. Instead, an ideal cellular death marker would
measure all types of cell death, however such a marker does not yet exist. The next ideal
candidate would measure the most prevalent form of cellular death and be present for the
longest detectable period of time. However, even this may be difficult to achieve. Others
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have demonstrated that the relative proportion of cells that undergo apoptotic cell death
can change quite dramatically based on the stressor applied, stressor intensity
(concentration and/or length of application), and the cells induced to undergo apoptosis38.
Problems therefore arise when examining patient samples as proper timing may be
necessary to capture cell death in the appropriate state. Even if ideal conditions were
satisfied, highly vascularized versus poorly vascularized/hypoxic tumors may respond
differently (i.e., different cellular death pathways) to antitumor agents due to differences
in drug concentrations received. The question then becomes whether the identification of
all early apoptotic CTCs is necessary for prediction of therapeutic efficacy and clinical
decision-making. Instead, could the identification of any apoptotic cells represent a
favourable prognosis for patients? In the study by Rossi et al. (2010)28, CTC analysis was
performed in blood from 8 breast cancer patients using the integrated M-30 assay on the
CSS (2µg/mL and exposure time 0.4s). The change in the number of live verses dead
(apoptotic) CTCs was determined and found to correlate with radiologic findings of
disease status (progressive versus stable disease/partial response), as determined by
radiology, with 100% concordance. Obviously larger follow up studies will have to be
performed before any meaningful conclusions can be drawn from these data, but the
results do appear promising.
In summary, we have demonstrated the detailed process of optimization that is
required for the development of a user-defined marker on the CSS. In addition, we have
shown that not all markers are suitable candidates for use with this platform and the
necessary troubleshooting that must be performed when dealing with markers that might
alter CTC identification characteristics. This study will act as an important
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troubleshooting guide for the future development of protein marker assays by users of
this platform.
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Chapter 5
Adaptation of semi-automated circulating tumor cell
assays for clinical and pre-clinical research applications
A version of this chapter has been published:
Lowes LE, Hedley BD, Keeney M, and Allan AL. J. Vis. Exp.. 2014; (84):e51248.

Abstract
The majority of cancer-related deaths occur subsequent to the development of
metastatic disease. This highly lethal disease stage is associated with the presence of
circulating tumor cells (CTCs). These rare cells have been demonstrated to be of clinical
significance in metastatic breast, prostate, and colorectal cancers. The current gold
standard in clinical CTC detection and enumeration is the U.S. Food and Drug
Administration (FDA) and Health Canada-cleared CellSearch® system (CSS). This
manuscript outlines the standard protocol utilized by this platform as well as 2 additional
adapted protocols that describe the detailed process of user-defined marker optimization
for protein characterization of patient CTCs and a comparable protocol for CTC capture
in very low volumes of blood, using standard CSS reagents, for studying in vivo preclinical mouse models of metastasis. In addition, differences in CTC quality between
healthy donor blood spiked with cells from tissue culture versus patient blood samples
are highlighted. Finally, several commonly discrepant items that can lead to CTC
misclassification errors are outlined. Taken together, these protocols will provide a useful
resource for users of this platform interested in pre-clinical and clinical research
pertaining to metastasis and CTCs.
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5.1

Introduction
In 2015 it is estimated that 589,430 individuals will die from cancer and that

1,658,370 new cases of this disease will be diagnosed in the United States alone 1. The
majority of these deaths occur subsequent to the development of metastatic disease 2. The
current lack of effective therapies in treating metastasis and a limited understanding of
the metastatic cascade makes this stage of disease highly lethal. The presence of
circulating tumor cells (CTCs) within the bloodstream has been demonstrated to correlate
with metastatic disease3. These cells are extremely rare and their detection is indicative of
overall survival in metastatic breast 4, prostate5, and colorectal6 cancer. In these patients,
the presence of ≥5 (breast and prostate) or ≥3 (colorectal) CTCs in 7.5mL of blood is
indicative of poorer prognosis when compared to those patients with fewer or no
detectable CTCs in the same blood volume. In addition, the change in CTC number
during or after therapeutic intervention has been demonstrated to be useful as a predictor
of treatment response, often sooner than currently utilized techniques7–10.
It has been estimated that, in metastatic cancer patients, CTCs occur at a
frequency of approximately 1 CTC per 105-107 blood mononuclear cells and in patients
with localized disease, this frequency may be even lower (~1 in 10 8). The rare nature of
these cells can make it difficult to accurately and reliably detect and analyze CTCs 11.
Several methods (reviewed previously12–14) have been utilized to enrich and detect these
cells by exploiting properties that differentiate them from surrounding blood components.
In general, CTC enumeration is a two-part process that requires both an enrichment step
and a detection step. Traditionally, enrichment steps rely on differences in physical
properties of CTCs (cell size, density, deformability) or on protein marker expression
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(i.e., epithelial cell adhesion molecule [EpCAM], cytokeratin [CK]). Following
enrichment, CTC detection can be performed in a number of different ways, the most
common of which are nucleic acid-based assays and/or cytometric approaches. Each of
these strategies are unique, having distinct advantages and disadvantages, however they
all lack standardization; a necessity for entrance into the clinical setting. The CellSearch ®
system (CSS) was therefore developed to provide a standardized method for the detection
and enumeration of rare CTCs in human blood using fluorescence microscopy and
antibody-based techniques4–6. This platform is currently considered the gold standard in
CTC enumeration and is the only technique approved by the U.S. Food and Drug
Administration (FDA) and Health Canada for use in the clinic15.
The CSS is a two component platform consisting of, (1) the CellTracks™
AutoPrep system (hereafter referred to as the preparation instrument), which automates
the preparation of human blood samples, and (2) the CellTracks™ Analyzer II (hereafter
referred to as the analysis instrument), which scans these samples following preparation.
The CSS is described previously in Chapter 2 and Figure 2.1.
In addition to providing a standardized method for CTC enumeration, the CSS
allows for characterization of CTCs for protein markers that are of interest to the user.
This interrogation can be performed at the single-cell level, using a fluorescein
isothiocyanate (FITC) fluorescence channel not required for CTC identification16.
Although this platform is capable of user-defined characterization, the detailed process of
protocol development and optimization is not well-defined. Three commercially available
markers have been developed by the manufacturer for use with the CSS, epidermal
growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), and
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insulin-like growth factor 1 receptor (IGF-1R). HER2 analysis, in combination with the
CSS, has been utilized by several groups to illustrate the potential for CTC
characterization to inform clinical decision-making and to potentially change existing
treatment guidelines. For example, Fehm et al., demonstrated that approximately one
third of breast cancer patients with HER2- primary tumors had HER2+ CTCs17. In
addition, Liu et al., recently reported that up to 50% of patients with HER+ metastatic
breast cancer did not have HER2+ CTCs18. Herceptin®, a HER2 recepter interfering
monoclonal antibody demonstrated to greatly benefit patients whose tumors express
sufficient levels of HER2, is a commonly utilized treatment for patients with HER2 +
primary tumors19–21. However, these studies suggest that Herceptin® may be being suboptimally utilized and that CTC characterization may aid in predicting treatment
response. Ultimately, CTC characterization may have the potential to improve
personalized care.
CTC research is unique in that it has largely utilized a bedside-to-benchtop
approach. This method, unlike benchtop-to-bedside research, which can often take years
to impact patient care, has allowed CTCs quick entry into the clinical setting. However,
physicians are hesitant to use results from CTC analysis in patient treatment decisionmaking due to a lack of understanding of their underlying biology. Therefore appropriate
pre-clinical mouse models of metastasis and complementary CTC analysis techniques
must be utilized in order to investigate these outstanding questions. In general, there are 2
types of pre-clinical models used to study the metastatic cascade, (1) spontaneous
metastasis models, which allow for the study of all the steps in the metastatic cascade,
and (2) experimental metastasis models, which only allow for the study of later steps in

151

the metastatic process such as extravasation and secondary tumor formation22.
Spontaneous metastasis models involve tumor cell injections into appropriate orthotopic
locations (i.e. injection of prostate cancer cells into the prostate gland for the study of
prostate cancer). Cells are then given time to form primary tumors and spontaneously
metastasize to secondary sites such as the bone, lung, and lymph nodes. In contrast,
experimental metastasis models involve direct injection of tumor cells into the
bloodstream (i.e. via tail vein or intracardiac injection to target cells to specific locations)
and therefore skip the initial steps of intravasation and dissemination to secondary
organs22. Thus far the majority of CTC enumeration in in vivo model systems has been
performed using either cytometry-based23 or adapted human-based CTC techniques (i.e.,
AdnaTest)24. Although useful, none of these techniques adequately reflect CTC
enumeration using the gold standard CSS. Based on the clinical approval, standardized
nature, and widespread usage of the CSS, the development of a CTC capture and
detection technique for in vivo modeling that utilizes equivalent sample preparation,
processing, and identification criteria would be advantageous as results would be
comparable to those obtained from patient samples. However, due to the volume
requirements of the preparation instrument it is not possible to process small volumes of
blood using this automated platform. In addition, previous work by Eliane et al., (2008)
has demonstrated that contamination of samples with mouse epithelial cells (which also
meet the standard CTC definition [EpCAM+CK+DAPI+CD45-]) can lead to
misclassification of mouse squamous epithelial cells as CTCs25. To address these issues,
an adapted technique that allows the utilization of the CSS CTC kit reagents combined
with a manual isolation procedure was developed. The addition of a FITC labeled human
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leukocyte antigen (HLA) antibody to the assay allows human tumor cells to be
distinguished from mouse squamous epithelial cells.
This manuscript describes the standard, commercially developed and optimized
CSS protocol for processing patient blood samples and common pitfalls that may be
encountered, including discrepant items that can lead to CTC misclassification errors. In
addition, customization of the CSS assay to examine user-defined protein characteristics
of captured CTCs and a comparable adapted CSS technique that allows for the
enrichment and detection of CTCs from small volumes of blood in pre-clinical mouse
models of metastasis are described.

5.2

Materials and methods

5.2.1

Standard CTC enumeration from patient blood samples
using the CellSearch® system (CSS)
All human studies described in this manuscript were carried out under

protocols #15569E and #16904E approved by Western University’s Human Research
Ethics Board (Appendices 1 and 2). Appropriate handling of human blood samples,
including both sample collection and preparation, is critical for efficient CTC
enumeration using the CSS. Specifically, using standard aseptic phlebotomy techniques,
a minimum of 8.0mL of human blood must be collected into a 10mL CellSave tube
(Janssen Diagnostics, Raritan, NJ; hereafter referred to as the CTC preservative tube),
which contains ethylenediaminetetraacetic acid (EDTA) and a proprietary cellular
preservative. This tube is then inverted a minimum of 5 times to prevent blood from
clotting. Samples are then processed immediately or stored at room temperature for up to
96 hours. Immediately prior to sample processing, CSS reagents should be removed from
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the fridge and allowed to warm to room temperature. Using a disposable 10mL pipette
and automated pipettor, 7.5mL of blood is collected from the CTC preservative tube and
slowly dispensed into an appropriately labeled preparation instrument processing tube
and 6.5mL of dilution buffer is added to each sample. All samples are then mixed by
inversion 5 times and centrifuged at 800 x g for 10 min with the brake in the “off”
position.
To ensure appropriate instrument operation, a control sample must be run once
each day human samples are processed. Control preparation involves an initial gentle
vortex of the control vial, followed by inversion 5 times to mix. The cap from the control
vial is then carefully removed and an inverted preparation instrument processing tube is
placed on top of the uncapped vial. In one swift motion, the control vial is inverted, and
the contents of the vial are poured into the processing tube. While inverted, the sides of
the control vial are gently flicked to release any remaining contents. The inverted control
vial is then carefully removed from the processing tube, ensuring that no liquid is lost.
Using a 1,000µL pipette, any remaining contents from the vial and lid are collected and
gently deposited into the processing tube. A single control sample (1 per day) and all
human blood samples are then loaded onto the preparation instrument by following the
on-screen instructions. Samples must be processed within 1 hour of preparation.
Following batch completion, the on-screen instructions on the preparation
instrument are used to unload all samples from the system. Each sample, in a separate
cartridge, in a magnetic device, must be tapped on the lab bench to release any bubbles
that are stuck to the edges of the cartridge. Once all the bubbles have been removed, the
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cartridge must be firmly capped, laid flat, and incubated in the dark for at least 20
minutes. Samples must be scanned within 24 hours of preparation.
Sample scanning is performed on the analysis instrument following lamp
initialization. Once warmed (~ 15 minutes), quality control measures are performed by
selecting the QC Test tab, loading the system verification cartridge, and following the onscreen instructions. Selection of the Patient Test tab allows for sample scanning. The
system will perform a coarse focus and edge detection on the magnetic device cartridge.
Edges should be adjusted as necessary using the directional keys. Following acceptance
of the described changes the system will perform a fine focus and begin sample scanning.
Validation of control samples must be performed using defined criteria for cells spiked at
high (CK+DAPI+CD45-APC+) and low (CK+DAPI+CD45-FITC+) concentrations.
Captured CTCs from human blood samples must be reviewed and classified using the
defined CTC criteria (CK+DAPI+CD45-).

5.2.2

CTC characterization for user-defined markers using the
CSS
CTC characterization using the CSS requires specific dilution of the antibody

of interest. Specifically, the antibody must be diluted using Bond Primary Antibody
Diluent (Leica Biosystems, Concord, ON) to the desired concentration in a marker
reagent cup using the formula (stock concentration = ([working concentration x 850µL] /
150µL)), where the working concentration is the concentration of the antibody after
addition to the sample and the stock concentration is the concentration of antibody in the
reagent cup. For multiple samples, antibody volumes need to be adjusted as described in
Table 5.1. Once diluted the reagent cup is placed in position 1 in the reagent cartridge and
loaded onto the CSS.
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Table 5.1. Total volume requirements for the CSS when processing various numbers of
samples with a user-defined marker.
# of Samples with User
Defined Marker Added

Total Volume to Add
to Reagent Cup (µl)

1

450

2

600

3

750

4

900

5

1050

6

1200

7

1350

8

1500

**This table has been adapted from the Veridex White Paper (available online:
http://www.veridex.com/pdf/CXC_Application_Guideline.PDF.)

156

Once prepared, human blood samples for which characterization is desired are
loaded onto the preparation instrument as described above in section 5.2.1. Selection of
User Defined Assay on the preparation instrument is required to enable custom marker
addition to selected samples. Following batch completion, sample scanning is performed
as outlined in section 5.2.1. Initialization of the FITC channel (Setup tab --> CellSearch
CTC --> CTC Research) is required for visualization of the marker of interest. Exposure
times can be edited as necessary. However, it is recommended that an exposure time of
1.0 sec not be exceeded when using the CSS CTC kit as this can increase bleed-through
into other fluorescent channels utilized for CTC identification.

5.2.3

Adaptation of the standard CSS protocol for use in preclinical mouse models
This protocol has been adapted from the Veridex Mouse/Rat CellCapture Kit

(Veridex; no longer commercially available). Blood collection (minimum of 50µL) is
performed from mice previously injected with human tumor cells (orthotopic, tail vein, or
intracardiac routes) using a 22 gauge needle, pre-coated with ~30µL of 0.5M EDTA.
Collected blood from the saphenous vein (for serial CTC analysis) or by cardiac puncture
(for terminal CTC analysis) is dispensed, following removal of the needle, into a 1mL
EDTA microtainer blood collection tube and mixed by inversion to prevent clotting.
Blood may be processed immediately or stored at room temperature for up to 48 hours
following the addition of an equal volume of CytoChex cellular preservative (Streck,
Omaha, NE).
Immediately prior to processing, the CSS reagents must be removed from
the fridge and allowed to warm to room temperature. The equivalent of 50µL of whole
blood is then transferred to a 12x75 mm flow cytometry (FCM) tube and 500µL of
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dilution buffer (Janssen Diagnostics, CellSearch CTC kit) is added to each sample,
washing down any blood that remains on the sides of the tube. If necessary, a short
centrifuge spin can be used to collect any remaining blood. Following a gentle vortex,
25µL of anti-EpCAM ferrofluid (Janssen Diagnostics, CellSearch CTC kit) is added to
each sample by placing the tip of the pipette directly into the sample. Next, 25µL of
Capture Enhancement reagent (Janssen Diagnostics, CellSearch CTC kit) is added to
each sample, followed by a gentle vortex to mix. Samples are then incubated at room
temperature for 15 min and subsequently placed into a magnet for 10 min. While still in
the magnet, residual liquid and unlabelled cells are carefully aspirated, without touching
the wall of the tube, using a glass pipette and discarded.
Sample tubes are then removed from the magnet and resuspended in 50µL of
Nucleic Acid Dye (Janssen Diagnostics, CellSearch CTC kit), 50µL of Staining Reagent
(Janssen Diagnostics, CellSearch CTC kit), 1.5µL of anti-mouse CD45-APC
(eBioscience, San Diego, CA), 5.0µL of anti-human HLA-AlexaFluor488 (BioLegend,
San Diego, CA) and 100µL of Permeabilization Reagent (Janssen Diagnostics,
CellSearch CTC kit). For multiple samples, these reagents may be pre-mixed and
206.5µL of this mixture may be added to each tube. Following a gentle vortex, each
sample is incubated for 20 min at room temperature. Dilution buffer (500µL) is then
added and the samples are placed into a magnet and incubated for 10 min. While still in
the magnet, a glass pipette is used to carefully aspirate the residual liquid and unlabelled
cells. Finally, the sample is resuspended in 350µL of dilution buffer and the entire
volume is carefully transferred into a cartridge in the magnetic device, starting at the
bottom and slowly withdrawing the tip as the sample is dispensed. Once loaded, the
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cartridge must be firmly capped as described in section 5.2.1. Bubbles may interfere with
sample scanning and therefore should be popped using a sterile 22 gauge needle prior to
capping. Samples must be incubated in the dark for at least 10 minutes and scanned
within 24 hours of preparation. Prior to sample scanning any existing data on the
magnetic device must be cleared using the Format Sample button under the Setup tab.
Sample information must then be input using the Edit button on the Patient Test tab and
samples can be scanned, following initialization of the FITC channel (exposure time set
to 1.0 sec), as described in section 5.2.1.

5.3

Results

5.3.1

Standard circulating tumor cell enumeration assay
The sensitivity and specificity of the CSS has been well documented in the

literature26. However, to validate equivalent CTC recovery, spiked (1,000 LNCaP human
prostate cancer cells) and unspiked human blood samples from healthy volunteer donors
were processed on the CSS using the standard CSS CTC protocol. As expected, unspiked
samples were free of CTCs, 0.00±0.00%, and CTC recovery was demonstrated to be
86.9±4.71% for spiked samples (Figure 5.1A). CSS gallery images obtained from spiked
samples were of optimal quality and CTCs were easy to distinguish from non-CTCs.
However, when processing samples obtained from cancer patients, identification of CTCs
is slightly more challenging, with many cells appearing smaller in size and being less
easily distinguishable from non-CTCs (Figure 5.1B). In addition, when reviewing patient
samples 6 categories of events were identified that were commonly discrepant items
between reviewers (Figure 5.1C). These 6 categories included, (1) small events that did
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Figure 5.1. CTC enumeration and interpretation using the standard CellSearch ®
system (CSS) protocol. (A) CTC recovery measured as a percentage of the number of
spiked cells. Cells were counted by hemocytometer and ~1,000 LNCaP human
prostate cancer cells were spiked into 7.5ml of human blood. Unspiked human blood
samples were used as a negative control (n=3). Data are presented as the mean ± SEM.
(B) Representative CSS gallery images of the differences in CTC quality observed in
spiked blood samples (i.e., healthy donor blood spiked with tumor cells from culture)
versus samples collected from cancer patients. (C) Representative CSS gallery images
of commonly discrepant items that are often misclassified. Orange squares indicate
acceptable CTCs, identified as CK+/DAPI+/CD45–. Images acquired at 10x objective
magnification.
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not meet the 4 µm size requirement for CTC classification; (2) items with dim CK and/or
DAPI staining; (3) justified (should be counted as a CTC) versus unjustified (should not
be counted as a CTC) bleed through into the CD45-APC channel caused by bright CK-PE
staining; (4) FITC+ events; (5) pixelated images in the CK and/or DAPI channels; and (6)
events with DAPI staining that is larger than CK images or those with DAPI staining that
does not overlap >50% with the CK image. For categories (2) and (5) specific criteria
exist for CTC classification. For category (2), items with dim CK/DAPI can be classified
as CTCs provided that an intact membrane can be observed in the CK channel and an
appropriately sized DAPI image is noted. For category (5), items with pixelated
CK/DAPI cannot be classified as CTCs if any pixelation is observed in the CK channel.
However, pixelation is acceptable in the DAPI channel provided that it is not too severe
(i.e., image is entirely white on a background, no grey areas—described by Janssen
Diagnostics as white paint on a black background) or diffuse (must still appear oval in
shape and fit within the CK).

5.3.2

User-defined marker assay development
Adaptation of the CSS to characterize CTCs for user-defined markers requires

significant work-up with rigorous controls and has been described previously16. As a
general rule, appropriate optimization of any user-defined marker requires that negative
controls be employed to ensure that results are specific. The best results are obtained
when spiked samples are processed with both a non-specific IgG control in place of the
target antibody and with the antibody diluent alone as described previously. Various
target antibody concentrations and exposure times should also be assessed and validated
using cell lines with high, low, and absent (negative) antigen densities. Optimal protocol
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conditions are achieved when the assay demonstrates both high sensitivity for the target
antigen and low background noise from non-specific binding16.
An example of this work-up using a CSC marker, CD44, is presented here.
Initial testing with this marker began using the standard CSS CTC kit (hereafter referred
to as the traditional CTC kit), which utilizes the FITC channel for user-defined marker
development. Using the traditional CTC kit, it was demonstrated that, after significant
optimization, the maximum number of CTCs that could be classified as CD44 + was
69.3±2.67% using samples spiked with 1,000 MDA-MB-468 human breast cancer cells,
known to demonstrate high CD44 expression with the majority of cells (98.4±0.90%; as
determined by FCM expressing this protein (Figure 5.2A). Based upon these findings it
was hypothesized that the commercially available CSS CXC kit might produce improved
results. This kit allows for improved visualization of markers with a lower antigen
density (~50,000 antigens/cell) compared with the traditional CTC kit (optimized for
markers with a density of ~100,000 antigens/cell) by reversing the fluorescence channel
in which the CK8/18/19 (traditionally represented in the PE channel) and the user’s
marker of interest (traditionally represented in the FITC channel) are represented
(therefore hereafter the CXC kit will be referred to as the low antigen density CTC kit) 27.
After significant optimization, it was demonstrated that this change allowed for improved
CD44 staining, with 98.8±0.51% of CTCs classified as CD44+ using CD44-PE at a
concentration of 1.0µg/mL and an exposure time of 0.6s (Figure 5.2A). Appropriate
optimization of any user-defined marker also requires validation using high antigen
density (MDA-MB-468), low antigen density (21NT), and negative (LNCaPs) cell lines
for the marker of interest (Figure 5.2B).
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Figure 5.2. Characterization of CTCs for user-defined markers using the CSS.
(A) Percentage of cells classified as CD44+ using the CTC and CXC kits on the CSS
(n=3). Data are presented as the mean ± SEM. *** = significantly different (P <
0.0005). (B) Representative CSS gallery images of blood from a healthy volunteer
donor (7.5ml), spiked with ~1,000 cells from the identified cell line, incubated with
1.5µg/ml of anti-CD44-PE, and scanned at an exposure time of 0.2s. Orange squares
indicate CD44+ CTCs, identified as CK+/DAPI+/CD45–/CD44-PE+.
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5.3.3

Circulating tumor cell analysis in pre-clinical mouse
models
To determine the sensitivity and specificity of the adapted mouse CSS

protocol, spiked (1,000 LNCaP human prostate cancer cells) and unspiked mouse blood
samples were processed manually and scanned on the analysis instrument and compared
to results obtained using the same cell line processed using the standard automated CSS
protocol on the preparation instrument (Figure 5.3A). As expected, unspiked samples
were free of CTCs using both assays, 0.00±0.00% and CTC recovery using the adapted
mouse kit (90.8±5.18%) was not significantly different from results obtained using the
standard automated system (86.9±4.71%; p > 0.05). Images obtained using the manual
mouse adapted protocol did not differ from those observed using the standard automated
technique, with the exception of the addition of the HLA-FITC marker. In addition,
mouse squamous epithelial cells do not stain positively for HLA-FITC (Figure 5.3B). To
confirm that this technique was as sensitive as the standard CSS protocol for the isolation
of low number of CTCs, serial dilutions were performed with spiked blood samples and
the correlation of expected number of cells versus recovered number of cells was
assessed (Figure 5.3C). Results demonstrate that CTCs could effectively be recovered
down to a sensitivity of 5 cells per 50µL of whole blood using this assay. These values
correlated with expected results with an r 2 = 0.99.

5.4

Discussion
Despite the development of many new CTC technologies since the introduction

of the CSS in 2004, this technique is still the only clinically approved technology on the
market today and therefore it is considered the current gold standard for CTC detection
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Figure 5.3. Adaptation of the CSS procedure for use in pre-clinical mouse models
of metastasis. (A) CTC recovery using the adapted mouse CSS protocol measured as
a percentage of the number of spiked cells and compared to results obtained using the
standard human CSS protocol. Cells were counted by hemocytometer and ~1,000
LNCaP human prostate cancer cells were spiked into 7.5ml of human blood. Unspiked
human blood samples were used as a negative control (n=3). Data are presented as the
mean ± SEM. ns = not significant. (B) Representative CSS gallery images of CTCs
captured the adapted mouse CSS protocol demonstrating that HLA-AF488 is able to
distinguish human from mouse cells. (C) Analysis of correlation and linear regression
of the expected versus recovered number of spiked tumor cells at various
concentrations. LNCaP human prostate cancer cells were initially counted by
hemocytometer and subsequently spiked into mouse blood at a concentration of
~1,000 tumor cells/50µl of blood. Spiked mouse blood was then serially diluted to a
concentration of 5 tumor cells/50µl and processed using the mouse adapted CSS
protocol (n=3).

166

167

and enumeration. This manuscript has demonstrated that although the CSS has rigorous
quality control standards it can be subject to interpretation bias and that CTC
identification in patient samples is much different from identification in spiked samples.
Six categories of commonly discrepant items were identified that can cause CTC
misclassifications to occur. These discrepant items highlight the need for multiple
reviewers on each patient sample processed on this instrument. In addition, the
differences observed in spiked versus patient obtained CTCs demonstrates that there is a
necessity for any new CTC technologies to be validated in both spiked and patient
samples. In addition, these new technologies must be compared to the gold standard CSS
using split sample testing of both spiked and patient samples, as efficient CTC capture
from spiked samples only does not necessarily reflect CTC capture efficiency in patient
samples.
Although the CSS has the capability to perform characterization of captured
CTCs, it is quite restricted with regards to highly customizable optimization. In general,
the only parameters that can be changed on this instrument for optimization of userdefined markers are the antibody concentration and the length of time that the
fluorophore is exposed to the mercury lamp. This limited capacity for optimization can
present problems when working-up user-defined markers on the CSS. One solution
proposed in this manuscript (described in detail previously16) is the use of the low antigen
density CTC kit which switches the FITC and PE fluorescent channels allowing for better
visualization of markers with a low antigen density. Regardless of which kit is utilized
(traditional- or low antigen density CTC kit) there are several necessary steps that must
be undertaken to ensure appropriate marker sensitivity, specificity, and optimization.
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First, assay sensitivity must be assessed in comparison to a well validated method, such
as FCM, that will allow determination of the expected detection level (i.e., the % of cells
in the cell population that express the marker of interest) of the user-defined marker16.
Secondly, the assay must be assessed for its ability to detect the marker of interest in cell
lines with various levels of expression (i.e., high and low antigen densities) and its
specificity must be validated in a cell line that is negative for the marker of interest. In all
cases, all cell lines must be tested using a cells only control (no antibody added), the
appropriate IgG control, and the antibody of interest at various concentrations and
exposure times to determine the most appropriate settings that will ensure optimization of
the user-defined marker. However, it should be noted that although characterization of
CTCs is possible on the CSS, currently only one user-defined marker of interest can be
explored in each sample, and that the system is very limited with regards to downstream
applications due to the harsh processing of the samples.
The unique bedside-to-benchtop approach utilized in CTC research has
allowed for quick entry of this useful assay into the clinical setting. However, it has
resulted in an inadequate understanding of the basic biology of these rare cells. Therefore
the development and optimization of assays that allow for assessment of CTCs in preclinical in vivo mouse models of cancer are needed. This manuscript describes an adapted
CSS protocol that allows for CTCs to be assessed in 50µL volumes of mouse blood,
ideally suited for serial CTC collection experimentation. This manuscript demonstrates
that CTC enumeration using this protocol is comparable to results obtained using the CSS
in combination with the traditional CTC kit, with no significant differences in CTC
capture efficiency between the automated and manual separation techniques. In addition,
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during the development of this assay it was recognized, as previously described in the
literature25, that mouse squamous epithelial cell contamination can make accurate
identification of CTCs more difficult and sometimes impossible. Therefore to combat this
issue a user-defined HLA-AlexaFluor488 was added to this protocol to ensure that only
human cells (CK+DAPI+CD45-HLA-AlexaFluor488+) are being appropriately assigned as
CTCs. It is important to note that the LNCaP cell line used in this manuscript is HLAlow
and therefore HLA-AlexaFluor488 may need to be titrated for cell lines with varying
HLA expression. Although we have added an HLA-AlexaFluor 488 to our protocol to
ensure accurate identification of CTCs, it is noteworthy that the vast majority of mouse
squamous epithelial cells were easily identifiable by morphology and were limited in cell
number. Higher cell numbers were only observed when blood collection, via cardiac
puncture, proved difficult and repeated attempts were necessary. Therefore we propose
that if desired, on-system characterization of CTCs could be accomplished by omitting
this marker. In addition, although not described here, we anticipate that downstream
characterization could be easily achieved as demonstrated previously28,29.
Although the CSS has been utilized clinically to effectively detect CTCs in the
blood of metastatic breast, prostate and colorectal cancer patients4,30,10, it does have
several limitations. In up to 35% of patients with various metastatic cancers, CTCs are
undetectable despite the presence of widespread systemic disease26. This lack of detection
has been proposed to be as a result of the epithelial-to-mesenchymal transition (EMT), a
well-documented process known to enhance cancer invasion, metastasis, and overall
aggressiveness31. This transition has been associated with a significant reduction in
epithelial markers, such as EpCAM, and a corresponding increase in mesenchymal
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markers32. Several studies have recently demonstrated that the presence of these
mesenchymal markers in CTCs are predictive of poorer prognosis and that many of these
cells lack expression of epithelial markers that would be necessary for their detection
using the CSS24,33–38. This suggests that the standard CSS definition may be missing some
of the most aggressive CTCs.
Despite these limitations, it is anticipated the protocols described in this
manuscript will be important tools for improved CTC analysis using the CSS,
development of novel CTC technologies, optimization of user-defined markers, and
improved understanding of CTC biology using in vivo pre-clinical mouse models. Taken
together, these protocols will provide a useful resource for users of this platform
interested in pre-clinical and clinical research pertaining to metastasis and CTCs.
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Chapter 6
Role of epithelial-to-mesechymal transition on
circulating tumor cell generation and metastasis in
prostate cancer
This chapter has been prepared for peer review:
Lowes LE, Goodale, D., Xia, Y., Postenka, C., Piaseczny, M., Paczkowski, F., and Allan
AL. In preparation for Clinical Cancer Research.

Abstract
Metastatic disease is responsible for the majority of prostate cancer (PCa)
deaths and is associated with the presence of circulating tumor cells (CTCs). Detection of
≥5 CTCs/7.5mL of blood predicts for poor prognosis in metastatic PCa. The U.S. Food
and Drug Administration (FDA) and Health Canada-cleared CellSearch® system (CSS) is
the current gold standard for CTC enumeration. However, using the CSS ~35% of
metastatic PCa patients have undetectable CTCs, which may result from the epithelial-tomesenchymal transition (EMT) and subsequent loss of necessary CTC detection markers.
Although valuable clinically, little is known about the biology of CTCs, due in large part
to a lack of appropriate CTC analysis tools in pre-clinical models of metastasis. In the
current study, we have developed two pre-clinical assays for assessing human CTCs in
xenograft mouse models of metastasis; one that is comparable to the EpCAM-based CSS
(dependent on EMT status) and one that detects CTCs semi-independent of EMT status
based on capture with EpCAM and HLA (human leukocyte antigen). Using mouse blood
spiked with PCa cell lines with varying epithelial (LNCaP and LNCaP C4-2B) and
mesenchymal (PC-3 and PC-3M) phenotypes, we demonstrate that the EpCAM-based
assay (comparable to the CSS) is unable to detect a significant number (~40-50%) of
mensechymal CTCs. In vivo analysis demonstrates that cell lines with an increasingly
mesenchymal phenotype shed a greater number of CTCs, and that these cells are shed
more quickly and have a greater metastatic capacity than cell lines with an epithelial
phenotype. Interestingly, the EpCAM-based CSS appears to capture the majority of
CTCs shed during the early-stages of disease, and it is only after the establishment of
metastases that a significant number of undetectable CTCs are shed into the circulation.
Overall these results provide a better understanding of the role of the EMT in CTC
generation and metastasis. In addition, this study also highlights that the pursuit of novel
technologies aimed at capturing CTCs that are currently presumed to be undetectable
may only be useful in the metastatic setting.
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6.1

Introduction
Prostate cancer (PCa) is the most commonly diagnosed cancer and third most

common cause of cancer death in Canadian men1. The majority of PCa deaths result from
the development of metastatic disease, due to a lack of effective treatment options for
patients with metastases. During the metastatic cascade, tumor cells disseminate from the
primary site (i.e., prostate) to distant locations throughout the body via the bloodstream2.
The presence of circulating tumor cells (CTCs) in the blood correlates with metastatic
disease and the enumeration of these rare cells has been demonstrated to be an indicator
of overall survival3–6. In metastatic PCa patients, the detection of ≥5 CTCs/7.5ml of
blood is indicative of poorer progression-free and overall survival compared to patients
with <5 CTCs in the same blood volume6. In addition, changes in CTC number
throughout the course of treatment have been demonstrated to be indicative of treatment
success7.
Due to the rare nature of CTCs (~1 CTC per 105-107 blood mononuclear cells
in a metastatic patient) extremely sensitive technologies are required in order to
accurately and reliably detect these cells8. Several techniques have been utilized to detect
CTCs, including polymerase chain reaction (PCR)-based assays9,10, density-gradient
centrifugation11,12, and flow cytometry (FCM)13–15 techniques. All of these techniques
have unique advantages and disadvantages, however all of these techniques lack
standardization, a necessity for use in the clinical setting. The development of the
CellSearch® system (CSS) by Janssen Diagnostics provides a standardized method for the
sensitive detection and quantification of these rare CTCs in human blood using
fluorescence microscopy and immunology based techniques4,6,5. The CSS is also the only
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CTC technology currently approved by the U.S.FDA (Food and Drug Administration)
and Health Canada for clinical management of metastatic PCa (as well as metastatic
breast and colorectal cancers) and therefore it is considered the current gold standard in
CTC technology.
The CSS distinguishes CTCs from contaminating leukocytes by first selecting
for cells with an EpCAM+ (epithelial cell adhesion molecule) phenotype and
subsequently performing differential fluorescent staining with cytokeratins (CK) 8/18/19
(CK), CD45 (leukocyte marker), and DAPI. CTCs identified by this assay are thus
defined as cells with an EpCAM+/CK+/DAPI+/CD45- phenotype. Therefore CTC
detection using the CSS is not based on the expression of tumor-specific markers, but
instead on the expression of epithelial-specific markers (EpCAM and CK), thereby only
allowing it to capture CTCs from tumors of epithelial origin (i.e., carcinomas).
Although the CSS has been utilized clinically to effectively detect CTCs in the
blood of metastatic PCa patients6, in up to 35% of patients CTCs are undetectable despite
the presence of widespread systemic disease16. This suggests one of two things, either (1)
CTCs are truly not present in ~1/3 of patients with metastatic disease or (2) CTCs are
present but are undetectable by the CSS as they do not meet the standard definition of
CTCs (EpCAM+/CK+/DAPI+/CD45-). This lack of detection has been proposed to be as a
result of the epithelial-to-mesenchymal transition (EMT), a process first described in the
setting of embryogenesis that is now being explored for its contribution to the metastatic
spread of various cancers of epithelial origin17–19. EMT has been demonstrated to result in
a significant reduction in various epithelial markers (EpCAM and E-cadherin), some of
which are necessary for CTC capture and enumeration17,20,21. In addition to a reduction in
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epithelial marker expression, EMT also results in a corresponding increase in
mesenchymal marker expression (N-cadherin and vimentin), and in doing so, has been
well documented for its role in enhancing cancer invasion, metastasis, and overall disease
aggressiveness17,18. This therefore suggests that the standard CSS definition of CTCs may
be missing some of the most invasive and highly metastatic cells in the bloodstream and
that the capture and subsequent characterization of these CTCs with an increasingly
mesenchymal phenotype may be more informative then those with a purely epithelial
phenotype. In fact, several studies have recently demonstrated that CTCs with a purely
mesenchymal phenotype are undetectable by the CSS, but that the presence of
mesenchymal marker expression on CTCs with a hybrid phenotype is predictive of
poorer prognosis20,22–27. This suggests that current technology may be limiting our ability
to capitalize on the full potential of CTCs and that a greater understanding of CTC
biology is necessary in guiding future research.
The unique bedside-to-bench approach utilized in the field of CTC research has
allowed for quick entry of this technology into the clinic. However, outstanding questions
regarding the biology of these rare cells has resulted in a hesitance in utilizing this
information to direct patient care. Unfortunately appropriate tools needed to address these
outstanding questions are lacking and therefore appropriate mouse models and
complementary CTC analysis techniques are necessary in order to move this field of
study forward. Previous work on CTC biology in our laboratory has shown that CTC
dissemination appears to occur at relatively early time points in the metastatic cascade
and that CTCs may also be generated by metastases in an orthotopic mouse model of
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breast cancer metastasis28,29. However, very little is currently known about the role of
EMT in CTC dissemination patterns and metastasis.
In the current study, we have developed two pre-clinical assays for assessing
human CTCs in xenograft mouse models of metastasis; one that is comparable to the
EpCAM-based CSS (dependent on EMT status) and one that detects CTCs semiindependent of EMT status based on capture with EpCAM and HLA (human leukocyte
antigen). Using these assays, differences in CTC capture efficiency and kinetics in vivo
was assessed using 4 prostate cancer cell lines (LNCaP, LNCaP C4-2B, PC-3, and PC3M) with varying EMT phenotypes. Additionally, primary tumor formation and
metastatic dissemination was compared for each investigated cell line. The novel results
presented here provide a better understanding of CTC biology and may shed light on
which CTCs are the most important to study and characterize, thereby guiding strategies
on how to utilize CTCs most effectively in a clinical setting.

6.2

Materials and methods

6.2.1

Cell culture and reagents
LNCaP30 (ATCC, Manassas, VA) and PC-3M31 (a kind gift from Dr. Paula

Foster, Western University, London, ON) human prostate cancer cell lines were
maintained in RPMI-1640 + 10% fetal bovine serum (FBS). LNCaP C4-2B32 human
prostate cancer cells (a kind gift from Dr. Katherine Stemke Hale, M.D. Anderson Cancer
Center, Houston, TX) were maintained in T-media + 10% heat-inactivated FBS. PC-333
human prostate cancer cells (ATCC, Manassas, VA) were maintained in F12K media +
10% FBS. MDA-MB-46834 human breast cancer cells (a kind gift from Dr. Janet Price,
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M.D. Anderson Cancer Center, Houston, TX) were maintained in αMEM + 10% FBS.
HeLa35 human cervical cancer cells (a kind gift from Dr. Jim Koropatnick, Western
University, London, ON) were maintained in DMEM + 10% FBS. Upon reaching 80%
confluency, cells were passaged using 0.25% trypsin/EDTA (ethylenediaminetetraacetic
acid). Media and 0.25% trypsin/EDTA was obtained from Life Technologies (Carlsbad,
CA). FBS was obtained from Sigma (St. Louis, MO).

6.2.2

RNA extraction, cDNA synthesis, and real-time PCR
Total RNA was isolated from the appropriate prostate cancer (LNCaP, LNCaP

C4-2B, PC-3, and PC-3M) and control (MDA-MB-468 and HeLa) cell lines using TRIzol
reagent (Life Technologies) following the manufacturer's instructions and quantified
using a Nanodrop ND-1000 (Thermo Scientific, Waltham, MA). Following
quantification, for each reaction 1.0 µg of total RNA was reverse transcribed into
complementary DNA (cDNA) by Superscript III reverse transcriptase and oligo(dT)20
primers (Life Technologies). Quantitative reverse-transcription polymerase chain
reactions (qRT-PCR) were performed in triplicate using Brilliant II SYBR Green qPCR
Master Mix (Agilent Technologies, Santa Clara, CA) on a Stratagene Mx3000P qPCR
system (Life Technologies). Sequence specific primers for E-cadherin, N-cadherin,
vimentin, EpCAM, α-catenin, and GAPDH were designed based on gene sequence
information from the National Center for Biotechnology Information (NCBI; Bethesda,
MD), and are presented in Table 6.1. The thermal cycling profile used for all genes was
40 cycles of 94°C for 1 min, 60°C for 1 min, and 72°C for 2 min. To account for
differences in GAPDH expression between cell lines, samples were normalized using a
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Table 6.1. Forward and reverse primers used for qPCR analysis of prostate cancer cell
lines.
Target
Gene

Forward Primer (5' → 3')

Reverse Primer (5' → 3')

E-cadherin

TGCTGATGCCCCCAATACCCCA

GTGATTTCCTGGCCCACGCCAA

N-cadherin

TGACTCCAACGGGGACTGCACA

AGCTCAAGGACCCAGCAGTGGA

EpCAM

CGACTTTTGCCGCAGCTCAGGA

GGGCCCCTTCAGGTTTTGCTCT

Vimentin

AACCAACGACAAAGCCCGCGTC

TTCCGGTTGGCAGCCTCAGAGA

α-catenin

CCACGTTTTACTGAGCAAGT

AGTCAGAGTCATCCAACTCC

GAPDH

TCCATGGCACCGTCAAGGCTGA

GCCAGCATCGCCCCACTTGATT
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standard curve generated using pooled qPCR human reference total RNA (Agilent
Technologies)36.

6.2.3

Immunoblotting
Human prostate cancer (LNCaP, LNCaP C4-2B, PC-3, and PC-3M) and

control (MDA-MB-468 and HeLa) cell lines were harvested from tissue culture using
either cell scraping (E-cadherin and N-cadherin analysis) or trypsinization (vimentin,
EpCAM, and α-catenin analysis). Cell lysates were collected from harvested cells using
1% NP-40 lysis buffer and samples were quantified using the DC Protein Assay (Biorad,
Hercules, CA). Protein (10µg) was subjected to sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE) and transferred onto polyvinylidene difluoride
membranes (PVDF; Millipore, Billerica, MA). Membranes were blocked using 5% skim
milk in Tris-buffered saline + 0.1% Tween-20 (TBS-T; Sigma). Anti-human primary
antibodies, diluted in 5% skim milk in TBS-T, were used as described in Table 6.2. Goat
anti-mouse IgG and goat anti-rabbit IgG secondary antibodies (Calbiochem, Billerica,
MA) conjugated to horseradish peroxidase, diluted in 5% skim milk in TBS-T, were
utilized at a 1:2,000 dilution for all proteins except E-cadherin (1:10,000). Protein
expression was visualized using Amersham ECL Prime Western Blotting Detection
Reagent (GE Healthcare, Wauwatosa, WI), and normalized using total protein based on
amido black (Sigma) staining on the transfer membrane. MDA-MB-468 and HeLa cell
lines were utilized as positive controls for E-cadherin/EpCAM and Ncadherin/vimentin/α-catenin expression, respectively.
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Table 6.2. Details of the anti-human antibodies utilized for western blot analysis of
prostate cancer cell lines.
Target
Protein

Clone

Commercial
Source

1° Host

kDa

N-Cadherin

EPR1791-4

Abcam

Rabbit

100

E-Cadherin

36/E-cadherin

BD
Biosciences

Mouse

120

Vimentin

V9

Millipore

Mouse

60

EpCAM

E144

Abcam

Rabbit

39

α-catenin

EP1793Y

Abcam

Rabbit

100

β-Actin

Polyclonal

Sigma

Rabbit

42
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1°
Conditions
1:1,000
(1 hr @ RT)
1:20,000
(1 hr @ RT)
1:1,000
(1 hr @ RT)
1:1,000
(1 hr @ RT)
1:50,000
(1 hr @ RT)
1:5,000
(1 hr @ RT)

6.2.4

Flow cytometry
Human prostate cancer (LNCaP, LNCaP C4-2B, PC-3, and PC-3M) and

control (MDA-MB-468 and HeLa) control cells were harvested from tissue culture using
either 1mM EDTA or 0.25% trypsin/EDTA, as necessary, and resuspended in flow buffer
(PBS + 2% FBS). For each cell line, 5 x 105 tumor cells were fixed and permeabilized
using the IntraPrep™ Fix/Perm kit (Beckman Coulter, Fullerton, CA, USA), and
incubated with blocking buffer (PBS + 5% BSA [bovine serum albumin]) for 15 min.
Cells were then washed with 1mL of flow buffer and incubated with either 0.80 µg of
anti-E-cadherin (36/E-cadherin; BD Biosciences, San Jose, CA), 0.15 µg of anti-EpCAM
(E144; Abcam, Cambridge, MA), 100µL of anti-CK 8/18/19-PE (Veridex, Raritan, NJ),
0.40 µg of anti-N-cadherin (EPR1791-4; Abcam), 0.80 µg of anti-vimentin (V9;
Millipore), and/or 0.35 µg of anti-α-catenin (EP1793Y; Abcam). Following 3 washes
with 1mL of flow buffer, samples were incubated with 1.0 µg of either AlexaFluor488
conjugated goat-anti-mouse IgG or AlexaFluor488 conjugated goat-anti-rabbit IgG
secondary antibodies (Life Technologies). Following 3 washes with 1mL of flow buffer,
samples were resuspended in 500µL of flow buffer and analyzed using either a Beckman
Coulter EPICS XL-MCL or Cytomics FC 500 flow cytometer. Flow buffer alone (cells
only), mouse IgG (BD Biosciences), mouse IgG2a,κ (Abcam), rabbit IgG (Abcam), and
10µL of PE conjugated mouse IgG (BD Biosciences) were used as negative controls at
corresponding assay-specific concentrations. MDA-MB-468 and HeLa cell lines were
utilized as positive controls for E-cadherin/EpCAM/CK and N-cadherin/vimentin/αcatenin expression, respectively.
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6.2.5

Immunofluorescence
LNCaP, LNCaP C4-2B, PC-3, and PC-3M prostate cancer cell lines were

seeded at cell line specific concentrations into Lab Tek 8-well glass chamber slides
(Thermo Scientific) pre-coated with 5 µg/mL of fibronectin (LNCaP and LNCaP C4-2B
cells; Santa Cruz Biotechnologies, Dallas, TX) and grown until confluent. Cells were
then fixed using freshly prepared 2% paraformaldehyde for 10 min and washed with PBS
(3 x 5 min). Following fixation, cells were permeabilized using 0.1% Triton X-100
(Sigma) for 5 min and washed with PBS (3 x 5 min). Cells were then blocked using PBS
+ 1% BSA for 1 hour and subsequently incubated with anti-E-cadherin and/or anti-αcatenin primary antibodies diluted (1:50) in PBS + 1% BSA for 1 hour. Following 3
washes with PBS, cells were fluorescently labelled using AlexaFluor488 conjugated
goat-anti-mouse IgG and/or AlexaFluor594 conjugated goat-anti-rabbit IgG (Life
Technologies) diluted (1:300) in PBS + 1% BSA for 1 hour. Finally, cells were washed
(3 x 5 min) using PBS and mounted using 20µL of VectaShield mounting media with
DAPI (Vector Laboratories, Burlingame, CA), coverslipped, and stored at 4°C until
analyzed and imaged at 60x magnification using an Olympus Provis AX70 microscope
(Olympus, Richmond Hill, ON).

6.2.6

Blood sample collection
A minimum of 100µL of whole blood was collected from 6-8 week old male

athymic nude (nu/nu) mice (Harlan Sprague-Dawley, Indianapolis, IN) via terminal
cardiac puncture of the right ventricle. Cardiac puncture was performed using a 22-G
needle, pre-coated with sterile 0.5M EDTA, attached to a 1mL syringe. Following
collection, the needle was removed, and whole blood was dispensed into a 1mL EDTA
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microtainer blood collection tube (BD Microtainer, Franklin Lakes, NJ) and mixed by
inversion to prevent clotting. Blood was either processed immediately or stored for up to
48 hours after the addition of an equal volume of CytoChex cellular preservative (Streck,
Omaha, NE). For EMT-dependent and semi-independent assay development, 50µL of
whole blood was "spiked" with either 1000 LNCaP, LNCaP C4-2B, PC-3, or PC-3M
tumor cells. To assess assay recovery of low numbers of spiked cells (100, 50, 10, 5)
serial dilutions were performed using whole blood (data not shown).

6.2.7

EMT dependent circulating tumor cell assay
This assay was adapted from the Veridex mouse/rat CellCapture kit (no longer

commercially available) and has been described in detail previously37. Briefly, following
blood collection, the equivalent of 50µL of whole blood was incubated with 25µL of
anti-EpCAM ferrofluid (Janssen Diagnostics; CellSearch CTC kit) and 25µL of Capture
Enhancement Reagent (Janssen Diagnostics; CellSearch CTC kit) for 15 min. Samples
were then incubated in a magnet for 10 min and unlabelled cells were aspirated using a
glass pipette. Fluorescent labelling of the remaining cells was performed using 50µL of
Nucleic Acid Dye (Janssen Diagnostics; CellSearch CTC kit), 50µL of Staining Reagent
(Janssen Diagnostics; CellSearch CTC kit), 0.30 µg of anti-mouse CD45-APC (30-F11;
eBioscience, San Diego, CA), 1.5 µg of anti-human HLA-AlexaFluor488 (W6/32;
BioLegend, San Diego, CA) and 100µL of Permeabilization Reagent (Janssen
Diagnostics; CellSearch CTC kit) for 20 min. Dilution buffer (500µL; Veridex;
CellSearch CTC kit) was added and samples were incubated in a magnet for 10 min.
Unlabelled cells were aspirated using a glass pipette and the remaining sample was
resuspended in 350µL of dilution buffer and transferred to a MagNest™ device for
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analysis using the CellSearch analyzer (Janssen Diagnostics). Events with an
EpCAM+/CK+/DAPI+/CD45-/HLA+ phenotype and a round/oval morphology were
classified as CTCs.

6.2.8

EMT semi-independent circulating tumor cell assay
Following blood collection, the equivalent of 50µL of whole blood was

transferred to a 5mL flow tube and red blood cells (RBC) were lysed using 2mL of 1x
NH4Cl for 10 min. Following RBC lysis, samples were washed with 2mL of dilution
buffer and centrifuged to collect cells. Cells were then fluorescently labelled using 0.2 µg
of anti-human HLA-PE (W6/32; BioLegend), 0.0075 µg of anti-human EpCAM-PE
(EBA-1; BD Bioscience), and 0.30 µg of anti-mouse CD45-APC and incubated for 20
min. Samples were washed with 1mL of dilution buffer and immunomagnetically
enriched using the EasySep APC Positive Selection kit (StemCell Technologies,
Vancouver, BC) as per the manufacturer's instructions. Following enrichment, the
fraction containing the tumor cells (supernatant) was centrifuged and the cell pellet was
resuspended in 100µL of Permeabilization Reagent and 50µL of Nucleic Acid Dye and
incubated for 20 min. Samples were then washed with 1mL of dilution buffer and cells
bound by PE-conjugated antibodies (HLA and/or EpCAM) were immunomagnetically
labelled using the EasySep PE Positive Selection kit (StemCell Technologies) as per the
manufacturer's instructions. Samples were washed, resuspended in 350µL of dilution
buffer, and transferred to a MagNest™ device for analysis using the CellSearch analyzer.
Events with an EpCAM/HLA+/DAPI+/CD45- phenotype and a round/oval morphology
were classified as CTCs.
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6.2.9

In vivo metastasis assays
All animal experiments were conducted under protocol #2012-031 approved by

Western University's animal care and use committee (Appendix 3). LNCaP, LNCaP C42B, PC-3, and PC-3M cancer cells were prepared in sterile Hank's buffered saline
solution (HBSS; Life Technologies) and injected (1x106 cells/40µL per mouse)
orthotopically into 6-8 week old male athymic nude (nu/nu) mice (Harlan SpragueDawley) via the right dorsolateral lobe of the prostate as described previously38,39. At
various time points post-injection (2, 4, 8, 12, and 16 weeks) mice were sacrificed,
necropsies performed to assess for gross metastases, and tissues collected for
pathohistological analysis. Blood (100µL) was also collected and processed using both
the EMT dependent and EMT semi-independent assays (50µL/assay), described above, to
assess differences in CTC presence in the bloodstream. Whenever possible, CTC sub-cell
lines were generated using excess blood not required for CTC analysis using the EMTdependent or EMT semi-independent assays. Specifically, any unused blood was lysed
using 1x NH4Cl (Beckman Coulter), washed with PBS, and plated (in 6 well dishes) for
tissue culture in the complete growth media utilized for the parental cell line. The cells
were grown for ~1-2 weeks, with regular media changes every 1-2 days to remove
contaminating blood cells until a sufficient number of cells were available for freezing.

6.2.10 Histology and immunohistochemistry
At necropsy, tissue (prostate, lymph nodes, liver, lungs, and bone) was
collected and fixed using 10% neutral-buffered formalin before processing. Tissue was
subsequently paraffin-embedded, sectioned (4 µm) and stained using standard
hematoxylin and eosin (H&E) staining. Slides were imaged at 400x magnification using
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an Aperio ScanScope microscope (Aperio Technologies,Vista, CA) and assessed for
tumor incidence and histological characteristics. Slides containing serial sections were
deparaffinised using xylene and rehydrated using a graded series of alcohols (100%,
95%, 80%, 75%) prior to tissue staining. Antigen retrieval was then performed via
immersion in 10 mM sodium citrate buffer + 0.05% Tween-20 at 100°C for 20 min,
followed by cooling for 20 min at room temperature, and washing with PBS + 0.05%
Tween-20 (3 x 2 min). Slides were incubated in BLOXALL Endogenous Peroxidase and
Alkaline Phosphatase Blocking Solution (Vector Laboratories) for 10 min, washed with
PBS + 0.05% Tween-20 for 5 min, and rinsed with running water (2 x 1 min). Tissue
staining for E-cadherin (1:100) and N-cadherin (1:750) was performed using the Polink
DS-MR-Hu kit (GBI Labs, Bothell, WA). Slides were stored at room temperature until
imaged at 40x magnification using an Aperio ScanScope microscope.

6.2.11 Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0 (San Diego, CA).
Analysis of CTC recovery using the EMT dependent and semi-independent assays was
performed using 1-way ANOVA with Tukey's post-test for multiple comparisons. To
assess differences in the mean number of CTCs between cell lines at a given time point
using either the EMT dependent assay, EMT semi-independent assay, or differences
between each assay within individual mice, a Mann-Whitney test was performed.
Comparison of differences between each assay in matched data sets within cell lines at a
given time point was performed using a Wilcoxon matched-pairs signed rank test.
Primary tumor weights and mean metastatic burden were compared using 1-way
ANOVA with Bonferroni's post-test for multiple comparisons. Differences in the
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incidence of primary tumors, lymph node metastasis, and distant metastasis were
assessed using Fisher's Exact Test. Differences in the mean number of CTCs in mice with
no metastasis versus those with metastatic disease were compared using a Student’s Ttest. Changes in EMT gene expression in isolated CTC sub-cell lines were compared to
the parental cell line using 1-way AVONA with Dunnett's post-test for multiple
comparisons. Linear regression and Spearman analysis was utilized to examine the
relationship between mean number of CTCs and primary tumor weight. Unless otherwise
stated, data are presented as the mean ± SEM. In all cases, p values of ≤0.05 were
considered statistically significant.

6.3 Results
6.3.1

Human prostate cancer cell lines display differences in
EMT phenotype
Four human prostate cancer cell lines (LNCaP, LNCaP C4-2B, PC-3, and PC-

3M) previously reported to have progressively increasing metastatic capacity40–43 were
characterized for epithelial (E-cadherin, EpCAM, and/or CK 8/18/19) and mesenchymal
(N-cadherin and vimentin) markers using qRT-PCR (Figure 6.1), western blot (Figure
6.2), and FCM (Figure 6.3). Results of this analysis demonstrated that the LNCaP and
LNCaP C4-2B cell lines had consistently higher expression of the epithelial-associated
markers E-cadherin and CK 8/18/19 (investigated by FCM only), while the PC-3 and PC3M cell lines had consistently higher expression of the mesenchymal-associated markers
N-cadherin and vimentin across all 3 assays. Although EpCAM levels appeared similar
between cell lines at the mRNA level (Figure 6.1), relative differences in EpCAM
expression were evident at the protein level, with the LNCaP and LNCaP C4-2B cell
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Figure 6.1. Human prostate cancer cell lines display differences in epithelial-tomesenchymal transition (EMT) phenotype at the RNA level. The expression of
epithelial-associated (grey bars) and mesenchymal-associated genes (black bars)
correlates with previously reported cell aggressiveness and in vivo metastatic capacity.
Results of real time quantitative PCR mRNA expression analysis for the epithelialassociated markers E-cadherin and EpCAM and mesenchymal-associated markers Ncadherin and vimentin are presented as relative expression compared to pooled
reference RNA (n=3).
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Figure 6.2. Human prostate cancer cell lines display differences in EMT
phenotype at the protein level as assessed by immunoblotting. The expression of
epithelial-associated (grey bars) and mesenchymal-associated proteins (black bars)
correlates with previously reported cell aggressiveness and in vivo metastatic capacity.
Results of western blot protein expression analysis for the epithelial-associated
markers E-cadherin and EpCAM and the mesenchymal-associated markers N-cadherin
and vimentin are presented as quantitative densitometric data relative to appropriate
positive control cell lines and normalized to total protein loaded as assessed by amido
black staining, and as representative western blots shown as cropped gel images (n=3).
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Figure 6.3. Human prostate cancer cell lines display differences in EMT
phenotype at the protein level as assessed by flow cytometry. The expression of
epithelial-associated (grey bars) and mesenchymal-associated proteins (black bars)
correlates with previously reported cell aggressiveness and in vivo metastatic capacity.
Results of protein expression analysis by flow cytometry for the epithelial-associated
markers E-cadherin and EpCAM and the mesenchymal-associated markers N-cadherin
and vimentin are presented as relative fluorescence intensity (expression) compared to
appropriate positive control cell lines (n=3).
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lines demonstrating higher levels of expression compared to the PC-3 and PC-3M cell
lines (Figure 6.2 and 6.3).
To further investigate the potential capacity for capture of these cells by the
EpCAM and CK 8/18/19 reliant CSS, differences in the co-expression of these proteins
on individual cells was assessed using FCM in order to determine relative differences in
co-expression of these proteins within each cell line (Figure 6.4). This analysis further
confirmed the differential EpCAM expression between these 4 cell lines, but interestingly
demonstrated a similar distribution of CK 8/18/19 expression. This suggested that any
differences in CTC capture between these 4 cell lines would likely be as a result of
differences in EpCAM expression and would be less impacted by differences in CK
8/18/19.
Finally, the ability of E-cadherin to maintain the epithelial phenotype of cells is
due, in part, to its localization on the cell membrane. In fact, this localization has been
reported to be a requirement for normal adhesive functions of epithelial cells 44,45.
Therefore localization studies using immunofluorescence were performed on the 4
investigated cell lines. These studies demonstrated that although E-cadherin expression
could be detected in the PC-3 cell line via western blot, the protein was aberrantly
localized to the cytoplasm in these cells, most likely due to a lack of α-catenin
expression, a protein necessary for appropriate E-cadherin membrane localization46. In
contrast, we observed that LNCaP and LNCaP C4-2B cell lines strongly expressed Ecadherin with appropriate membrane localization (Figure 6.5). Validation of the loss of
α-catenin expression in the PC-3 and PC-3M cell lines was further confirmed using qRTPCR, western blot, and FCM (Figure 6.6).
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Figure 6.4. Human prostate cancer cell lines express similar levels of CK 8/18/19
but variable levels of EpCAM as assessed by flow cytometry. (A) Representative
flow cytometry dot plots of the differential expression of EpCAM (AF488) and CK
8/18/19 (PE) in investigated prostate cancer cell lines. (B) Results of flow cytometry
protein expression analysis for epithelial-associated markers, EpCAM and CK
8/18/19, presented as the mean (± SEM) fluorescence intensity of the investigated
proteins for each cell line (n=3).
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Figure 6.5. E-cadherin cell membrane localization is aberrant in human prostate
cancer cell lines that do not express α-catenin. (A) Representative
immunofluorescent images of E-cadherin (green) and DAPI (blue) stained PC-3, PC3M, LNCaP, and LNCaP C4-2B cell lines cultured on glass chamber slides. (B)
Representative immunofluorescent images of co-localization (yellow) of E-cadherin
(green) and α-catenin (red) in PC-3, PC-3M, LNCaP, and LNCaP C4-2B cell lines
cultured on glass chamber slides (DAPI [blue]). Images were obtained at 60x
magnification, scale bars = 15 µm (n=3).
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Figure 6.6. α-catenin mRNA and protein are aberrantly expressed in PC-3 and
PC-3M human prostate cancer cell lines. (A) Results of real time quantitative PCR
mRNA expression analysis for α-catenin in the investigated cell lines (PC-3M, PC-3,
LNCaP C4-2B, and LNCaP) are presented as relative expression compared to pooled
reference RNA (n=3). (B) Results of western blot protein expression analysis for αcatenin in the investigated cell lines are presented in quantitative densitometric form
relative to an appropriate positive control cell line and as a representative western blot,
shown as a cropped gel image (n=3). (C) Results of flow cytometry expression
analysis for α-catenin in the investigated cell lines are presented as relative
fluorescence intensity (expression) compared to an appropriate positive control cell
line (n=3).
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6.3.2

Circulating tumor cell recovery using the CellSearch®
system is lower for prostate cancer cells with a
mesenchymal phenotype
As the current gold standard CTC detection technology, the CSS relies solely

on the expression of the epithelial-associated marker EpCAM for CTC capture. However,
this marker has been shown to be downregulated in cells with an invasive phenotype 47,
suggesting that EpCAM-based CTC detection techniques such as the CSS may be
missing at least a portion of the CTCs that enter the bloodstream. In order to assess this,
we developed 2 novel CTC assays for use with pre-clinical models of cancer metastasis;
one that would recapitulate the EpCAM-based CTC capture of the CSS in a mouse model
(“EMT dependent assay”), and one that would capture all the CTCs shed into the
circulation regardless of EMT status (“EMT semi-independent assay”). Following
development, all 4 prostate cancer cell lines were spiked into mouse blood at a known
concentration (1000 tumor cells/50µL blood) and were assessed using both assays to
determine differences in CTC recovery relative to the EMT phenotype of the cells
(Figure 6.7). Use of the EMT dependent assay resulted in significantly reduced recovery
of CTCs with a mesenchymal phenotype (PC-3 and PC-3M) when compared to CTCs
with an epithelial phenotype (LNCaP and LNCaP C4-2B; p ≤ 0.05) (Figure 6.7A).
However, when the EMT semi-independent assay was utilized, although overall the CTC
recovery was lower than that demonstrated using the EMT dependent assay, the percent
recovery was not significantly different across all 4 cell lines regardless of EMT status
(Figure 6.7B). The reasons underlying the reduced recovery of the EMT semiindependent assay was further investigated by incorporating the additional sample
handling steps required for the EMT semi-independent assay (i.e. red blood cell lysis and
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Figure 6.7. CTC recovery using the CellSearch® system (CSS) is lower in human
prostate cancer cells with a mesenchymal phenotype. Prostate cancer cells were
counted by hemocytometer and spiked at a concentration of 1,000 tumour cells/50µl
of whole mouse blood. 50µl of mouse blood was subsequently processed using a 1 of
2 mouse-adapted protocols and CTC recovery was measured as a percentage recovery
of the number of spiked cells. (A) CTC recovery using the EMT dependent assay is
significantly lower in cells with a more mesenchymal and metastatic phenotype. (B)
CTC recovery using the EMT semi-independent assay is lower relative to the EMT
dependent assay. However, equivalent recovery is observed across all 4 cell lines
regardless of EMT phenotype. (C) Reduced recovery observed when using the EMT
semi-independent assay was further investigated and determined to be as a result of
extra processing steps required in this protocol. Data are presented as the mean ± SEM
(n=3; * = significantly different [p ≤ 0.05]).
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additional washes) into the EMT dependent assay. The results demonstrated that when
using the same reagents and a highly epithelial cell line (LNCaP C4-2B), addition of the
extra processing steps resulted in additional sample loss between matched samples as
previously seen when comparing both assays (Figure 6.7C).

6.3.3

Tumors generated from prostate cancer cell lines with an
increasingly mesenchymal phenotype have an enhanced
capacity for circulating tumor cell shedding in vivo and
may produce circulating tumor cells that are
undetectable by the CellSearch® system
LNCaP, LNCaP C4-2B, PC-3, and PC-3M prostate cancer cells were injected

into 6-8 week old male nude mice via the right dorsolateral lobe of the prostate (1x10 6
cells/mouse) to assess spontaneous metastasis. At several time points post-injection (2, 4,
8, 12, and 16 weeks) mice were sacrificed and blood (100µL) was collected and
processed using both the EMT dependent and EMT semi-independent assays
(50µL/assay) and CTC numbers were normalized to the assay-specific cell line recovery
determined in Figure 6.7. Throughout the study mice were occasionally sacrificed at
modified time points (±1-2 weeks), either due to morbidity or other technical issues.
However, to ensure an adequate number of animals were included for the final statistical
analysis, mice were categorized based on time of sacrifice (1-3, 4-6, 8-10, 11-13, and 1416 weeks). For simplicity, the data will be presented at the initially defined time points
(2, 4, 8, 12, and 16 weeks). Unfortunately, due to the rapid progression of the PC-3M cell
line, CTC analysis in this group of mice could only be assessed at 2 and 4 weeks. We
observed that, using the EMT dependent assay, the highly mesenchymal PC-3M cell line
shed CTCs very quickly post-injection and the number of CTCs shed was significantly
greater than all other cell lines at both time points investigated (2 and 4 weeks; p ≤ 0.05)
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(Figure 6.8A). Additionally, the mesenchymal-like PC-3 cell line shed a similar number
of CTCs as the epithelial LNCaP and LNCaP C4-2B cell lines until week 12, at which
time the number of CTCs increased significantly compared to the LNCaP C4-2B cell line
(p ≤ 0.05). Although this trend appeared to continue at 16 weeks post-injection, it was not
significantly different from the LNCaP and LNCaP C4-2B cell lines. Similarly, using the
EMT semi-independent assay the PC-3M cell line shed a significantly greater number of
CTCs then all other cell lines at 2 weeks, and greater than the LNCaP and LNCaP C4-2B
cell lines at 4 weeks (p ≤ 0.05) (Figure 6.8B). When considering the PC-3 cell line,
unlike with the EMT dependent assay, no significant differences were observed between
any of the cell lines at 12 weeks. However, significant differences between the PC-3 and
LNCaP C4-2B cell lines were observed at 16 weeks (p ≤ 0.05).
To quantify differences in CTC recovery based on EMT status, normalized
CTC values obtained using both assays from each time point were compared. The results
demonstrated there were no significant differences observed in CTC recovery between
the EMT dependent and EMT semi-independent assays at any time point examined,
except for the C4-2B cell line at 8 weeks (data not shown). To assess if the lack of
statistical significance observed was due to a truly non-significant result or due to a high
level of variability with regards to CTC number in individual mice within each time point
further investigation was undertaken to assess the difference in CTCs recovered using
the EMT dependent and EMT semi-independent assays within individual animals. To
assess this, the normalized number of CTCs identified using the EMT dependent assay
were subtracted from the normalized number of CTCs identified using the EMT semiindependent assay and presented as the mean for each time point (Figure 6.8C). In this
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Figure 6.8. Human prostate cancer cell lines with an increasingly mesenchymal
phenotype have an enhanced in vivo capacity for shedding CTCs that are
undetectable by the CSS. PC-3M, PC-3, LNCaP C4-2B, and LNCaP prostate cancer
cells were orthotopically injected into 6-8 week old male nude mice via the right
dorsolateral lobe of the prostate (1x106 cells/mouse) to assess spontaneous metastasis.
At several time points post injection (2, 4, 8, 12, and 16 weeks) mice were sacrificed
and blood (100 µl) was collected and processed using both the (A) EMT dependent
and (B) EMT semi-independent assays (50 µl/assay) to assess differences in CTC
recovery. Data are presented as the mean ± SEM (n=5-12 mice/group). (C)
Comparison of the observed difference in the number of CTCs detected using the
EMT dependent and EMT semi-independent assays in matched samples. Data are
presented as the mean (± SEM) difference in the number of observed CTCs between
both assays (# captured by EpCAM/HLA assay - # captured by EpCAM assay) at a
given time point (n=5-12 mice/group). Negative values represent groups in which
more CTCs were detected with the EMT dependent assay. Positive values represent
groups in which more CTCs were detected with the EMT semi-independent assay. * =
significantly increased relative to the PC-3 cell line; α = significantly increased
relative to the LNCaP C4-2B cell line; δ = significantly increased relative to the
LNCaP cell line (p ≤ 0.05).
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way, negative values represent time points in which more CTCs were detected with the
EMT dependent assay and positive values represent groups in which more CTCs were
detected with the EMT semi-independent assay. Based on this analysis it was
demonstrated that the epithelial cell lines LNCaP and LNCaP C4-2B had similar CTC
recovery numbers across both assays at all time points investigated. However, the
mesenchymal cell lines PC-3 and PC-3M showed increased numbers of CTCs recovered
using the EMT semi-independent assay at later time points, with significant differences
observed when comparing the PC-3s to the LNCaP C4-2Bs and the PC-3s to the LNCaPs
at 12 weeks post-injection (p ≤ 0.05).

6.3.4

Prostate cancer cell lines with an increasingly
mesenchymal phenotype have an enhanced capacity for
primary tumor formation and metastasis
In addition to differences in CTC kinetics, comparison of the metastatic

capacity of these 4 prostate cancer cell lines and the relationship between CTC
dissemination and metastasis, has not yet been established in the literature. Therefore, at
each time point, mice were sacrificed and tissue (all major organs and bone) was
collected and assessed for the presence of primary and metastatic lesions based on both
gross observations at necropsy (all organs) and microscopic (prostate, lymph nodes, liver,
lung, and bone) analysis following standard H&E staining. In addition, the prostate and
bladder were weighed as a surrogate of primary tumor volume, as caliper measurements
of primary tumors in the prostate gland were not possible in live animals.
Incidence of primary tumor formation and tumor weight was significantly
increased in the highly mesenchymal PC-3M cell line compared to all other cell lines
investigated (p ≤ 0.05), except when considering tumor weight of the PC-3s at 2 weeks
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post-injection (Figure 6.9A, B). All other cell lines showed comparable primary tumor
incidence and weight at all of the investigated time points. Additionally, when
considering primary tumor weight and CTC number (using the EMT-semi-independent
assay), for all cell lines there was a positive correlation between the weight of the primary
tumor and the number of CTCs shed into the circulation (Figure 6.9C), with larger
primary tumors shedding a greater number of CTCs.
Additional differences between the mesenchymal and epithelial cell lines were
observed when considering the incidence of metastasis and metastatic burden to the
lymph nodes. Microscopic histology analysis revealed that the PC-3M cell line had a
significantly increased incidence of lymph node metastases compared to all other
investigated cell lines at 4 weeks (p ≤ 0.05), while the PC-3 cell line had a significantly
increased incidence at weeks 8 and 12 compared to the LNCaP C4-2B cell line (p ≤
0.05). Interestingly, the incidence of metastases to the lymph node did not differ
significantly between the PC-3 and LNCaP cell lines (Figure 6.10A). However, when
metastatic burden to the lymph node was assessed, the PC-3 cell line demonstrated
significantly increased metastatic burden compared to both the LNCaP C4-2Bs and the
LNCaPs at 12 weeks post-injection (p ≤ 0.05) (Figure 6.10B). Therefore, it appears that
although these cell lines have a similar capacity to disseminate to the lymph nodes, they
do not have the same capacity for subsequent growth in this organ. Finally, differences in
metastases to distant sites were also investigated, based on both gross assessment at
necropsy, and microscopic assessment following H&E staining. We observed that both
the PC-3M and PC-3 cell lines were able to disseminate to and establish gross
macrometastases in a number of distant organs. In fact, no visible macrometastases were
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Figure 6.9. The highly mesenchymal PC-3M cell line exhibits a greater incidence
of primary tumour formation and mean tumour weight compared to other
investigated cell lines and all cell lines show a positive correlation of CTC
number with primary tumour weight. (A) Incidence of primary tumour formation of
PC-3M, PC-3, LNCaP C4-2B, and LNCaP prostate cancer cell lines based on
microscopic histological examination of formalin fixed, H&E stained tissue following
orthotopic injection. Data are presented as the percentage of mice per cell line per time
point with detectable primary tumours (n=6-39 mice/group). (B) Mean combined
weight of prostate and bladder at time of sacrifice following orthotopic injection of
prostate cancer cell lines. Data are presented as the mean ± SEM (n=6-39 mice/group).
(C) Mean normalized number of CTCs/50 µl of blood (assessed using the EMT semiindependent assay) positively correlates with the primary tumour weight in all of the
investigated cell lines. * = significantly different (p ≤ 0.05).
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Figure 6.10. The mesenchymal PC-3M and PC-3 cell lines exhibit a greater
incidence of lymph node metastases and mean lymph node metastatic burden. (A)
Incidence of lymph node metastasis of PC-3M, PC-3, LNCaP C4-2B, and LNCaP
prostate cancer cell lines based on microscopic histological examination of formalin
fixed, H&E stained tissue following orthotopic injection. Data are presented as the
percentage of mice per cell line per time point with detectable lymph node metastases
(n=7-39 mice/group). (B) Quantitative analysis of tumour burden (mean % of lymph
nodes occupied by tumour) following orthotopic injection of prostate cancer cell lines.
Data are presented as the mean ± SEM (n=7-39 mice/group). * = significantly
different (p ≤ 0.05).
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observed in mice injected with either the LNCaP and LNCaP C4-2B cell lines at
necropsy (Figure 6.11). However, microscopic histology analysis of the lung and liver
revealed distant metastases to these organs for all of the investigated cell lines. Analysis
of the overall metastatic capacity of the investigated cell lines, based on the incidence of
gross distant metastases to any of described organs, demonstrated that the more
mesenchymal PC-3M and PC-3 cell lines had a significantly increased metastatic
capacity compared to the more epithelial LNCaP and LNCaP C4-2B cell lines (p ≤ 0.05).
Specifically, the PC-3M cell line had an increased incidence of distant metastases
compared to the LNCaP and LNCaP C4-2B cell lines at both 2 and 4 weeks postinjection (p ≤ 0.05), and to the PC-3s at 4 weeks post-injection (p ≤ 0.05). Similarly, at
later time points the PC-3s had an increased incidence of distant metastases compared to
the LNCaP C4-2Bs (16 weeks) and the LNCaPs (12 and 16 weeks; p ≤ 0.05) (Figure
6.12A).
Finally, we wanted to determine the relationship between CTCs and metastatic
spread. CTC numbers were compared in mice that had the presence of metastasis to the
lymph node or any distant organ (based on gross or microscopic analysis) to those
without metastasis (Figure 6.12B). This data clearly demonstrates that the number of
CTCs was significantly higher, across all 4 cell lines, in mice with metastatic disease,
compared to those without, validating the relationship between CTC dissemination and
metastasis, and that the mean CTC numbers were higher in those cell lines with the
greatest metastatic capacity.
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Figure 6.11. Human prostate cancer cell lines with an increasingly mesenchymal
phenotype have an enhanced in vivo capacity for metastasis to distant organs.
Incidence of metastasis to distant organs of PC-3M, PC-3, LNCaP C4-2B, and LNCaP
prostate cancer cell lines based on gross observations at necropsy (left panel) and
microscopic histological examination (right panel) of tissue following orthotopic
injection. Data are presented as the percentage of mice per cell line per time point with
detectable distant metastases to the lung, liver diaphragm, intestines, kidney, and/or
spleen/pancreas (n=7-39 mice/group).
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Figure 6.12. The mesenchymal PC-3M and PC-3 human prostate cancer cell lines
exhibit a greater capacity for metastasis and this correlates with CTC
dissemination. (A) Incidence of metastasis to distant organs of PC-3M, PC-3, LNCaP
C4-2B, and LNCaP prostate cancer cell lines based on gross observations at necropsy
following orthotopic injection. Data are presented as the percentage of mice per cell
line per time point with detectable distant metastases (n=7-39 mice/group). (B) The
mean number of CTCs/50 µl of blood, assessed using the EMT semi-independent
assay, are presented for mice with either metastasis to the lymph nodes or any distant
organ (based on gross and/or microscopic analysis) or mice with no evidence of
metastasis at any time point (n=6-47 mice/group). * = significantly different (p ≤
0.05).
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6.3.5

Prostate cancer cell lines maintain their established EMT
phenotypes in vivo
Although it appeared that cell lines with an increasingly mesenchymal

phenotype had a higher capacity for CTC shedding and metastatic capacity, we wanted to
confirm that the investigated cell lines demonstrated comparable epithelial and
mesenchymal phenotypes in vitro and in vivo. Therefore immunohistochemistry was
performed on tissue collected at necropsy for E-cadherin and N-cadherin expression
(Figure 6.13 and 6.14). As expected, following orthotopic injection, primary tumors
from all investigated cell lines displayed E-cadherin and N-cadherin expression in
patterns similar to that seen using in vitro analysis techniques (western blot and FCM;
Figure 6.13). However, interestingly, it did appear that the PC-3M cell line expressed a
low level of E-cadherin in vivo, versus nearly absent expression in vitro (Figure 6.2 and
6.3). Additionally, immunohistochemistry performed on metastases from each cell line to
the lymph nodes and lung showed similar expression for these markers in the
mesenchymal cell lines, however slight increases in N-cadherin expression were noted in
the lymph nodes and lungs for the LNCaP and LNCaP C4-2B cell lines respectively
(Figure 6.14). However, further assessment of this trend will need to be explored in all
mice positive for metastases to the lymph nodes and/or lungs to confirm this result.

6.3.6

Circulating tumor cells acquire a more mesenchymal
phenotype during disease progression
To further investigate the EMT profile of CTCs shed into the circulation, blood

that was not utilized for CTC analysis using the EMT dependent and EMT semiindependent assays was used to generate CTC sublines representing different timepoints
along the metastatic cascade. Unfortunately due to the low number of CTCs collected
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Figure 6.13. Prostate cancer cell lines maintain their established EMT
phenotypes when forming primary tumors in vivo. PC-3M, PC-3, LNCaP C4-2B,
and LNCaP prostate cancer cells were orthotopically injected into 6-8 week old male
nude mice via the right dorsolateral lobe of the prostate (1x10 6 cells/mouse). At 2
weeks post injection mice were sacrificed and prostate tissue was collected, formalin
fixed, and assessed for tumour cells using standard H&E staining, as well as
immunohistochemistry for E-cadherin (red) and N-cadherin (brown) expression on
selected animals. Sections stained with hematoxylin alone (cells only) and appropriate
secondary antibodies (secondary only) are presented as negative controls. Histological
sections are presented at 40x magnification. Scale bars = 50 µm.
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Figure 6.14. EMT phenotype may change between primary tumors and
metastases in vivo. PC-3M, PC-3, LNCaP C4-2B, and LNCaP prostate cancer cells
were orthotopically injected into 6-8 week old male nude mice via the right
dorsolateral lobe of the prostate (1x106 cells/mouse). At various time points post
injection mice were sacrificed and (A) lymph nodes and (B) lung were collected,
formalin fixed, and assessed for tumour cells using standard H&E staining, as well as
immunohistochemistry for E-cadherin (red) and N-cadherin (brown) expression. PC3M and PC-3 cell lines demonstrate a similar EMT phenotype following metastatic
dissemination to the lymph nodes and lung as that demonstrated using in vitro assays.
However, some differences are observed in N-cadherin expression of the epithelial
cell lines (LNCaP and LNCaP C4-2B) following dissemination. Histological sections
are presented at 40x magnification. Arrowheads on H&E images indicate regions of
tumour within the given tissue. Scale bars = 50 µm.
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from the LNCaP and LNCaP C4-2B cell lines, CTC growth following plating did not
occur. However several cell lines were created for both the PC-3 and PC-3M cell lines.
To explore differences in EMT expression in CTCs, the PC-3 parental cell line (initially
expressing a mesenchymal-like phenotype), as well as 3 sub lines collected at 8, 12, and
16 weeks, were assessed via western blot for expression of various EMT markers,
including E-cadherin, N-cadherin, EpCAM, and vimentin. Based on this analysis, it was
demonstrated that there is a significant reduction in E-cadherin expression in CTCs
collected at all time points compared to the parental cell line (p ≤ 0.05) (Figure 6.15).
Additionally, there was an increase in N-cadherin expression at all timepoints, however
this difference was only significantly different from the parental cell line at 12 and 16
weeks (p ≤ 0.05). Although there was a trend toward a reduction in EpCAM and an
increase in vimentin expression at all the timepoints investigated, the expression was not
statistically different from the parental cell line. This data suggest that CTCs may become
more mesenchymal as disease progresses, however additional analysis of the remaining
CTC sublines will need to be conducted to validate these results.

6.4

Discussion
Although CTCs are now being utilized for prognostication in the clinical

settings of metastastic breast, prostate and colorectal cancer, their underlying biology
remains poorly understood. This lack of information stems from both the unique bedsideto-bench approach that has been employed in the CTC field, as well as the lack of
appropriate tools for studying CTCs in vivo in pre-clinical models of metastasis.
Inadequate knowledge in the area of CTC biology has ultimately led to confusion with
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Figure 6.15. Circulating tumour cells acquire a more mesenchymal phenotype
during disease progression. Following orthotopic injection of PC-3 prostate cancer
cells into the right dorsolateral lobe of the prostate (1 x 10 6 cells/mouse) blood
collected at 8 weeks, 12 weeks, and 16 weeks post-injection was lysed with sterile 1x
NH4Cl, washed with PBS, and plated for tissue culture. Following 1-2 weeks of
growth, with regular media changes to remove contaminating blood cells, the
remaining CTCs were assessed using western blot for the expression of the epithelialassociated markers E-cadherin and EpCAM and the mesenchymal-associated markers
N-cadherin and vimentin. Results are presented in quantitative densitometric form
normalized to β-actin and as representative western blots, shown as cropped gel
images (n=3).
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regards to which CTCs are the most valuable to capture, and which will serve as the best
tools for personalized cancer treatment based on CTC molecular characterization. We
believe that improved understanding of the biology of CTCs and how these cells relate to
the dynamic processes of EMT and metastasis will provide important translational
information that will help inform the use of CTCs as valuable biomarkers of cancer
progression in the clinic.
In the current study we have utilized 2 CTC enumeration assays to assess the
differences in CTC capture using the epithelial-based CSS (EMT-dependent) and a
human versus mouse based (EMT semi-independent) capture technique to assess the
generation of mesenchymal CTCs that would be missed by current technologies.
Additionally, we performed a comprehensive assessment of the EMT phenotype in 4 of
the most commonly utilized prostate cancer cell lines and compared the potential of these
cell lines for CTC generation and metastasis.
Significant effort is currently being focused on the development of CTC
capture techniques capable of recovering not only CTCs expressing epithelial markers
(i.e., EpCAM and CK), but also those with a highly mesenchymal phenotype. This
pursuit is largely based on the current understanding of EMT, specifically regarding
phenotypes imparted by this process on the primary tumor (i.e., enhanced invasiveness,
increased metastatic capacity, reduced apoptosis, improved therapy resistance, and the
generation of stem cell-like properties). However, the results of the current study
demonstrate that although prostate cancer cell lines with an increasingly mesenchymal
phenotype shed more CTCs early in disease compared to epithelial cell lines, the majority
of CTCs shed from these mesenchymal cells are captured, at least before the
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establishment of metastatic disease, by the CSS. This thereby suggests that CTCs shed
early in disease have a hybrid EMT phenotype and still express sufficient levels of
EpCAM and CK 8/18/19 for detection using epithelial-based techniques. While the
observation that cell lines with an increasingly mesenchymal phenotype are more
invasive and metastatic is not surprising17, it appears that CTCs with a hybrid phenotype
may be those that are most important for establishing metastasis and therefore the most
interesting to characterize, at least in early-stage patients. In fact, some have suggested
that CTCs with a hybrid phenotype may be of particular importance based on their
plasticity for EMT and MET related phenotypic changes27.
Based upon our data, however, it appears that following the establishment of
distant metastases there is a significant increase in the number of mesenchymal CTCs
that are undetectable by the CSS. This increase in the mesenchymal characteristics of
CTCs in later stage disease has also been demonstrated in clinical samples with a number
of studies reporting an increase in CTCs (captured by epithelial methods) expressing
mesenchymal markers in metastatic versus primary breast cancer patients48,49. Therefore
further studies are needed to determine if and how these undetectable CTCs are
contributing to disease progression and metastasis.
Despite widespread speculation, there is very little evidence in the literature to
support the hypothesis that CTCs with a highly mesenchymal phenotype have any
additional prognostic value compared to CTCs with a hybrid epithelial-mesenchymal
phenotype or even a purely epithelial phenotype in patient samples. However, we must
consider that technological limitations with regards to mesenchymal CTC capture may
significantly hinder the ability to test this hypothesis in the clinic. In addition, we cannot
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rule out the possibility that highly mesenchymal CTCs are present in early-stage disease
but not in high enough number to significantly contribute to differences between the 2
assays presented here. In fact, the cancer stem cell (CSC) hypothesis posits that only a
small number of cells that make up the bulk primary tumor efficiently complete the
metastatic process50. Based upon this theory it is possible that the dramatic increase in
mesenchymal CTCs following the development of metastases is due to a selective
outgrowth of highly mesenchymal CSCs. Therefore, although this study provides many
valuable insights into the role of EMT in CTC dissemination and kinetics, many
questions remain, for which the assays developed here will be very useful in answering.
In addition to the contributions this manuscript makes towards understanding
CTC biology and its relationship to EMT, to our knowledge it is also the first
comprehensive head-to-head comparison and EMT characterization of the in vivo
behavior of 4 of the most commonly utilized cell lines in prostate cancer research.
Specifically, this manuscript describes the EMT phenotype of the PC-3M, PC-3, LNCaP
C4-2B, and LNCaP cell lines at both the mRNA and protein level. It also details
differences in primary tumor incidence, CTC dissemination and kinetics, and metastatic
capacity to multiple organs. This will therefore serve as an incredibly valuable tool for
future research in the field of prostate cancer.
Overall the results presented here highlight that how CTC characterization is
utilized in a clinical setting may greatly depend on disease stage. Specifically, in earlystage patients, it has been suggested by our group and others that the use of novel CTC
technologies capable of capturing highly mesenchymal CTCs could result in an increase
in the overall number of detectable CTCs and thereby increase the potential prognostic
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power of CTCs in these patients. However, our data suggest that the application of these
novel technologies may not lead to a dramatic increase in CTC enumeration in these
patients and that instead the detection of an increased number of CTCs will require the
processing of additional blood (>7.5mL) on traditional epithelial-based CTC detection
technologies such as the CSS. In addition, the data also suggest, as has been previously
reported17, that primary tumors with an increasingly mesenchymal phenotype may have
an enhanced metastatic capacity and therefore the detection of CTCs with a hybrid
phenotype may be of prognostic importance in these patients. In contrast, when
considering metastatic patients, we have demonstrated a significant increase in
undetectable highly mesenchymal CTCs. Therefore further research in this patient cohort
will need to examine the functional role of these CTCs versus those with an epithelial or
hybrid phenotype in disease progression and, importantly, in therapy resistance.
Ultimately a better understanding of the biology of CTCs will aid in the identification of
those cells that would be most valuable for determining individualized treatment.
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Chapter 7
Overall Discussion

Prostate cancer (PCa) is a leading cause of death in men and the majority of
these deaths result from metastatic spread1,2. The presence of circulating tumor cells
(CTCs) is associated with metastatic disease and has been demonstrated to be prognostic
in metastatic prostate cancer patients, predicting for progression-free and overall
survival3. Prior to the initiation of this work, CTCs were utilized almost exclusively in the
metastatic setting with little known about their role in early-stage PCa3,4. Additionally,
significant focus had been placed on the characterization of CTCs and their potential for
optimizing patient treatment with limited understanding of the underlying biology of
these cells5–7. This lack of exploration of CTC biology was due, in large part, to
inadequate tools for studying CTCs in experimental mouse models of metastasis.
Therefore this thesis aimed to investigate the role of CTCs in early-stage prostate cancer
and assess their potential for determining prognosis as has been demonstrated for
metastatic patients3,8. Additionally, we sought to provide detailed protocols that would
allow users of the regulatory-approved CellSearch® system (CSS) to capitalize on its
potential for CTC molecular characterization and to develop novel tools that would allow
for detailed investigation of the biology of CTCs.
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7.1

Summary of key experimental findings

1.

CTCs are detectable in early-stage PCa patients post-prostatectomy undergoing
treatment with adjuvant or salvage radiation therapy (RT) for recurrent or
residual disease.

2.

The CTC status (presence/absence) of PCa patients in the adjuvant and salvage
settings correlates with the clinical observations of local versus systemic
relapse associated with previously described clinicopathologic risk factors
(margin status, extracapsular extension [ECE], and seminal vesicle invasion
[SVI]), suggesting that CTCs may relate to disease localization in these
patients.

3.

The presence of either ECE or SVI in combination with CTC pos disease prior to
RT in adjuvant and salvage PCa patients predicts for poorer response to
localized treatment compared to CTCneg patients with the same
clinicopathologic risk factors. In addition, CTCpos status at any point
throughout treatment correlated significantly with time to biochemical failure
(BCF) and incidence of BCF at 2 years. This suggests that the addition of
CTCs to a patient’s clinicopathologic "risk profile" (ECE, SVI, and margin
status) may further enhance our ability to discriminate patients with localized
versus systemic recurrence.

4.

Although promising in theory, the detailed process of optimization required for
the development of user-defined markers on the CSS requires significant workup with rigorous controls. In addition, not all markers may be suitable
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candidates for use with this platform and therefore marker selection should be
carefully considered.
5.

Prostate cancer cell lines display differences in EMT status at both the RNA
and protein level. Cell lines with an increasingly mesenchymal phenotype (PC3M and PC-3) demonstrate an enhanced capacity for CTC generation and
metastasis when compared to cell lines with a more epithelial phenotype.

6.

CTCs with a highly mesenchymal phenotype may be undetectable by
epithelial-based detection systems. However, these undetectable CTCs only
appear in significant number following the establishment of metastatic disease.

7.2

Implications of experimental findings

7.2.1

Circulating tumor cells are detectable in early-stage
prostate cancer patients and may be useful in guiding
clinical decision-making
When this work was first initiated, CTC enumeration and characterization was

being utilized almost exclusively in the setting of metastatic disease and very little
research was exploring the prognostic value of these rare cells in patients with early-stage
disease3,4,8–11. Current research has begun to focus on the clinical value of CTCs in earlystage patients, however the majority of this research has been performed in nonstandardized systems that do not have FDA or Health Canada approval for use in the
clinic4,12–16. Our group was the first to describe the detection and enumeration of CTCs in
early-stage PCa patients undergoing salvage or adjuvant radiation therapy using the only
regulatory-approved CTC technology, the CSS17. In addition, we also demonstrated that
CTCs may contribute to a patient's clinicopathologic risk profile and that the detection of
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CTCs prior to or following localized treatment with radiation therapy may be an indicator
of residual/recurrent disease and ultimately treatment failure.
This data suggests that the detection of CTCs at any disease stage may be a
sign of the potential for metastatic spread, regardless of the clinical confirmation of
macrometastatic disease. CTCs, especially those detected early, may alert clinicians of
aggressive disease sooner than currently used techniques thereby suggesting that more
aggressive treatment options should be considered for these patients and/or that these
patients may be spared unnecessary localized treatments8,9,11,18. Additionally, these
results provide clinical support that CTCs shed early aid in the establishment of
micrometastatic disease and these CTCs may be of particular value for CTC
characterization.
Unfortunately based on the low number of CTCs detected in these patient
cohorts, characterization would require either additional blood (>7.5ml) to be processed
if using the CSS or for novel CTC technologies with greater sensitivity to be utilized in
this regard. However, CTC characterization in these patient populations may provide
valuable clinical information regarding which CTCs have the greatest capacity for
metastatic dissemination. In fact, characterizing CTCs in early-stage patients may be of
particular value as the disease will have had less opportunity for significant mutation, as
compared to patients with metastatic disease, and may better represent the phenotype of
the cells that are capable of metastasis. Additionally, identifying the CTCs with the
greatest metastatic capacity may be easier in early-stage patients as there will be fewer
"contaminating" CTCs with phenotypes that do not necessarily represent the phenotype
of metastasis-initiating CTCs. Currently, there is a need for novel biomarkers that could
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be utilized for prognosis in clinically challenging early-stage patients. Our data suggests
that CTCs may serve as a valuable tool for clinical decision-making in early-stage PCa.

7.2.2

Novel tools developed throughout this thesis will be
important for future work in the area of CTC biology and
in clinical samples
The field of CTC research is exceedingly reliant on appropriate technology

development. The rarity of CTCs in the bloodstream presents significant challenges for
the detection, enumeration, and characterization of these cells. Additionally, the
overwhelming number of technologies developed in recent years has made the field
extremely complicated and made choosing an appropriate technology for both clinical
and research uses difficult 19–21. However, thus far the only CTC platform approved for
use in the clinic is the CSS, thereby making it the current gold standard in CTC
technology3,10,11. It is for this reason that throughout the course of this thesis we have
provided a detailed description of common discrepancies encountered during CTC
enumeration from clinical samples and a guide to CTC molecular characterization using
the CSS that will aid users of this platform in the development of user-defined protein
markers22,23. In addition, we have also provided novel techniques that can be utilized to
study CTCs in pre-clinical mouse models of metastasis22. These tools hold particular
value as they not only allow for the study of CTC biology based on CTCs that would be
captured by the gold standard technology, but also allow for the study of CTCs that
would be missed using this system. Although CTC enumeration has previously been
performed in in vivo model systems, due to the capture methods utilized, these results do
not necessarily represent the results that would be obtained using the CSS24,25.
Particularly in this field, where CTCs are extremely rare, there can be dramatic
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differences in the sensitivity and specificity of given assays and these results are not
necessarily able to be generalized to all other platforms26–29. Ultimately these tools will
allow users of the CSS to capitalize on its limited potential for CTC characterization and
also to investigate important biological questions regarding the CTCs which are both
captured and missed by the standard clinical assay used on this platform.

7.2.3

Prostate tumors displaying a mesenchymal phenotype
may predict for an enhanced capacity for CTC shedding
and metastatic spread of disease.
While the observation that the epithelial-to-mesenchymal transition (EMT)

imparts cells with an enhanced capacity for invasion and migration30, very little is known
about the influence EMT has on CTC generation and the timing of metastasis. The data
presented in this thesis indicates that primary prostate tumors that possess an increasingly
mesenchymal phenotype will have an enhanced capacity for CTC generation and
metastasis. Ultimately this suggests that further investigation of the EMT status of
primary tumor specimens and their impact on patient prognosis may be warranted. In
fact, a number of studies have performed such investigations and demonstrated a
correlation between EMT status and patient outcomes31–33. Additionally, not only did we
demonstrate that mesenchymal primary tumors may shed more CTCs than those with an
epithelial phenotype, but also that these CTCs may be shed earlier in disease. From a
clinical perspective, this therefore suggests that patients with mesenchymal primary
tumors may already have undetectable micrometastatic disease at the time of diagnosis
and therefore are at greater risk for metastatic dissemination and subsequent relapse
following localized first-line treatments. Therefore incorporating analysis of EMT status
of primary tumors into a patient’s clinicopathologic risk profile may improve the ability
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to discriminate patients with aggressive versus indolent disease and ultimately improve
our ability to choose appropriate treatment options for PCa patients.

7.2.4

Technologies aimed at capturing mesenchymal CTCs
may fail to enhance the prognostic value of CTCs in the
setting of early disease
One interesting observation that was made using our in vivo model of PCa

metastasis was that highly mesenchymal CTCs that are undetectable by the standard CSS
assay are not shed in significant numbers until the establishment of metastatic disease.
This result suggests that CTCs with a purely epithelial and/or hybrid EMT phenotype are
those capable of establishing initial metastases and that novel technologies aimed at
capturing these cells will not enhance the prognostic value of CTCs in the setting of early
disease. Alternatively (or additionally), highly mesenchymal CTCs capable of metastasis
are very rare at the early stages of metastatic dissemination and present only in very low
numbers, thereby making them difficult to visualize using these assays and only
noticeable after metastatic dissemination and selective outgrowth of these aggressive
clones. Either way, this suggests that the clinical value of CTC molecular characterization
may be greatly affected by the patient population chosen for proof-of-principle studies.
Until the importance of these highly mesenchymal, undetectable CTCs are understood
from a biological perspective, careful consideration must be made when choosing these
patient cohorts for clinical trials and assay validation.
This data may also have a significant impact on how we view EMT and
cellular plasticity. Currently much focus is being placed on finding highly mesenchymal
CTCs as they are viewed as the most aggressive and valuable to characterize34–42.
However this may not be the case and CTCs with a hybrid phenotype, allowing for quick
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phenotypic switching may be more important, as has been previously suggested43,44. This
data also suggests that the mixed results seen in clinical trials examining the utilization of
CTC molecular characterization for individualized cancer treatments may be due to a lack
of understanding of the biology of these cells, resulting in inappropriate trial design, and
not due to lack of appropriate technologies for capturing CTCs that are highly
mesenchymal45–49.

7.3

Possible limitations of the thesis work
The data presented throughout this thesis has described novel findings in the

areas of CTC biology, clinical uses, and technology development. Although these results
represent significant contributions to the field of CTC research and PCa metastasis, as
with all research, there are limitations that exist. These limitations are discussed below.

7.3.1

Clinical studies
In Chapter 2, we performed a pilot study in 26 early-stage PCa patients

consented to undergo salvage RT. From this small patient cohort we found that CTCs
were detectable in ~70% of these patients. In this study, we also demonstrated that
changes in CTC number (increased, decreased, or unchanged) before initiation and
following completion of salvage RT correlated with BCF17. However, these results were
only correlative, and no significant differences were observed. Regardless, we anticipated
that significant results would be possible by increasing the number of accrued patients
and therefore we sought to recruit 55 patients for a follow-up study. In addition, based on
the high CTC detection rate demonstrated in the first study (~70%) we also decided to
include patients in the adjuvant setting, thus reducing the number of salvage patients
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accrued. Unfortunately in the follow-up study presented in Chapter 3, the number of
patients with detectable CTCs dropped significantly to ~15% and therefore limited the
statistical power of our follow-up study. The choice to include patients from both the
adjuvant and salvage settings may have limited our analysis of results from both cohorts
and the selection to study either salvage or adjuvant patients may have led to more
conclusive data.
Additionally, analysis of the results from Chapters 2 and 3 were also limited
due to the low number of CTCs detected in individual patients, with the vast majority
having CTC counts of ≤ 2 and only 1 patient having 5 CTCs (the number that predicts for
poor outcomes in metastatic PCa3). If financially feasible, it may have been beneficial to
increase the amount of blood collected and processed at each time point from individual
patients (>7.5mL). The detection of additional CTCs would reduce the potential for false
negative and positive results and likely increase the number of patients in the CTCpos
group, thereby enhancing the statistical power of this study. The detection of more CTCs
in the follow-up study would have allowed for comparison of pre- and post-treatment
numbers (increased, decreased, or unchanged), as was performed in the pilot study17 and
utilized for patients in the metastatic setting8, which may be more informative then the
presence or absence of CTCs alone.
Finally, during the analysis of the follow-up study a small group of patients
(n=3) initially presenting in the adjuvant setting shortly thereafter were found to have a
detectable PSA and were instead considered salvage patients by the time of RT initiation.
These patients in particular appeared to be more likely to have CTC pos disease (66%)
compared to the patients with less aggressive disease. Therefore we anticipate that more
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conclusive results may have been possible if stricter inclusion criteria were set that
selected for patients with intermediate or high-risk disease. However, it is also important
to consider that these stricter criteria would likely have significantly slowed patient
accrual as there may have been fewer patients presenting in this setting and fewer may
have been recommended for RT.

7.3.2

Technology development studies
Although the protocol described in Chapter 4 outlined the proper development

of user-defined protein markers for on-system CTC molecular characterization, the
optimization of these assays requires the use of cell lines with known protein expression
and relative antigen density comparisons. For example, when optimizing the CD44
marker for use with the CSS, a panel of cell lines were chosen to represent high (MDAMB-468), low (21NT), and negative (LNCaP) expression of this marker. However, in
doing so, assumptions are being made regarding the expression levels of this protein in
patient samples, which could be much higher (leading to significant bleed-through and
misclassification of CTCs) or much lower (leading to false negatives) than anticipated.
Therefore, comparison and validation of user-defined protein markers in patient samples
should be considered as the final optimization step. Unfortunately this was not performed
here. In addition, we have demonstrated that not all user-defined protein markers can be
properly optimized for use with the CellSearch CTC kit and instead for low antigen
density markers the CellSearch CXC kit must be utilized. However, FDA and Health
Canada approval have only been given for the traditional CTC kit and not the CXC kit as
it has been shown to have reduced CTC recovery due to the switching of PE and FITC
fluorophores for CK 8/18/19 detection50. Therefore, when utilizing the CXC kit, the
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unique advantage imparted on the CSS over other enumeration and characterization
technologies (i.e., the ability to perform CTC enumeration and characterization in
individual cells on a regulatory-approved platform) is lost.

7.3.3

In vivo prostate xenograft studies
The time points (2, 4, 8, 12, and 16 weeks) and number of mice per group

(n=12) utilized for the in vivo studies performed in Chapter 6 were chosen based on
previously reported data regarding each cell line51–57. However, this was our laboratory's
first experience with these cell lines in vivo and our first experience with orthotopic
injection into the prostate gland. Therefore there was uncertainty with regards to the
number of mice utilized and the time points chosen that would allow for comparison of
the various steps in the metastatic cascade across all 4 of the investigated PCa cell lines.
Although the chosen time points appeared reasonable, the PC-3M cell line was highly
aggressive and the longest surviving animal was sacrificed at 6 weeks post-injection, with
the majority being sacrificed earlier than anticipated, at 4-5 weeks post-injection.
Additionally, the 16 week time point may have been too long, as the early sacrifice of
mice originally allocated to this time point, due to significant morbidity, led to an
enrichment of this group specifically with healthy animals (with no evidence of primary
tumors) compared to the other groups. Ideally it would have been advantageous to
exclude these healthy animals from the subsequent analysis, however due to the modest
number (n=12) of mice chosen for each group this would have reduced our ability to do
appropriate statistical analysis and therefore these mice had to be included.
Regardless of the challenges in mouse number, the results obtained in Chapter
6 demonstrated that some CTCs may be missed by the EMT dependent assay
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(representative of CSS based capture) due to its reliance on EpCAM expression.
However, it is important to remember that the EMT semi-independent assay also has
some reliance on EpCAM expression as it selects cells based on expression of both
EpCAM and HLA. Therefore if HLA and/or EpCAM are significantly down-regulated in
the circulation this assay may not work as expected in vivo. The downregulation of HLA
has previously been described to occur as a method of immune evasion and demonstrated
to enhance tumorigenicity in immunocompromised mice58. Ideally, a simple assessment
would be to compare HLA and EpCAM expression on CTCs to that of the primary tumor
following orthotopic injection. However, unfortunately, as these antigens are used for
CTC capture, cells with significant EpCAM and/or HLA downregulation may not be able
to be captured and subsequently assessed for expression.
Finally, as with all xenograft models there are always concerns with regards to
the use of human cell lines in an immunocompromised mouse background and how
accurately this represents human disease. To reduce as many confounding variables as
possible we performed orthotopic injections directly into the dorsolateral lobe of the
mouse prostate instead of subcutaneously or into the renal capsule (other common sites
utilized for xenograft models of PCa)59. Despite the technical difficulty of the surgery
itself and the limitations with regards to the volume of sample that can be delivered to
this site, we felt it was most appropriate, compared to other sites, as it best mimics the
microenvironment and vasculature of human PCa59. However, we must also consider that
the mouse prostate is quite dissimilar from the human prostate. Specifically the mouse
prostate is a multi-lobular structure composed of 4 lobes, the anterior, ventral, dorsal, and
lateral lobes versus the human prostate, composed of a single "lobe" divided into 3 zones,
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the peripheral, transitional, and central60. The majority of human prostate cancers develop
in the peripheral zone and the dorsal and lateral lobes of the mouse prostate (often
referred to as the dorsolateral lobe) has been described as being the most similar to this
zone, hence why it was chosen for these studies61. However, there is no histological
evidence that a relationship exists between any one lobe of the mouse prostate and a
particular zone of the human prostate gland62. In addition to the observed structural
differences, the use of immunocompromised mice may also have an impact on the
metastatic capacity of the investigated cell lines. The immune system plays a large role in
PCa and cannot be discounted as a confounding factor of this study63–66. Finally, the use
of human prostate cancer cell lines is always a point of contention when investigating
xenograft models as the majority of cancer cell lines are isolated from patients with
highly aggressive disease and are often not collected from the primary site, but instead
from a metastatic lesion, as are all the cell lines described in this thesis 67–70. Ideally these
experiments would be repeated with human primary cells isolated from isolated primary
tumors. However, such attempts have proven difficult and based on the number of mice
utilized in this study this would likely not be feasible59,71,72.

7.4

Future directions
The work presented here will have a significant impact on guiding future CTC

research. In addition, the results obtained from both pre-clinical and clinical studies have
raised a number of new questions to be addressed in future studies.
From our clinical studies we have demonstrated that consideration should be
given to using CTCs as biomarkers in early-stage patients and not solely in the metastatic
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setting. Inclusion of CTC analysis in these patients specifically, may aid in the
stratification of patients into low and high risk groups, and ultimately result in improved
progression-free survival and overall survival in patients with poor prognosis, and in
improved quality of life (due to less aggressive treatment options) in patients with good
prognosis. However, the added benefit of inclusion of CTCs into a patient's
clinicopathologic risk profile in determining prognosis will need to be validated in larger
patient cohorts in the future. Based on the work presented here we suggest that this
validation could occur by using the gold standard CSS alone or in combination with
newer emerging technologies, but that larger blood volumes would likely need to be
utilized to allow for an increase in the number of CTCs captured and ultimately allowing
for more rigorous statistical analysis to be performed. The capture of additional CTCs
would also allow for comparison of CTCs pre- and post-treatment, which may have
greater prognostic value. Finally, the results presented here highlight the need for
appropriate patient selection in the development of these future validation studies.
Potentially the greatest area in need of future work is in understanding the
underlying biology of CTCs. The results of this work suggest that the search for highly
mesenchymal CTCs that are missed by EpCAM-based technologies may not lead to the
added prognostic value that has been proposed. Our results suggest that CTCs with a
hybrid phenotype may be the most important in initially establishing metastatic disease
and that those CTCs with a highly mesenchymal phenotype only appear in significant
number after metastasis has occurred. Therefore future research needs to address the role
that both these highly mesenchymal and hybrid CTCs play in disease progression across
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all stages of disease. The tools developed throughout the course of this thesis will aid in
answering these questions.
Additionally, many outstanding questions remain regarding the impact of EMT
on the various steps of the metastatic cascade. Specifically, how phenotypic switching of
EMT to MET phenotypes or vice versa at different stages of disease progression would
impact CTC generation and metastasis is an important area for future investigation.
Unfortunately the timeline of this thesis did not allow for such investigation. However
future work in this area will be important in better understanding EMT and its
contribution to metastatic spread.
Finally, although careful consideration was given when selecting both the PCa
cell lines and site of injection utilized in our xenograft models in order to best represent
disease conditions in the clinic, we did not have time to investigate the implications of
therapy related interventions (i.e., surgical removal of the prostate and/or localized versus
systemic therapies) on the results presented here. It would be interesting to investigate
differences in CTC generation and/or metastasis in response to these typical clinical
intervention strategies. Additionally, it has been suggested that androgen deprivation may
be important in the generation of EMT phenotypes73, and as it is known that eventually
PCa will progress to an androgen-independent state74. Therefore it may be beneficial to
further explore the role of androgen deprivation on CTCs and metastasis in vivo.

7.5

Final conclusions
Throughout this project, we have demonstrated that CTCs may be valuable

biomarkers in the setting of early-stage PCa, and that their inclusion in a patient's
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clinicopathologic risk profile may change clinical decision-making. In addition, several
detailed guides have been presented enable users of the CSS to capitalize on its full
potential for both CTC enumeration and molecular characterization. Finally, we have
reported on the role of EMT in CTC generation and metastasis and the capacity for
mesenchymal CTC capture using the current clinical gold standard CTC technology.
Overall, the knowledge gained in these studies is important from several
different perspectives, including; (1) the therapeutic perspective, defining the relationship
between therapy response and CTC detection in the setting of early stage prostate cancer
and salvage/adjuvant radiation; (2) the technical perspective, identifying the limitations
of existing CTC methodologies and aiding in the development/optimization of novel
CTC enumeration/characterization techniques; and (3) the biological perspective,
providing a more detailed understanding of the metastatic process in prostate cancer, its
mechanism(s) and the molecular characteristics of the cells involved.
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